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i. Summary: 
This thesis is about the Tukula Fenna Project (TFP) that was set up at the Home Care 
Department of St. Raphael of St Francis Hospital (Nsambya Hospital) in Kampala, Uganda. 
In 2003, Associazione Casa Accoglienza alla vita “Padre Angelo” (ACAVPA) or “HOUSE 
FOR LIFE, Father Angelo” and other Italian partners; in particular, PENTA Foundation and 
University of Padova, Department of paediatrics collectively signed a memorandum of 
understanding (MoU) with Nsambya Hospital. The aim of the MoU  was to collaborate with 
the hospital in the fight against HIV particularly in children and adolescents, orphans and 
vulnerable children (OVC) and their families in Kampala and three surrounding districts 
(Mukono, Wakiso and Mpigi). Thus, the MoU officially established the children’s HIV 
programme at Nsambya Hospital, Home Care Department in 2003. The programme was then 
called the “PCP Project” because the initial intervention was among other things, providing 
Cotrimoxazole prophylaxis against Pneumocystis Carinii pneumonia (PCP, also known as 
Jiroveci Pneumonia). As more resources including provision of antiretroviral drugs (ARVs) 
from external sources and expertise became available over the years, the project evolved into 
a full-blown HIV programme for infants, children and adolescents as well as their families 
and caretakers. Additionally, the name “PCP”, was replaced by “Tukula Fenna”, which 
means “growing up together” in the local language (Luganda).  
The project was implemented at the Home Care Department within an existing community 
home-based care (CHBC) model that evolved in response to the HIV epidemic in Uganda, 
and other high-burden resource-limited settings. The TFP provides comprehensive HIV care, 
treatment and psychosocial support services (PSS) and apart from operating at the Home 
Care department of Nsambya Hospital, it also operates at Ggaba Parish Outreach Clinic and 3 
other outreach clinics in and around Kampala.  
 
This thesis describes the research outcomes of the project that was managed by Dr. Massavon 
from 2008 to 2013. It reviews the published literature from the key milestones of the HIV 
epidemic to the post-conflict health reforms in Uganda and their relevance to current health 
outcomes, the national AIDS response and health systems strengthening. The literature 
review also examines the human resources for health (HRH) crisis and task shifting in the 
scaling up of ART in high-burden resource-limited settings. In addition, the review looks at 
the evolution of complementary HIV service delivery models like community and home-
based care as a spontaneous response to the HIV epidemic in many resource-limited settings 
including Uganda. Finally, the literature documents that, there are relatively few paediatric 
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HIV services in the country, leading to poor geographical access and a low antiretroviral 
therapy (ART) coverage for children and that, HIV-infected children and in particular, AIDS 
orphans are an underserved and an understudied population.  
 
At the time of this thesis, approximately 2,100 infants, children and adolescents had been 
enrolled into care in the TFP; about 1140 were active in care, and about 60% were on ART. 
Approximately, 47% of children and adolescents in the project are orphans.  
 
This thesis therefore aims at contributing to improving paediatric HIV management through 
operational research in the context of a CHBC model in Kampala, Uganda. The findings 
cover key outcomes such as retention in care, attrition and loss to follow up (LTFU), 
treatment failure, mortality on antiretroviral therapy (ART) and operationalization of dried 
blood spots (DBS) for viral load testing among HIV-infected children. The thesis also 
included a specific study on HIV-Epstein-Barr Virus (EBV) co infections in children and 
adolescents, considered relevant to the project setting. 
 
Except for study 5 (EBV study) which was a cross-sectional study, the studies were generally 
retrospective cohort studies conducted at the Home Care Department of Nsambya Hospital in 
Kampala, Uganda. The methodology of the operational research was based on an 
implementation schema derived from the ART guidelines of the WHO and Uganda (Figure 
17). The selection of the outcomes for the operational research was based on the rationale 
that, they have direct bearings on implementation and potentially could improve the same.  
The findings and implications from the six studies that constitute the chapters of the thesis are 
summarized as follows: 
Study 1:  
This retrospective observational study compared HIV and TB outcomes from adults and 
children in the Nsambya CHBC with national averages from 2007-2011. The core findings 
show that Nsambya CHBC activities enhance and complement national HIV and TB 
management, and resulted in better outcomes when compared to the national averages.  
This approach may hold the potential for chronic disease management in resource-limited 
settings. Scaling up CHBC could have wider positive impacts on the management of not only 
HIV and TB, but also other chronic diseases as well as the general health system. A long-
standing “faith-based solidarity” among international donors and partners has been pivotal to 
the survival and evolution of the Nsambya CHBC. 
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Study 2:   
This is a retrospective cohort analysis of attrition and LTFU and their predictors among 
children and adolescents aged 0-20 years. Over the study period, 5.34% (62) of patients died, 
37.61% (437) were LTFU, and thus overall attrition was 42.94% (499).  
Generally, attrition and LTFU were relatively high among children and adolescents in the 
TFP. Not receiving ART was the single factor significantly associated with attrition in the 
cohort, while both baseline BMI z-scores and receipt of ART were protective against LTFU 
among HIV positive children and adolescents. Efforts should be made to initiate ART among 
all paediatric patients as soon as possible, and to provide aggressive follow-up for those not 
yet receiving ART. Orphans need more nutritional support to reduce the burden of 
malnutrition and improved access to early ART, which could also promote growth responses 
in this vulnerable and understudied group. 
Study 3:  
This retrospective cohort study reviewed records from HIV positive children age 0 to 18 
years engaged in a CHBC and a Facility-based, family-centred approach (FBFCA) from 2003 
to 2010 focussing on retention in care, loss to follow-up, mortality, use of ART, and clinical 
characteristics.  
Irrespective of model of care, children receiving ART had better retention in care and 
therefore long-term survival. Encouragingly, if children were on ART, then their survival was 
as good, if not slightly better, in the CHBC compared to the FBFCA. Based on our 
observations, substantial improvement in child survival can be achieved in either a 
community-based or a family-care model as long as HIV- infected children are identified 
early and begun on ART. To ensure this occurs, early identification of HIV infected children 
requires strong linkages of pregnant HIV- infected women to prevention of mother to child 
transmission (PMTCT) services; active tracking to ensure all HIV exposed infants receive 
Polymerase Chain Reaction-based early infant diagnosis. Additionally, rapid early initiation 
of ART among HIV infected infants and children are essential.  
Study 4:  
This is an observational study that included HIV-infected children attending the Beira Central 
Hospital (Mozambique) and the Nsambya Hospital, Home Care Department (Uganda), and 
evaluated clinical and immunological failure according to the WHO 2006 guidelines. 
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Two hundred and eighteen of 740 children with at least 24 weeks follow-up experienced 
treatment failure ((29% 95%CI (26-33)), with crude incidence of 20.0 events per 100 person-
years (95%CI 17.5-22.9). Having tuberculosis co-infection or WHO stage 4, or starting a 
non-triple cART significantly increased the risk of failure. Drug toxicity (18.3%), drug 
availability (17.3%) and anti-tuberculosis drug interactions (52, 25.7%) were the main 
reported reasons while only 9 (4%) patients switched cART for clinical or immunological 
failure.  
Considerable delay in switching to second line cART may occur despite an observed high 
rate of treatment failure. Our findings reinforce the need for simplification of more effective 
clinical and immunological criteria for prompt recognition of cART treatment failure. 
Children presenting with advanced disease and TB co-infection should be targeted for closer 
and more sensitive monitoring of treatment response. This should  be matched with a 
constant provision of appropriate antiretroviral drugs with optimization of first line drugs and 
treatment sequencing. Supply of new paediatric formulations for second line regimens and 
drug optimization should be considered as critical milestones to allow scaling up of early 
cART and reduction of treatment failure in children. 
 
Study 5:  
In this cross-sectional study, dried blood spot (DBS) samples from 213 HIV-1 infected 
children were collected and EBV DNA was extracted and analysed for quantification of EBV 
types 1 and 2 and for quantification of 16S ribosomial DNA (16S rDNA), a marker of 
microbial translocation. 
Ninety-two of 140(66%) children on ART and 57 of 73(78%) ART-naive children had 
detectable EBV levels. Co-infection with both EBV types was significantly less frequent in 
ART-treated than in ART-naïve children (OR=0.54, 95%CI 0.30;0.98, p=0.042). HIV-1 
inducing microbial translocation and a state of persistent immune activation, may lead to 
EBV replication and expansion of EBV-infected B-cells, thus increasing the EBV-DNA load. 
Super-infection by both types of EBV in HIV-1 infected subjects may represent an additional 
risk for the onset of EBV-related malignancies. ART, by limiting HIV-1 replication, 
microbial translocation and related immune activation, may prevent super-infection by both 
EBV types and keep EBV viremia down, thus reducing the risk of EBV-associated 
lymphomas. 
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Study 6:  
This was a retrospective study to evaluate viral load (VL) using DBS and to explore the 
accuracy of clinical and immunological criteria for treatment failure (TF) in a cohort of HIV-
1-infected children. In this cohort, immunological and clinical criteria as per WHO 2010 
guidelines poorly predicted the presence of a viral load greater than either 1000 cp/ml or 
5000 cp/ml (whole blood) from DBS.  The low sensitivity and positive predictive values for 
immunological and/or clinical failure confirm those reported by the literature. This finding 
further supports the WHO recommendations that VL monitoring should be implemented and 
used to identify cases of treatment failure earlier.  
Policy implications of key findings of thesis 
Scaling up CHBC could have wider positive impacts on the management of not only HIV and 
TB, but also other chronic diseases as well as the general health system. 
In this thesis, and in line with the literature, Early ART initiation was associated with 
improved survival and retention in both community-based and facility-based approaches.   
ART is potentially protective against EBV-related lymphoproliferative disorders in HIV-
EBV co infected children. This calls for early ART initiation and close monitoring in such 
children. 
Operationalization of the use of DBS in viral load monitoring in HIV-infected children in low 
and middle-income countries is feasible and should be encouraged to improve the quality of 
paediatric HIV management in such settings. 
The low ART coverage among children calls for urgent, greater and more effective 
decentralization of paediatric ART services within primary health care services at the district 
and sub-district levels in the general health system in Uganda. 
Children presenting with advanced HIV disease and TB co-infection should be targeted for 
closer and more sensitive monitoring of treatment response.  
Orphans need more nutritional support to reduce the burden of malnutrition and improved 
access to early ART, which in turn could promote growth responses in this vulnerable and 
understudied group. 
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ii. Riassunto della tesi in italiano 
Questa tesi descrive il Progetto Fenna Tukula (TFP) in corso presso il Home Care 
Department dell'Ospedale St. Raphael e St. Francis (Nsambya Hospital) a Kampala 
(Uganda). 
Nel 2003, l'Associazione Casa Accoglienza alla Vita "Padre Angelo" (ACAVPA) insieme 
ad altri Partner (in particolare la Fondazione PENTA e l'Università di Padova), hanno 
firmato una lettera di intenti con il Nsambya Hospital. L'obiettivo di questo documento 
era di collaborare con l'ospedale nella lotta all'AIDS nei bambini ed adolescenti, orfani 
(OVC) e le loro famiglie a Kampala e nei distretti circostanti di Mukono, Wakiso e 
Mpigi. 
Il progetto è stato chiamato inizialmente "PCP project" in quanto l'intervento consisteva 
essenzialmente  nella profilassi con il Cotrimoxazole per la prevenzione della polmonite 
da Pneumocystis Carinii (conosciuta anche come Jiroveci Pneumonia). Dopo due anni 
dall’inizio del progetto grazie ad una aumentata disponibilità di risorse è stato possibile 
fornire ai bambini che ne avevano necessità la terapia con farmaci antiretrovirali (ARVs) 
da  e quindi il progetto si è indirizzato verso un programma 'tout-court' di lotta all'AIDS 
pediatrico con un approccio globale, che includeva anche le famiglie e non solamente i 
bambini. Di conseguenza, il nome "PCP" è stato rimpiazzato da "Tukula Fenna", che 
significa "crescere insieme" nella lingua locale (luganda). 
Il progetto si è caratterizzato con l’implementazione di un modello di cure domiciliari 
(CHBC) adattato alla realtà dell’ Uganda andando quindi oltre i confini dello NHC fino a 
comprendere delle strutture periferiche tra cui la Clinica della Parrocchia di Ggaba ed 
altre 3 cliniche nei dintorni di Kampala. 
Questa tesi descrive i risultati dell’attività di ricerca svolta nell’ambito del progetto che è 
stato coordinato dal Dr. Massavon tra il 2008 e il 2013. La tesi si articola in una prima 
parte di revisione della letteratura con particolare riferimento alla realtà ugandese sia da 
un punto di vista dell’ epidemiologia dell’ HIV che dell’ organizzazione sanitaria nel 
paese con particolare riferimento all'evoluzione dei modelli sanitari finalizzati alla lotta 
all'AIDS, come modelli di cura comunitaria o domiciliari.  L’analisi della  letteratura ha 
documentato che, in Uganda vi sono relativamente pochi servizi specialistici sull’ HIV 
pediatrico. Tale aspetto ha come conseguenza una disparità tra le varie regioni del paese e 
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un limitato accesso alla terapia antiretrovirale  per i bambini soprattutto coloro che sono 
senza genitori naturali.  
A dicembre 2013 circa 2.100 bambini ed adolescenti sono stati arruolati nel TFP. 1.140 
sono seguiti regolarmente e il 60% di loro sono in terapia con ART. Il 47% dei bambini è 
orfano. 
La finalità ultima della tesi è quello di contribuire al miglioramento delle cure nei 
bambini HIV positivi in Uganda attraverso la valutazione di un modello di assistenza 
domiciliare. In quest’ottica l’attività di ricerca si è articolata nella valutazione delle 
caratteristiche dei pazienti persi al follow-up, dell’outcome della terapia antiretrovirale e, 
in un ambito più prettamente clinico, nello studio dell’ impatto della infezione da EBV 
sulla progressione della malattia da HIV.  
L’attività si è sviluppata attorno diverse linee di ricerca i cui risultati sono stati pubblicati 
(o in corso di pubblicazione) nei lavori i cui elementi fondamentali sono riassunti di 
seguito:  
Studio 1:  
Studio osservazionale retrospettivo che analizza i risultati del follow-up dei pazienti  con 
HIV e TB (adulti e bambini) seguiti presso lo Nsambya Hospital confrontandoli con i dati 
nazionali tra il 2007 e il 2011. I risultati mostrano che il modello seguito allo Nsambya ha  
prodotto migliori risultati in termini di morbilità e mortalità rispetto alle medie nazionali. 
Il modello descritto basato sull’assistenza  domiciliare potrebbe essere utilizzato anche in 
altri contesti nei paesi in via di sviluppo. 
 
Studio 2:   
Analisi di coorte retrospettiva per la valutazione delle caratteristiche dei pazienti persi al 
follow up (LTFU) e dei fattori di rischio associati, nei bambini ed adolescenti tra 0 e 20 
anni. Nel corso del periodo di follow up considerato, il 5,3% dei pazienti è deceduto, il 
37,6%  è stato perso al follow-up con un “attrito” globale del 42,9%. 
In generale,  LTFU sono stati relativamente alti tra i bambini e gli adolescenti nel TFP. La 
terapia con ARV e la crescita regolare sono stati fattori associati con la permanenza in 
follow up e con la sopravvivenza. Tali osservazioni suggeriscono come gli sforzi 
dovrebbero essere indirizzati ad iniziare la ART nei pazienti pediatrici il prima possibile, 
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e a fornire un follow-up regolare a coloro che non sono ancora in terapia. Particolare 
attenzione va data agli orfani  che necessitano di un supporto alimentare particolarmente 
attento e di un follow up regolare per definire il momento migliore quando iniziare la 
ART. 
Studio 3:   
Studio di coorte retrospettivo che ha studiato i bambini HIV positivi tra 0 e 18 anni 
inseriti in un programma di assistenza domiciliare  con un approccio centrato sulla 
famiglia (FBFCA) dal 2003 al 2010, focalizzandosi sulla  perdita al follow-up, la 
mortalità, l'uso di ART e le caratteristiche cliniche. 
A prescindere dal modello di cura, i bambini che ricevevano l'ART sono seguiti piu’ 
regolarmente e di conseguenza hanno una sopravvivenza a lungo termine maggiore. 
Basandosi sulle nostre osservazioni, un miglioramento sostanziale nella sopravvivenza 
dei bambini può essere raggiunto sia con un modello basato sulla assistenza domiciliare 
che sul coinvolgimento attivo della comunità.  
Studio 4:  
Studio osservazionale prospettico che ha incluso bambini HIV positivi assistiti presso il 
Beira Central Hospital, in Mozambico e lo Nsambya Hospital, che ha valutato il rischio di 
fallimento immunologico e clinico secondo le linee guida del WHO del 2006. 
218 su 740 bambini con almeno 24 settimane di follow-up ha avuto un fallimento della 
terapia ((29% 95% CI (26-33)), con una incidenza di 20.0 eventi su 100 anni-persona 
(95%CI 17.5-22.9). La coinfezione con la TB, la presenza di AIDS  (WHO stadio 4), o 
l’inizio della ART con uno o due farmaci aumenta  significativamente il rischio di 
fallimento terapeutico.  
Un ritardo considerevole nel passaggio alla seconda linea di cART si è osservato  
nonostante un alto tasso di fallimento terapeutico. Tali osservazioni sottolineano ancora 
una volta l’importanza di garantire un efficace monitoraggio clinico e immunologico per 
poter modificare la terapia prima che insorgano ceppi virali resistenti. Insieme alla 
necessità di un corretto monitoraggio va sottolineata l’importanza di garantire una 
fornitura di farmaco regolare senza interruzioni e le formulazioni pediatriche per i 
bambini più piccoli 
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Studio 5:   
Studio trasversale, effettuato su campioni raccolti in cartoncini assorbenti (DBS) prelevati 
da 243 bambini affetti da HIV-1 da cui è stato estratto il DNA del EBV per analisi e 
quantificazione dei tipi 1 e 2, e per la quantificazione di 16s DNA ribosomiale (16S 
rDNA), un marker di traslocazione microbica. 
92 su 140 (66%) dei bambini in terapia con ART e 57 su 73 (78%) di bambini non trattati 
sono risultati positivi all’ EBV. La coinfezione con entrambi i tipi di EBV è stata 
significativamente meno frequente in coloro in terapia con ART (OR=0.54, 95%CI 0.30; 
0.98, p=0.042). Tale osservazione è compatibile con il fatto che ' HIV-1, che induce una 
traslocazione microbica e uno stato di persistente attivazione immunitaria, può portare a 
una replicazione di EBV ed ad una espansione di cellule B infette, aumentando di 
conseguenza il DNA dell'EBV. 
La co-infezione da EBV in soggetti affetti da HIV-1 può rappresentare un rischio 
addizionale per lo scatenarsi di tumori (linfomi) associati all’EBV. Il trattamento con 
ART, riducendo la replicazione dell’HIV-1, la traslocazione microbica e la relativa 
attivazione immunitaria, può prevenire la super infezione da EBV e mantenere la viremia 
EBV bassa, riducendo il rischio di linfomi ad esso associata. 
Studio 6:  
Studio retrospettivo per valutare la carica virale dell’HIV (VL) su campioni raccolti in 
DBS e per esplorare l'accuratezza dei criteri clinici ed immunologici per la definizione del 
fallimento terapeutico. La bassa sensibilità e valore predittivo del fallimento clinico e/o 
immunologico, da noi osservate, confermano quanto riportato in letteratura. Questa 
osservazione supporta ulteriormente la raccomandazione del WHO che il monitoraggio 
della carica virale debba essere implementato ed utilizzato per identificare precocemente 
casi di fallimento del trattamento. 
 
Implicazioni dei risultati della tesi e messaggi chiave 
Il modello assistenziale centrato sull’ assistenza domiciliare è risultato molto efficace per 
ridurre il rischio di perdita al follow up. Tale modello potrebbe quindi essere considerato 
anche per l’assistenza dei malati di TB o con altre malattie croniche.  
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Le nostre osservazioni supportano quanto già riportato in letteratura che l’inizio precoce 
dell’ART è era associato non solo  aduna migliore sopravvivenza ma anche ad un minor 
rischio di perdita al follow up.  
Il trattamento ART è potenzialmente protettivo contro patologie linfoproliferative 
correlate al EBV nei bambini con coinfezione da HIV ed EBV.  
L’uso del DBS per il monitoraggio della carica virale nei bambini HIV positivi si è 
rivelato fattibile sia da un punto di vista organizzativo che della qualità dei campioni da 
testare. Tale metodica dovrebbe quindi essere incoraggiata per migliorare la qualità della 
gestione pediatrica dell'HIV soprattutto nei paesi in via di sviluppo 
La bassa copertura di ART tra i bambini richiede un urgente, maggiore e più efficace 
decentramento dei servizi pediatrici centrali e la loro integrazione con i servizi sanitari di 
base a livello distrettuale e sub-distrettuale in Uganda. 
I bambini che presentino uno stadio avanzato di infezione HIV e coinfezione da TB 
dovrebbero essere sottoposti a monitoraggio più serrato per iniziare il trattamento ART 
appena ciò si renda necessario. 
Gli orfani necessitano un particolare attenzione sia per quanto riguarda il supporto 
nutrizionale che il monitoraggio clinico e immunologico necessario per iniziare 
correttamente la ART. 
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1.0. Brief overview of the HIV epidemic milestones  
This section of the literature review looks at some key milestones on the path of the HIV 
epidemic through time, as they contribute to the context within which this thesis project was 
developed. 
In 1981, the U.S.  Centers for Disease Control and Prevention (CDC) reported an outbreak of 
opportunistic infections and Kaposi’s sarcoma among a small number of homosexual men in 
San Francisco and New York in its weekly morbidity and mortality reports [1, 2]. A hallmark 
of the cases was severe immunosuppression, and the disease eventually became known as the 
acquired immunodeficiency syndrome (AIDS) [3-6]. Reports show that, the disease was also 
identified among injection drug users, patients with hemophilia, transfusion recipients and 
infants of infected mothers within the first year of its description [3, 7]. However, little did 
the world know that those cases would explode into an epidemic that would decimate 
populations around the globe.  
With the reporting of the first cases of Pneumocystis pneumonia and Kaposi’s sarcoma, 
scientists and researchers raced to find the cause of the disease and within two years, the 
human immunodeficiency virus (HIV) was identified as the cause of AIDS [2, 8]. With that 
discovery in 1983,  scientists and researchers switched gears to develop diagnostic tests and 
treatment for HIV/AIDS [9]. In 1985, the first test to diagnose HIV was licensed; the first 
International AIDS Conference was held in Atlanta (USA), and a National AIDS Response 
was launched in Uganda. A year later, the WHO launched the AIDS Control Programme [10, 
11].  By the mid-1990s, the first brands of antiretroviral drugs (ARVs) were available in the 
rich northern countries. In addition, those countries were able to implement preventive 
measures such as counselling and testing, condom distribution; risk-reduction programmes, 
for example, needle–exchange programmes and safe blood transfusions [9, 12]. Nevertheless, 
the HIV epidemic gained momentum and by the end of the first decade, about 10 million 
people had been infected, including a heterosexual epidemic affecting more women in 
Central Africa [2, 3].  
By the second decade, AIDS-related deaths started  declining in the advanced and resource-
rich  countries as well as a substantial reduction in mother-to-child HIV transmission. The 
situation was however, very different to other parts of the world [13]. Indeed, time, inaction, 
and the absence of ART / PMTCT intensified the epidemic in the high burden resource-
limited settings such as sub-Saharan Africa, resulting in one of the worst epidemics in recent 
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times; by all measures. It is reported that, in 2001, there were 36 million people living with 
HIV, some 20 million people had already died, and sub-Saharan Africa remained the 
epicenter of the HIV epidemic [14].  
As the global epidemic gained more attention, United Nations (UN) member states made a 
historic declaration of commitment on HIV/AIDS in 2001. That declaration led to what have 
become the global health initiatives (GHI), global partnerships and regional collaborations to 
respond to the epidemic. The Joint United Nations Programme on HIV/AIDS (UNAIDS) was 
set up to coordinate the global response to the HIV epidemic, in line with that declaration.  
That was soon followed by the Global Fund to fight AIDS, Tuberculosis and Malaria 
(GFATM), the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and the 
World Bank’s Multiple ART Programmes (MAP) for Africa. The UN political declaration on 
HIV/AIDS was revised in 2011 setting the targets for 2015 [12, 15-17].  
 By the third decade, ART / PMTCT became available in some resource-limited settings as a 
result of the GHIs [9, 12, 18]. However, new challenges soon emerged. Evaluation studies 
showed that, various set targets were either not met or could not be achieved principally 
because of weak health systems and shortages of professional health workers [19-21]. 
Additionally, many health systems in SSA countries are witnessing a demographic transition 
with high burdens of communicable and chronic non-communicable diseases [22-25].   
The fourth decade has seen some progress in all spheres of prevention, care and treatment [9, 
18]. In the last few years, researchers and scientists cautiously discuss possible ‘functional 
cure’ of HIV, as demonstrated by the cases of the Berlin patient [26], the Massachusetts baby 
[27, 28] and the Visconti cohort of France [29]. 
The HIV pandemic will certainly be remembered for the great devastation in terms of loss to 
human life and HIV-related morbidities. It will also be remembered for breaking down 
barriers and uniting communities, civil society, all kinds of leaders, activists, researchers and 
scientists to work together for a crucial humane cause,  resulting in a global solidarity and 
one of the most notable worldwide responses in modern times [9, 18, 30].  
1.1. Burden of HIV Disease 
Globally, 35.3 million (32.2-38.8 million) people were living with HIV by the end of 2012. It 
is estimated that, 2.3 million (1.9-2.7million) new HIV infections and 1.6 million (1.4-1.9 
million) AIDS-related deaths occurred in the same period. Overall, 10.6 million people 
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received antiretroviral therapy (ART), with 9.7 million (91.5%) in low- and middle-income 
countries (LMIC) in 2012, representing 61% of those eligible for ART according to the 2010 
WHO treatment guidelines. However, going by the 2013 WHO consolidated guidelines, this 
ART coverage only represents 34% (32-37%) of the 28.3 million eligible people in LMIC in 
2013 [31].  
Approximately, seventy percent of all people living with HIV were in SSA, including 1.4 
million (1.2-1.5million) pregnant women, 3.0 million (2.7-3.3 million) children less than 15 
years and 1.7 million of the global 2.1 million (1.7-2.8 million) adolescents aged 15-19 years. 
Among the adolescents, about two-thirds of the new infections were among girls aged 15-19 
years. SSA recorded 210,000 new HIV infections with women making up 59% (56–63%), 
97,000 AIDS-related deaths among adolescents aged 10-19 years and about 85% of the 17.8 
million (16.1-21.6 million) AIDS orphans [11, 32, 33].  
 Globally, by the end of 2012, there was a 35% decline in new infections among children 
aged less than 15years compared with 2009. In the same period, 260,000 new infections 
occurred among children less than 15years in LMIC in 2012, whereas 850,000 new infections 
were averted in the same age group between 2005 and 2012 in LMIC. Only 39% of infants 
were tested for HIV within two months of birth in 2012 in LMIC. Additionally, the majority 
of children diagnosed with HIV in 2012 did not start ART, resulting in 210,000 (190,000-
250,000) AIDS-related deaths among children. Furthermore, children under 15 years old who 
needed ART were less likely than adults to receive it. That is a major concern, as in the 
absence of timely initiation of ART, one-third of infants living with HIV will die before their 
first birthday, and more than half will die before the age of two years [11, 31, 34]. 
Overall, ART coverage for children aged less than 15 years was 34% compared to 64% in 
adults in LMIC. Whereas the coverage for PMTCT reached 62% in the 22 Global Plan 
Priority countries, compared with 57 per cent in 2011 and 49 per cent in 2010  [21, 32].   
 
In Uganda, the national HIV prevalence was 7.3%  (6.4-8.4%) among adults aged 15-49years 
in 2012, and an estimated 1.5 million (1.4-1.8 million) people were living with HIV, 
including 100, 000 (88,000-120,000) pregnant women, and 190,000 (160,000-230,000) 
children aged less than 15 years, approximately 58% of whom needed ART. ART coverage 
was 33% (28-41%) for children aged less than 15 years, 70% (64-78%) among adults and 
72% (62-82%) for PMTCT. Adolescents aged 10-19 years made up 24.5% of the total 
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population and 7% of all people living with HIV in the country. About 10.0% (6,300)of all 
AIDS-related deaths were among adolescents aged 10-19years in that year [31, 32, 35]. 
 
1.2. Global Trends in new infections and AIDS-related deaths among children adolescents 
and young people 
!
Figure! 1:" Estimated! number! of! new! HIV! infections! in! children! (aged! 0–14):! Global! trend! and!
projections,!2001–2015!
"
Figure 1 above, shows an important decline in new HIV infections in children aged 0-
14years. The trajectory of the projected trend provides even steeper decline during the period 
between 2012 and 2015, the timeline for achieving the Global Plan target of 90% reduction in 
new infections. The observed trend is encouraging and most likely due to the impact of 
PMTC.  
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Figure! 2:! Estimated!number!of! new!HIV! infections! among! children! aged!0–14,! adolescents! aged!
15–19!and!young!people!aged!20–24,!2000–2012!
"
"
Figure!3:!Estimated!number!of!AIDSLrelated!deaths!among!children!aged!0–4,!younger!adolescents!
aged!10–14,!older!adolescents!aged!15–19!and!young!people!aged!20–24,!2000–2012!
"
Overall, the global trends in Figures 1 and 2 illustrate declines in new infections in children, 
adolescents and young people. Although Figures 3 shows declines in AIDS-related  deaths 
from 2004 onwards for age groups 0-4, and young people aged 20-24 years, AIDS-related 
deaths are gradually increasing among adolescents (10-19 years). The literature reports of 
barriers to HIV treatment access for adolescents, including increased vulnerability and may 
be contributing to the increased deaths among adolescents.  
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On the other hand, despite the slow increase in ART coverage among children aged, 0-
14years, AIDS-related deaths have declined most probably due to the impact of PMTCT 
programmes. By lowering the levels of viral loads within populations, ART is slowing down 
HIV transmission [32] and directly promoting survival through treatment. 
1.3. Paediatric HIV and co infections 
Studies have consistently shown that, the intertwined relationship between HIV infection and 
other co infections, such as tuberculosis, malaria, hepatitis, Epstein - Barr virus (EBV) or 
herpes virus infection, have a great impact on immune response, treatment efficacy and 
correct diagnosis. This is particularly important in infants and young children living in 
resource-limited settings where disease epidemiology widely differs from western countries 
[36-39]. 
The highest TB incidence rates occur in sub-Saharan Africa and South-East Asia where 
antenatal HIV prevalence is high and interventions to prevent mother-to-child transmission of 
HIV infection are not widely implemented. The literature also documents that infants and 
young children of less than three years are particularly at risk of developing TB disease 
following exposure [40-42]. Apart from HIV infection; other important risk factors for 
acquisition of TB infection and disease in children include poverty, overcrowding and 
malnutrition. With this background, current research in paediatrics in high burden countries 
aims at optimizing co treatment and the use of Isoniazid preventive therapy (IPT) to cure 
latent tuberculosis, while working towards the identification of context-appropriate 
approaches for intensive case finding (ICF) [43, 44].  
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2.0. Overview of Uganda Health Outcome Indicators: the Health Systems 
Reforms   
The HIV epidemic has put the spotlight once more on the health systems in high-burden 
resource-limited settings, including Uganda. This section, therefore, presents an overview of 
the health systems reforms that were pursued in the post-conflict era and their relevance to 
current health outcomes, the national response to the HIV epidemic and health system 
strengthening in the Uganda. 
2.1. Background to Uganda Health Systems Reforms   
Prior to independence from Britain in 1962, Ugandans depended mainly on traditional 
medical practice (non-western) for their health care needs. After independence, Uganda 
inherited a colonial health system that needed expansion in terms of capacity, redesign and 
strengthening to meet the health needs of the growing population. Consequently, several 
hospitals and health centres were built throughout the country. That initiative was 
accompanied by the setting up of medical training institutions, resulting in more native 
Ugandans being trained in the allied health sciences from within the country. However, 
political and economic upheavals led to the collapse of the health system and many services 
in the1970s and 1980s. For instance, government funding was chronically insufficient, 
leading to late and meager salaries for health workers, permanent shortages of drugs and 
supplies and worn-out  health infrastructure. That situation triggered an exodus among 
professional health workers; and traditional medicine once more became the main form of 
health care [45-49]. 
The quest for solutions encouraged Uganda to embrace the concept of primary health care 
(PHC) following the WHO’s Alma Ata Declaration in 1978. Like many other developing 
nations, Uganda adopted a ‘selective PHC’ due to scare resources. However, implementation 
of the PHC concept was not as effective as expected and only minimal improvements were 
achieved in health services delivery [50-52].   
Even though, the HIV epidemic affected almost every sector, the health sector bore the brunt. 
Like in other countries with high HIV burden, the health system in Uganda was faced with 
increased demands for services, translating into increased workloads for health workers, 
aggravating an existing HRH crisis, and increased pressure on health infrastructure. On the 
other hand, the GHIs brought in significant resources, including funding into the health 
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sector, but such funds were often channeled through projects that operated parallel health 
systems [14, 30, 53, 54].  
2.2. Rationale for the health systems reforms 
Indeed, the poor health indicators in the 1980 /90s and inefficient use of scarce resources 
prompted the government of Uganda (GoU) and development partners to embark on an 
extensive health system reform to improve the performance of the sector. For example, a 
large proportion of the government budget (66 % in 1999/2000) was allocated to large 
hospitals and the central ministry of health (MoH), whose activities did not benefit the district 
health facilities providing primary care for the large population of the rural poor [55]. 
Although international donors provided the greater part of development assistance to Uganda, 
donor projects had high overheads, focused on investment goods, and were inefficient in 
providing basic health care inputs. User fees did not raise appreciable revenue as intended, on 
the contrary, they became a significant barrier to the poor in accessing health care services, 
and exemption policies failed to protect the vulnerable populations [47].  Additionally, the 
disproportionate allocation of health budgets with urban biases left meager funds for basic 
health care inputs such as medicines, health workers’ salaries and health facility maintenance 
in the rural areas, where ~84% of the population lives. Furthermore, the HIV epidemic 
exposed the fragile linkages and weaknesses within the health system and presented another 
reason for health systems strengthening [56-59].  
2.3. The Uganda Health Systems Reforms 
The reforms were implemented from the year 2000 and included the following:  
-The sector-wide-approach (SWAp) reform that was characterized by government ownership 
and a holistic platform for the coordination of development assistance for the health sector 
with emphasis on: policy design, strategic and operational management, pooling of  financial 
resources, overall resources allocation and common arrangements for monitoring and 
evaluation. The blueprint for the SWAp was the Health Sector Strategic Plan (HSSP) of 
2000/01 - 2004/05, which has been revised and updated over the years [60-62]. The 
principles governing this reform were described in a memorandum of understanding (MoU) 
between the government of Uganda (GoU) and development partners. They encouraged 
government development partners to align their support for a common government-led 
‘basket funding’ mechanism. The main goal of the SWAp was to improve the performance of 
the health systems [63-65]. 
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-Abolition of user fees in public health facilities: this triggered an immediate increase in the 
utilization of out-patients’ services in government public health facilities as well as private-
not-for-profit (PNFP) facilities [66]; 
-The Medicines’ reform improved management systems, particularly in the finance, purchase 
and supply of drugs and medical supplies [67]; 
-Public-private partnerships reforms brought on board private providers and harnessed some 
of the potentials of the private health sector [68]; 
-Decentralization of health services delivery reform: It led to more resources and capacity 
building to strengthen district health systems [69]; 
-Improved resources allocation: larger shares of resources were allocated to district PHC 
services, as well as PNFP providers [55]; 
-Health financing reform: donors switching from project-based funding to budget support  
and less reliance on user fees [47, 70]; 
-Political leadership: the roles of the president, ministers of health and finance in working 
towards and through the reforms [47].     
 2.4. Results of the health systems reforms in Uganda 
Overall, the findings from evaluating the impact of the reforms suggest that there have been 
improvements in all four key functions of the health systems according to the WHO 
definition; notably, stewardship, service delivery, resource generation and financing. As an 
illustration, GoU budget for the health sector increased by a modest 18% during the reforms 
[47].   
Apart from being a reform on its own, the SWAp served as a catalyst that provided the 
needed platform, management systems, processes and mechanisms to facilitate the other 
reforms that were launched concurrently in the country. Hence, it could be argued that, the 
SWAp may have contributed directly and indirectly to the post-reforms health outcomes and 
indicators. 
Even though, the abolition of user fees was associated with an immediate increase in the 
utilization of ambulatory health services at the GoU public health facilities and the PNFP 
units (Figure 1), there were also issues with quality of services. Drug stocks-outs were 
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frequent at many public facilities resulting in clients seeking health care at private facilities, 
including the poor. On the contrary, financial support from the GoU to many PNFP facilities 
enabled them to reduce user fees, to some extent, while continuing to provide some of the 
basic drugs and medical supplies. That scenario encouraged an increase in demand of their 
services. Similarly, the medicines' reform was associated with an increased demand for 
services. That observation has been linked with the notion that having drugs at health 
facilities signifies quality in the health services. However, that state of affairs was soon 
replaced by persistent drug stock-outs leading to shorter and fewer notable effects of the 
reform, particularly in the rural areas [71-73].   
In terms of maternal and child health, the results showed stagnation of maternal health 
outcomes and minimal improvement in infant mortality rates. They fell below the United 
Nations’ millennium development goals (MDGs) targets as depicted in Table 1 and Figure 3). 
An important product of the SWAp was the tracking studies. They played vital roles in 
monitoring and evaluation in addition to providing evidence to inform policy and decision-
making. This was particularly important to the case of the flow of funds from the central 
ministry to the peripheral health systems and drugs and other medical supplies. 
 
Table 1: Stagnating health outcome indicators in Uganda in the 1990s  
Indicator 1995 2000 PEAP1 
Target 
(2005) 
MDG2 
Target 
(2015) 
Infant Mortality Rate 
(Deaths <1 year per 1000 live births) 
 
81 
 
88 
 
68 
 
41 
Maternal Mortality Rate 
(Deaths per 100,000 live births) 
 
527 
 
505 
 
345 
 
131 
Source: Tashobya et al (2006): Health Systems Reforms in Uganda: processes and outputs 
1Poverty Eradication Action Plan.,     2Millennium Development Goal. 
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Figure 4: Utilization Rates of New Outpatient Attendances in Government of Uganda 
and Private-Not-For-Profit Health Units 
 
Source: Tashobya et al (2006): Health Systems Reforms in Uganda: processes and outputs 
 
 
Figure 5: DPT3 Immunization Rates DPT3 for Children under One Year 
 
Source: Tashobya et al (2006): Health Systems Reforms in Uganda: processes and outputs 
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Figure 6: Proportion of Babies delivered in Government and Private-Not-For-Profit 
Health Units 
 
Source: Tashobya et al (2006): Health Systems Reforms in Uganda: processes and outputs 
 
Figure 7: Government of Uganda Budget Allocations for Medicines 
 
Source: Tashobya et al (2006): Health Systems Reforms in Uganda: processes and outputs 
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Figure 8: Government of Uganda Budget Expenditure and Total Outpatient 
Attendances 
 
Source: Tashobya et al (2006): Health Systems Reforms in Uganda: processes and outputs 
 
2.5. Uganda Health Systems Outcomes: a decade after reforms (2013) 
  
o Per capita out patients department (OPD) utilization rate was 1.1 above the annual 
HSSP target of 1.0 but less than the 1.2 in 2011/12. 
o According to the Uganda Demographic Health Surveillance of 2011, Maternal 
Mortality Ratio (maternal deaths per 100,000 live birth) increased from 
o 435/100,000 to 438/100,000 
o 31% of pregnant women attended 4 ANC sessions in 2012/13. HSSP target 55% for 
2012/13. 
o 41% of pregnant women delivered in health facilities. HSSP target 65% for 2012/13. 
 
o Infant Mortality Rate (per 1,000 live births) was 54 
 
o 87 % of children less than one year old were immunized with 3rd dose pentavalent 
vaccine (DPT3). HSSP 2012/13 target (85%) 
 
o 13.5% (228) of health facilities experienced drug stock-outs in 2012/13 
 
Source: MoH Uganda, Annual Health Sector Performance Report 2013 
 
2.6. Have the reforms contributed to improve health outcome indicators? 
Approximately 10 years after the health reforms, many of the indicators listed above have 
maintained positive trends compared to the baseline values reported in Table 1 and Figures 1-
4 above. For instance, per capita OPD utilization rate has increased steadily from 0.42 in 
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2000 to 1.1 in 2012/13. Similarly, DPT3 for children under one year old increased from 41% 
in 2000 to 87% and above the HSSP target of 85%; the proportion of pregnant women who 
delivered at health facilities increased modestly from 25% in 2000 to 41% in 2012/13 but 
24% points below the HSSP target of 65%. Although maternal mortality rate decreased from 
505/100,000 live births in 2000 to 435/100,000 live births in 2011/12, it increased to 
438/100,000 live births in 2012/13. Infant mortality rate stood at 88/1000 live births in 2000 
and decreased slightly to 54 in 2012/13. The pace of decline remains well below the targets 
for MDG 4 and 5.   
 With respect to drug stock-outs, 13.5% of health facilities experienced drug stock-outs in 
2012/13.  
Generally, the recent health outcome indicators may be described as a ‘mixed bag’ when 
compared to the post-reforms outcome indicators of 2000/01. As shown above, the changes 
in maternal deaths and infant mortality have been very minimal and at a very slow pace or 
near stagnation. 
Additionally, some gains of the reforms appear to have been reversed over the years. Recent 
studies report of the re-introduction of user fees at some public health facilities and persistent 
shortages of drugs and basic supplies virtually at all levels of the health systems [70, 74-77]. 
With these findings, one wonders if the Medicines reforms and decentralization of health 
services to district and sub-district levels have been effective.  
Undoubtedly, the reforms established policy frameworks, developed partnerships, and 
brought about coordination, important mechanisms, and development of processes and 
systems. As an illustration, the SWAp processes literary ‘redefined’ health funding as they 
promoted coordination of international donor and partner aid for government budget support 
and overall resource allocation to the health sector. These measures and the resultant 
synergies may have facilitated the implementation of the different specific reforms.  
In conclusion, the health reforms in Uganda raised awareness and provided vital inputs for 
the health sector resulting in improvements in some service delivery as reflected in some 
health outcome indicators. However, recent studies show that maternal and infant mortality 
figures have not improved much after the reforms. In addition, some gains of the reforms 
appear to have been eroded.  
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2.7. Have the Uganda Health Reforms contributed to the National AIDS Response? 
While the global response to the HIV/AIDS epidemic may have exposed the weaknesses of 
the existing health systems, it has also galvanized concerted efforts to deal with systemic 
challenges such as HRH crisis, physical infrastructure, drugs and supply chains as well as 
health financing and health information systems [56]. 
Uganda adopted a multi-sectoral approach to its national AIDS response. The response 
combined prevention, care and treatment with impact mitigation in line with the global and 
African AIDS responses [3, 78-80]. The impact mitigation component focused largely on 
poverty eradication programmes as the impact of the epidemic is experienced most severely 
at the household level where it exacerbates poverty [81-83].   
The health systems reforms established policy frameworks, brought in huge funding mainly 
from international donor sources and developed systems as described earlier. These in turn 
facilitated the establishment of the pillars of the national AIDS response. In a chronological 
order, the pillars included:  
 1986, formation of the AIDS Control Programme, 
 1987, creation of the AIDS Support Organisation (TASO) and other community 
home-based programmes (CHBC) such as Kitovu Mobile HIV programme and 
Nsambya Home Care to support people living with HIV, 
 1988, establishment of a number of research collaborations between Ugandan and 
international university partners  including Medical Research Council Uganda; the 
Makerere University- Johns Hopkins University  Research Collaboration and  the 
Joint Clinical Research Centre (JCRC) to conduct HIV/AIDS-related research.  
 1992, establishment of the  AIDS Information Centre (AIC) to provide voluntary 
counselling and testing services; the Uganda AIDS Commission (UAC) to coordinate 
the multi-sectoral response to HIV and the multi-sectorial National Operational Plan 
and HIV/AIDS Policy Guidelines, 
 1993, formation of the multi-sectoral National Operational Plan (NOP) and 
HIV/AIDS Policy Guidelines, 
 1997, development of a Five-year National Strategic Framework (NSF) for 
HIV/AIDS that was extended to 2005 and 
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 2007/2008- 2011/2012, Implementation of the national HIV prevention strategy, 
within in the National Strategic Plan for HIV/AIDS (NSP) [9, 11, 18].  
 
According to the UNAIDS’ Benchmark study and some reports, the Uganda AIDS response 
has made appreciable progress, but much remains to be achieved. A few selected response 
outcomes show that in 2012, Uganda had ART coverage of 33% for children aged less than 
15 years, 70% among adults and 72% for PMTCT (please see under HIV burden of disease, 
p29.paragraph 3). Safe male circumcision (SMC) coverage was 11% as of December 2012 
[31, 78, 84].  
Generally, the Uganda National AIDS response has been  characterized by strong political 
commitment, supportive policies, open dialogue, involvement of religious and community 
leaders, multi-sectoral and decentralized interventions and coordination, with emphasis on the 
involvement of local communities, investment in research and impact mitigation [85, 86]. 
Nonetheless, the gains of the Uganda National AIDS Response may be threatened by several 
factors. The recent Uganda Demographic and Health Survey (UDHS) in 2011 showed that 
HIV prevalence has increased from 6.4% in 2004 to 7.3% in 2011 [87]. This observation 
shows that treatment access has improved and even if incidence remained the same, or 
reduced a bit, prevalence would still go up as more people are surviving because of ART. 
Additionally, there may be issues with behavioural change campaign activities, and lack of 
resources. Although the policies appear elaborate, the national AIDS response does not seem 
to have adequate provisions for key populations such as commercial sex workers (CSW), 
men who have sex with men (MSM), prisoners and injection drug users (IDU) who have the 
potential to sustain or drive the epidemic for a longtime. There are already signs of donor 
fatigue especially in the wake of the global financial crises [88, 89]. As illustrated under the 
reforms, GOU budget increased was a modest 18%, which may not be sufficient to continue, 
expand and sustain the national response for a considerable period.  
To conclude, the Uganda health reforms set the stage for the establishment of the pillars of 
the national response, which in turn facilitated the strategies used to implement the various 
interventions. As illustrated by the literature, significant progress has been made, but future 
progress will depend on greater inclusion of key populations, substantial increment in GoU 
budget support for the national response and dealing with the low ART coverage for children, 
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the slow pace of SMC, persistent shortages of drugs and medical supplies and emerging 
challenges.  
2.8. Have the health reforms strengthened the Uganda health systems? 
The WHO defines health systems strengthening as building capacity in critical components of 
health systems (policy, funding, human resources, service management and information and 
monitoring systems) in order to achieve more equitable and sustained improvements across 
health services and improved health outcomes [57, 90]. 
The results of the Uganda health reforms were associated with GoU leadership, stewardship 
roles, responsiveness and some improvements in service delivery all of which contribute to 
health systems strengthening. As shown under the national AIDS response, the reforms 
established vital policy guidelines, provided platforms, developed processes and mechanism 
and coordinated resources that resulted in the re-organization of health service's delivery.  
Specifically, the abolition of user fees, decentralization of health services to primary care 
facilities at the district and sub-district levels, medicines reform and HRH and infrastructural 
development interventions seem to have promoted financial and geographical accessibility to 
some extent.  
Nevertheless, recent studies from Uganda and elsewhere have demonstrated that, access, 
equity and coverage for health services remain important challenges, and that implementation 
of the health reforms may have inadvertently resulted in impoverishing care as well as 
fragmented care [91-95]. Indeed, in the absence of adequate health insurance, there are  
catastrophic out of pocket (OOP) health expenditures for households that on average has been 
quoted as 54% of total health expenditure  [74, 96],  for a setting where 38% live below the 
poverty line [47]. The recent renewed interest in project-based funding by powerful GHIs 
could mean reversing of international donor support for government budget and weakening of 
the SWAp initiatives. The re-introduction of user fees in public health facilities [59] and the 
persistent shortages of drugs including ARVs, anti-tuberculosis drugs and essential or basic 
drugs, raise questions about the effectiveness of the related reforms. Additionally, the reforms 
have been associated with paradoxes. As an illustration, the post-reforms results showed that, 
there were trained health workers who could not be employed because of some policy 
decisions. Moreover, in the district and sub-district levels, the reports mention a mismatch 
between health infrastructure development and the planning of health services, vis a vis, the 
availability of health workers. Consequently, there were newly constructed health 
43"
infrastructure at the sub-district levels that were underutilized [73, 97]. Finally, the data 
management system is weak, fragmented and unable to provide real-time warning advice 
[98]. 
In conclusion, the health systems reforms were timely and created favourable conditions that 
channeled a wide range of resources into the health sector and contributed to health systems 
strengthening in one way or the other. About a decade after the reforms, stock-outs of drugs 
and medical supplies and issues with access, equity and coverage for various health services 
remain.  
The renewed interests in GHIs call for collective efforts towards effective and functional 
decentralization of vertical programmes such as HIV voluntary counselling and testing, ART 
prescription and refills, PMTCT/EID and TB services by integration at the primary care level. 
Such an approach could promote geographical accessibility especially for the rural majority 
and indirectly, universal access. However, the success of such a measure will depend among 
other factors on the availability of polyvalent health workers, motivated, regularly trained and 
supervised at the primary care level. Some of the countries that have successfully followed 
such a path include Swaziland, Mozambique and Cambodia [99-101].   
2.9. Challenges to the Uganda health reforms 
 The renewed interests in project-based funding by powerful GHIs have potentially 
destabilizing effects on the SWAp processes and mechanisms. The quest for rapid 
results could mean a return to priority disease-specific interventions that may have 
geographical biases. Clearly, such approaches lead to parallel systems with high 
administrative costs and inefficiencies, fragmentation and duplication of efforts, none 
of which support health systems strengthening, as defined by the WHO. 
 The SWAp was a unifying mechanism and a catalyst for other health reforms, but 
because of this intrinsic influence it was difficult to disentangle the impacts of other 
reforms implemented simultaneously, 
 Reliance on aid funds raises concerns about predictability and sustainability of the 
flow of aid funds into the country in an era of global financial crisis, 
 an important limitation of the analyses of the health outcomes following the reforms 
was the use of intermediate measures of performance because demographic and health 
statistics are collected every five years in Uganda, 
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 another limitation was the relatively small number of indicators used in the immediate 
post-reforms analyses, which raises issues with extrapolation of the outcomes, 
 furthermore, the zeal for the reforms seems to have waned over the years, for instance 
the tracking studies that  tracked progress through periodic monitoring and 
evaluations have either stopped all together, or are being pursued with little interest. 
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3.0. Evolution of Complementary HIV service delivery models (CHIVSDM) 
Complementary HIV service delivery models (CHIVSDM), as the name suggests are various 
approaches aimed at providing a wide range of support to households and communities 
infected and affected by the HIV epidemic. Such models may be owned by local people, for 
example, The AIDS Support Organization (TASO) of Uganda, local and or international 
faith-based organizations and local or international non-governmental organizations (NGOs) 
collaborating with local communities or health institutions. In terms of structural design, they 
may be community-based, comprehensive home-based care (HBC), community and home-
based care, facility-based with community outreach clinics or various configurations dictated 
by their missions, visions and objectives. CHIVSDM may operate within existing health 
facilities, serves as bridges between traditional health facilities and community initiatives or 
operates as ‘stand-alone’ community-based models at the community levels. [83, 102, 103]. 
The services provided by such initiatives cover a wide range and are often dictated by their 
objectives and more importantly, available resources. Generally, the services include, pre-
enrolment care like, VCT, pre and post-test counselling, linkage to care and treatment, follow 
up while in care or on treatment, psychosocial support (various form of counselling, material 
assistance, including food supplements, assistance for income generating ventures and 
orphans and vulnerable children support programmes). Additionally, some organizations 
provide orphans care, palliative care, and community volunteer support and participate in 
HIV-related research [104-106]. 
Apart from developing their own infrastructure or  ‘nesting’ in traditional health facilities, an 
enabling feature that appears to be common to many of these CHIVSDM is their ability to 
use existing community resources such as public places (e.g. markets and church premises) 
and engaging non-professional health workers through task shifting to provide HIV/TB 
services. This innovative approach does not only overcome some of the shortages of health 
infrastructure and professional health workers,  but it also provides some basic services 
relatively closer to communities thus promoting geographical accessibility at the same time. 
As illustrations, a local NGO, Uganda Cares operates an HIV clinic within the Balekudembbe 
Market in Kampala, while the Home Care Department of Nsambya Hospital operates 
outreach clinics on the premises of Christ-The-King and Ggaba parishes in Kampala under its 
community and home-based care HIV service delivery model. These approaches often 
complement their workforce by engaging PLHA as expert patients or as community 
46"
volunteers in task shifting. The mother-2-mother peer-support for PMTCT  is a special case 
where HIV positive mothers who have experienced PMTCT are trained as mentors to support 
other HIV positive women in PMTCT interventions (from antenatal care through delivery to 
post-delivery care) by offering counselling, home visits and other forms of psychosocial 
support such as adherence support. The literature suggests these initiatives are culturally 
acceptable [99, 107, 108]) and some have been recognized both nationally and internationally 
with policy guidelines to support, monitor and regulate their operations. A case in point is the 
community and home-based care HIV service delivery model in Uganda [109]. 
CHIVSDM may have evolved in response to the HIV epidemic in many resource-limited 
settings, particularly settings with high HIV disease burdens. However, the literature presents 
considerable variations in their structural compositions, objectives (some overlapping), scope 
and reach, as shown above. These findings seem to suggest that, the various CHIVSDM may 
not have all evolved from a particular design but rather spontaneously with respect to 
contextual needs. It is also possible that some modifications have occurred over time 
reflecting changes in trends in service provision, as dictated by the available resources and 
programme objectives.  
3.1. Community Home Based-Care HIV service delivery in Resource-limited settings  
 
Community and Home-Based Care includes any form of care (physical, psychosocial, 
palliative and spiritual) given to the sick and the affected in their own homes and care 
extended from the hospital or health facility to their homes through family participation and 
community involvement [110, 111]. CHBC has also been defined as the care given to an 
individual in his/her own environment (home) by his/her family and supported by skilled 
welfare officers and communities to meet not only the physical and health needs, but also the 
spiritual, material, and psychosocial needs [103]. Generally, CHBC has been described as 
“the programme that offers health care services to support the care process in the home of the 
HIV infected person”.[112].  
The global scaling-up of ART has undoubtedly saved or prolonged the lives of millions by 
transforming HIV/ AIDS: a deadly disease into a manageable chronic condition. This positive 
impact comes with additional challenges for the already weak health systems in SSA. Some 
of the challenges include: the worsening of the HRH crisis (please see literature review on 
‘HRH and Task shifting’ below), exacerbation of pressure on health infrastructure, and the 
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need for  innovative healthcare delivery approaches to maintain a large and growing 
population of PLHA on ART for life [113-115]. 
The impact of the HIV/AIDS epidemic on healthcare delivery systems in SSA [116-119] has 
indeed demonstrated that, the traditional healthcare delivery model; the facility-based model, 
needs modification, strengthening and an extended service delivery capacity to provide and 
ensure continuity of care, for a large and growing population of PLHA in their homes and 
communities beyond the traditional health facilities. 
In 1987, home care programmes, providing a variety of services to PLHA and their families 
were developed in Africa. In 1989, the World Health Organization’s (WHO) Global 
Programme on AIDS conducted a descriptive study of six programmes selected from Uganda 
and Zambia. The objective of the study was to learn lessons from those programmes that 
could be used and adapted by policymakers and programme planners in their own settings 
when deciding on "their" model of home care [120].  
Various configurations of Hospital-outreach HBC models were the first to be established but 
these were costly and unable to provide the types of non-medical services needed by large 
numbers of clients in the communities. Five additional models of CHBC programmes have 
been developed. They include : NGO-based, Faith-based, Community-rooted, Support groups 
for PLHAs and Self-help groups” [83].  
CHBC is culturally acceptable to the communities and mitigates some important challenges 
such as: distance, transport costs to health facilities and the opportunity costs of time spent to 
seek health care at health facilities. A Cochrane systematic review [121] found in two studies 
from Uganda and Zambia, very high acceptability and uptake of VCT when testing and or 
results were offered at home, compared to the standard (facility-based testing and results). A 
study from Botswana [122], documented an increase in community home-based care (CHBC) 
following a shift from hospital care to CHBC because of the HIV/AIDS epidemic. However, 
there is the need for CHBC programmes to strengthen the capacity of the home and 
communities to care for PLHA by building on traditional family structures which support all 
chronically ill people [123].  
The CHBC model has demonstrated the potential to extending health care delivery services 
beyond the traditional health facilities to PLHA in their homes and communities. This is a 
potential for the design of Chronic Disease Management Model in resource-limited settings, 
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and it is crucial that such a model integrates the management of other chronic diseases like 
TB, hypertension (HPT) and Diabetes in HIV/AIDS management. Various studies [124-127] 
have shown that, such an approach would not only minimize stigma to HIV and TB patients 
and improve treatment outcomes, but also avoid further fragmentation of health systems; 
characteristic of vertical programmes and promote Health Systems Strengthening.  
CHBC may be promising but there are also significant challenges. Although recognised, 
currently, CHBC does not appear integrated in the government healthcare delivery systems 
and remains mainly an initiative of NGOs, missionary institutions and faith-based 
organizations with little or no support from governments, which also explains the very low 
coverage with respect to the burden of HIV/AIDS [128].   
3.2. CHBC and Health Systems Strengthening: bridging the gaps in the health systems in 
resource-limited settings including Uganda 
 As the number of PLHA increases, the gap continues to widen between the demand for, and 
the availability of health care services. Relying mainly on the family and community as 
caregivers, community home-based care (CHBC), has become a significant contributor in the 
treatment, care and support of those infected and affected by HIV/AIDS [103]. CHBC 
provides an approach that goes beyond the traditional facility-based health service delivery to 
response to the demand of the growing population of PLHA in their homes and communities, 
thus, maintaining the continuum of care [56].  
Infrastructural limitations have often dictated the capacity or scope of services that could 
be delivered at health facilities [129]. By adopting the CHBC model, communities can 
provide PLHA with basic services such as VCT, palliative care and ART refills through 
outreaches closer to their homes.  Additionally, the literature demonstrates that CHBC   
reduces bed occupancy rates in hospitals, that in turn benefits patients and their families and 
contributes to decongesting the health systems [111, 130]. 
Appointment systems and ambulatory clinics have proven suitable and vital for stable 
patients on therapy.-This means that with basic infrastructure vital services could be provided 
and perhaps at even lower costs to clients [131]. According to the WHO Global TB Report 
for 2010, in ensuring community involvement in TB care and prevention, community-based 
approach was 40-50% more cost-effective compared to the traditional facility-based 
approach[132]. 
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HRH crisis and Task shifting: as shown under the literature review on ‘HRH crisis and 
Task shifting’ below, the concept of Task shifting neither started with HIV nor is it confined 
to HIV. However, the HIV epidemic has made Task shifting perhaps more visible through an 
explosion of publications linking Task shifting in HIV care and ART programmes globally. 
Some of the headlines that highlighted the crisis are captured below: 
1. “Help Wanted”[133], 
2. “The real challenges for scaling up ART in sub-Saharan Africa”[134], 
3. “Task shifting for antiretroviral treatment delivery in sub-Saharan Africa: not a 
panacea”[135], 
4.  “Scaling up access to ART programmes in Southern Africa: who will do the 
job?”[136], 
 
5. “Task shifting: rational redistribution of tasks among health workforce teams: Global 
recommendations and guidelines”[137]. 
 
Perhaps, among other things, Task shifting may have made a difference between 
implementing and not implementing important HIV programmes in many high-burden 
resource-limited settings with critical HRH shortages.  
Promoting geographical access to services: outreach services and community-based 
programmes are practical ways of expanding access to care at the periphery of health systems 
and promoting universal access at primary care levels. The CHBC  takes services closer to 
clients and somehow deals  with some of the challenges of geographical accessibility and 
mitigates the opportunity costs  of long waiting times at health facilities [116, 138]. VCT in 
the communities and home delivery of results have often resulted in improvements in the 
uptake of those services [139].  
WHO Reports and independent studies have demonstrated that community involvements in 
chronic diseases management are often associated with improvements in outcomes.  Uganda 
is one of the 22 high-burden countries with respect to TB and provides an example. In 1990, 
the country implemented a community-based TB care (CBTBC) strategy to promote access to 
TB services. By 2002, it had achieved 100 percent DOTS population coverage.  That  
achievement led the Ministry of Health (MoH) to formally adopt the community-based TB 
care (CBTBC) strategy in the country [40, 104, 140].  
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 The CHBC framework has crucial components in the communities that promote 
decentralization of ART, TB and other chronic disease services in primary care. That feature 
makes CHBC a vital model for community and public health interventions. In 2008, the 
WHO described community-directed treatment of Onchocerciasis (river blindness) as one of 
the most successful public health campaigns ever conducted in the developing world. 
Recently,  community involvement in Brazil’s HIV treatment programmes has been reported 
to yield visible impacts [23, 141].  
Several studies in Uganda and other high-burden resource-limited settings have shown that 
HIV-infected patients managed in community-based approaches were more likely to achieve 
viral suppression, have better adherence, better retention and survival outcomes, when 
compared to patients managed at hospitals. In addition, community-based programmes were 
slightly more cost-effective compared to patients treated in a hospital setting [142]. 
From the foregoing points and findings from Paper1, clearly,   the CHBC model has the 
potential to integrate and decentralize interventions to support community or public health 
approaches, which is crucial for both  chronic disease management and  health systems 
strengthening in resource-limited settings [111, 143].  
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4.0. Literature review on HRH crisis and Task shifting  
Africa has 12% of the global population, 24% of the global disease burden, only 3% of the 
global workforce and commands less than 1% of the world health expenditure [144, 145]. 
Africa remains the global epicentre of the AIDS epidemic, and sub-Saharan Africa (SSA) 
with an adult HIV prevalence of 5 % (4.7%-5.2%) is the region with the largest AIDS burden 
[31, 146].  
The 2006 World Health Report estimated that there was a global health workforce deficit of 
more than four million trained health care workers. The deficits in many of the countries of 
SSA, and in parts of Asia and the Americas were critical. The report also documented that 
thirty-six of the fifty-seven countries with critical shortages of HRH were in SSA. For 
instance, from 2005-2010, Africa had a health workforce density of 2 physicians and 11 
nurses and midwives per 10,000 of people, and Malawi’s shortage of health workers was so 
extreme that there was only around one doctor for every 10,000 people [144, 145, 147].  
In 2000, the United Nations Millennium Development Goals (MDGs) initiative was set into 
motion [148, 149]. The initiative soon triggered a global reaction among world leaders. 
Subsequently, in 2001, leaders from 189 United Nations member states met in an historic 
session of the United Nations General Assembly to adopt the Declaration of Commitment on 
HIV/AIDS. The declaration aimed at providing comprehensive, time-bound targets for the 
delivery of effective HIV prevention, treatment, care and support needed to stop as well as 
mitigate the impacts of the global epidemic by 2015 [15, 150]. With time, the declaration 
galvanized the transformation of international response into Global Health Initiatives (GHIs) 
[3]. 
Consequently, in December 2003, the WHO’s “3 by 5” initiative was also launched[90]. 
Other partners such as the Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM) 
[151, 152], The United States President’s Emergency Plan For AIDS Relief (PEPFAR) [153], 
and The World Bank’s Multi-country AIDS Programme for Africa (MAP) [16] soon 
followed suite in providing resources for the mass scaling-up of ART/PMTCT services. 
Primarily, the GHIs aimed to save and prolong the lives of the millions in need and in so 
doing mitigate some of the devastating impacts such as the increased death rates, morbidity 
and escalating demands for health services in many countries. Certainly, the global scaling-up 
of ART is the single largest global health intervention; there are simply no precedents on a 
similar scale in SSA ([54, 154]. 
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Years after the implementation of some of these GHIs, evaluation studies have shown that 
many sub-Saharan African countries were not on track with respect to many of the set targets 
[90, 149, 155]. Apart from weak health systems and lack of absorptive capacity, prominent 
among the reasons for the failures was the lack of HRH. There were just not enough skilled 
health workers to do the job. Many SSA health systems currently do not have the capacity to 
provide the minimum health care delivery packages let alone the added burden from 
HIV/AIDS [136, 156]-. Studies have also shown that there have been significant advances 
recently in terms of global AIDS funding and that the real challenge was the severe HRH 
crisis facing  health systems in SSA [114, 157, 158]. 
4.1. SSA and the HRH situation 
The WHO’s “Health for ALL” standard of one doctor per 5,000 population is not met by 
thirty-one SSA countries and at least twenty of those countries have no more than one doctor 
per 20,000 population. The WHO has documented that thirty-six of the fifty-seven countries 
with critical shortages of health workers are in SSA. Some of the reasons for the critical 
shortages of professional health workers include: limited capacity to train the needed health 
staff [61], HRH policies that are not coordinated, often leading to inconsistencies such as 
multiple staffing norms, varieties of contradicting organizational charts, uncoordinated in-
service training and conflicting instructions to health training institutions [47, 159] and 
maldistribution. Also notable among the policy defects are policy decisions, which do not 
take into account the dynamics of the global labour market [160]. Furthermore, the adoption 
of macroeconomic policies under structural adjustments reforms often associated with 
widespread capping of public sector spending placed added limitations on the training and 
recruitment capacities of MoH facilities in the 1980s and 90s . It is thus paradoxical to find 
trained health workers unemployed in some countries with severe or critical shortages of 
health workers [145, 161]. In terms of attrition, brain drain accounts for between 1% to over 
70% of African health professionals abroad [162], poor salaries, burnt-out syndrome and 
generally demotivating working environments are other reasons for health workers leaving 
the health sector [46].   
 
Adding to the existing chronic shortage of health workers are the impacts of HIV/AIDS on 
the health workforce. They include: increased workload from dwindling numbers of health 
workers from death, absenteeism from work for own sickness or attending to sick relatives or 
funerals and  early retirements from fear of contracting HIV from the workplace  [163, 164]. 
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Another twist to the HIV/AIDS-HRH crisis in SSA is the fact that the global scaling-up of 
ART has transformed HIV/ AIDS; a deadly disease into a manageable chronic condition 
([119, 165-168] with implications not yet fully known for the health systems involved. 
Although HIV-related admissions may have decreased compared to the late 1980s to early 
2000s, the population of PLHA on chronic care keeps growing in many SSA countries [169-
171]. Clearly, the health workforce may not be keeping pace with the increasing demands for 
health care delivery services.  
4.2. How many health workers are required to scale-up ART? 
Based on doctor-centred ART delivery model (the model by default in most countries), 
copied from industrialized countries, various studies estimate that SSA will have to triple its 
current workforce in order to come close to reaching the Health Millennium Development 
Goals [172, 173]. Kurowski et al comment that, Tanzania and probably many low-income 
countries in SSA will require human resources far in excess of the number likely to be 
present in 2015 for the scaling-up of priority interventions to achieve health improvements 
similar to the Millennium Development goals [173, 174].  For Zambia and Mozambique, it 
was projected that to scale –up ART to all clinically eligible within the next ten years or so 
would require, two and four times as many doctors, respectively, as their current total stock 
of doctors [134]. These estimates clearly demonstrate that a doctor-centred ART delivery 
model is labour intensive and not feasible for most SSA countries with high HIV/AIDS 
burden and severe or critical health worker shortages. 
4.3. What are the proposed solutions for the shortages of HRH?  
The proposed solutions include: increasing  the numbers and capacities of the training 
institutions [175-177], increasing recruitments of trained health workers, introducing  
retention schemes and capacity building programmes of health workers  and importation of 
foreign health workers from abroad [178, 179].  
Another option is utilizing the available human resources for health through the delegation of 
tasks or task shifting. Compared to the other proposed solutions, task shifting is relatively 
rapid. For instance, it takes approximately 6 years to train a batch of doctors and 3 to 4 years 
to train a batch of nurses in Uganda, while the epidemic rages on [180]. From the estimations 
of the required human resources for the scaling-up of ART, the proposed solutions and the 
current human resources crises, there is certainly the need for an alternative ART delivery 
model, which should be relatively less labour intensive and context specific [181]. 
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4.4. In practical terms, what are the high burden countries doing to scale-up 
ART/PMTCT?  
The WHO 2007 Report shows that more than 25 sub-Saharan African countries are already 
implementing task shifting as a pragmatic response to dealing with their HRH crisis and to 
varying degrees in the provision of HIV/AIDS services as well as general health care delivery 
services [137, 182, 183].  
4.5. What is task shifting? 
The WHO defines task shifting as a process which involves the rational redistribution of tasks 
among health workforce teams whereby specific tasks are moved, where appropriate, from 
highly qualified health workers to health workers with shorter training and fewer 
qualifications in order to make more efficient use of the available human resources for health 
[182]. Task shifting thus expands the pool of HRH and in so doing increases access to 
services. Reorganization and decentralization of services using task shifting could promote 
universal access through increasing access to services at the peripheral levels of care [182]. 
From the existing evidence task shifting can be classified broadly into four types, as follows: 
 
Task shifting type I – The extension of the scope of practice of non-physician clinicians in 
order to enable them to assume some tasks previously undertaken by more senior cadres (e.g. 
medical doctors). 
Task shifting type II – The extension of the scope of practice of nurses and midwives in 
order to enable them to assume some tasks previously undertaken by senior cadres (e.g. non-
physician clinicians and medical doctors). 
 
Task shifting type III – The extension of the scope of practice of community health workers 
(often called non-professional health workers or lay providers), including people living with 
HIV/AIDS, in order to enable them to assume some tasks previously undertaken by senior 
cadres (e.g. nurses and midwives, non-physician clinicians and medical doctors). 
 
Task shifting type IV – People living with HIV/AIDS, trained in self-management, assume 
some tasks related to their own care that would previously have been undertaken by health 
workers. 
In the classification of task shifting, the defining factor for task shifting types is the 
cadre that assumes the new task. For example, any extension of the scope of practice of 
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nurses and midwives is defined as task shifting type II [182]. Figure 9 below provides a 
graphic illustration of the concept of task shifting. 
 
 
Figure 9: Graphic illustration of the concept of Task shifting to expand the pool of human resources for 
health 
Source: WHO 2007 
 
4.5.1. Task shifting type 1:  
The Ministry of Health (MoH) in Zambia scaled-up HIV/AIDS care and treatment services at 
the primary care clinics using predominantly Non-physician clinicians [184, 185]. Non-
Physician Clinicians play crucial roles in the decentralization of ART. They have been 
trained to diagnose, prescribe, initiate and follow up patients on ART in Ethiopia, Kenya, 
Malawi and Uganda [104, 147, 186, 187]. 
4.5.2. Type shifting type II:  
Shifting ART initiation to nurses has been central in the rapid scale-up of HIV treatment and 
care with high coverage at the primary health care level in the Lusikisiki sub-district (Eastern 
Cape Province of South Africa). The National Strategic Plan predicted that by 2011 most 
people in need of ART would receive their treatment from nurses at the primary healthcare 
clinics and not from doctors in hospitals [188]. In 2004 when the health authorities in 
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Botswana realized that a physician-centred ART delivery model was not feasible, a nurse-
centred ART delivery model: where ART-trained nurses clinically manage stable ART 
patients was piloted in two projects. The findings show increased access reflected in 
shortening of waiting lists  [137, 158]. 
4.5.3. Task shifting type III:  
Medecins Sans Frontieres (MSF) in the Thyolo district of Malawi piloted community 
participation in HIV care, treatment and support by involving community caregivers. Their 
findings have shown clinical outcomes  to be better when community caregivers were 
involved in the provision of services [189]. Partners in Health (USA) and a Haitian 
Organization (Zanmi Lasante) working together to provide ART have integrated ART into 
the primary health care delivery services. Using the Directly Observed Therapy Short Course 
(DOT) approach for both TB and ART patients, community health workers 
(accompagnateurs) provide ART at the community level with supervision. Patient outcomes 
have been reported to be good and adherence, impressive [137, 190].  
4.5.4. Task shifting is not new 
Historically, many nations both rich and poor have used health care providers who were not 
trained as physicians but who are capable of many of the diagnostic and clinical functions of 
medical doctors. Depending on the countries or regions and roles of the health cadres 
involved, they may be known as Non-Physician Clinicians, “mid-level cadres”, “substitute 
health workers”, Community Health Workers and others [137, 182, 186, 187, 191-193]. The 
Alma Ata Declaration of 1978 [50], the Kasongo project of the Institute of Tropical Medicine 
(Antwerp) and the expert patients concepts provide further examples of the involvement of 
non-professional health workers in the provision of health care [165, 194, 195]. 
4.5.5. Why the renewed interests in task shifting practice?  
Task shifting is promising and appears most pragmatic given the current HRH crisis and 
HIV/AIDS scenario in SSA [135, 179, 196]. The renewed interests call for research to 
explore further the potentials of task shifting as an innovative strategy in finding solutions to 
the mismatch between HRH crisis and health services utilization in SSA. 
4.5.6. In summary, what can be said about Task shifting? 
Task shifting may be promising, but that potential will be better harnessed when there are 
clearly established career development pathways for non-professional health workers to 
progress through further training, regular supportive supervision, some form of remuneration 
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and a formal recognition. In that way, task shifting may serve as an entry point for interested 
but non-professional health workers to become professional health workers.  Consequently, 
task shifting may serve the dual purpose of expanding the pool of non-professional as well as 
professional workers, while promoting the rational redistribution of the few skilled 
professionals. 
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5.0. The Tukula Fenna Project setting:  
The TFP is a paediatric HIV programme that was set up at the Home Care Department of St. 
Raphael of Francis Hospital (Nsambya Hospital) in Kampala, (Uganda) in 2003. Uganda is a 
land-locked country on the equator. It is located in East Africa and shares frontiers with 
Kenya to the east, Tanzania, Rwanda and Lake Victoria to the south, and the Democratic 
Republic of Congo to the west and South Sudan to the north (please see Figure 10 below). 
According to the 2013, State of Uganda Population and the UNFPA Reports, Uganda had a 
population of 35.4 and 37.6 million respectively. Approximately 51% were children aged less 
than 15 years, 33% were adolescents aged 0-19 years and the youth (people aged < 30 years 
made up 78%. The average annual population growth rate was 3.2% and 3.3% respectively. 
About 84% of the population lives in rural settings. Kampala, the capital city has about 2.0 
million inhabitants. The gross domestic product (GDP) was (US $) 533 [197, 198]. HIV, 
Malaria and TB are major public health problems for the country. 
 
Figure 10: Map of Uganda 
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Source: World Atlas (www.worldatlas.com) 
St. Raphael of St. Francis Hospital (Nsambya Hospital) is a Catholic Missionary hospital 
located in the Nsambya area of Kampala. It belongs to the private-not-for-profit (PNFP) 
health facilities coordinated by the Uganda Catholic Medical Bureau (UCMB). It is a tertiary 
referral hospital and offers services in all the basic specialties including primary health care. 
 
Figure 11: Front view of Nsambya Hospital, Kampala, Uganda 
5.1. Nsambya Hospital, Home Care Department (Nsambya Home Care) 
The Home Care Department; popularly called Nsambya Home Care (NHC) is dedicated to 
disease control (vertical) programmes (HIV, ART, PMTCT/EID and TB). Although NHC has 
a management team to ensure effective management and coordination of the vertical 
programmes, the hospital administration provides oversight. Thus, the arrangement between 
the Home Care Department and the hospital provides an example of integrated vertical and 
horizontal health systems at the same health facility (hospital) effectively operating within the 
general health system of the country. Whereas this arrangement may not be designed, it 
provides a feasible contextual adaptation to the health needs of the country.  The Mulago 
hospital complex and many large and referral hospitals with collaborations running vertical 
programmes provide further examples, suggesting that both systems are necessary [199, 200].  
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Figure 12: New building for the Home Care Department of Nsambya Hospital (NHC) supported by the 
TFP.  
 
 
Figure 13: Inauguration of new TB clinic provided by TFP to strengthen HIV/TB co infection 
management in the Nsambya CHBC model. 
5.2. Community involvement in Community Home Based-Care:  
Community involvement and linkage is one of the crucial pillars of the Nsambya CHBC 
model, and different methods have been employed to achieve that. They include a community 
61"
volunteer network, training sessions and workshops for community leaders, media 
involvements like announcements in churches and mosques and other public places, AIDS 
awareness campaigns and the NHC music dance and drama (MDD) club. It may be worth 
noting that some members of the volunteer network and the MDD club are expert patients 
who play roles in the fight against HIV in the communities. The volunteer network is made 
up of 50 individuals carefully selected from their communities of residence to cover the entire 
catchment area of the model. They are trained in basic health care and communication skills 
and assisted with bicycles and a mobile phone network to facilitate their work. Their primary 
role is working closely with the multidisciplinary team (counsellors, social workers, nurses, 
and sometimes clinicians) from the department, traditional leaders, religious leaders, and 
local council (local government) leaders to sensitize and mobilize communities to access HIV 
services. Additionally, community volunteers do home visits, track defaulting clients (HIV 
and TB), link them back to care and refer clients from the communities to the outreach clinics 
as well as the department for the needed services. Other roles of the volunteers include 
working with counsellors and social workers to coordinate and provide PSS to identified 
clients as well as mobilizing clients and caregivers for various workshops. The volunteers 
also perform various tasks at the ambulatory and outreach clinics from time to time. As a 
reward, they receive monthly stipends as well as financial assistance in the form of starting 
capitals for income generating activities. One is aware of the debates surrounding stipends for 
“volunteers”. However, it is argued that, in a setting where a significant proportion of the 
population lives below the poverty line [201], where the traditional social safety nets may 
have developed “holes” [202], and HIV/AIDS has impoverished many [82, 203, 204], 
perhaps stipends and financial assistance for income generating activities are the way 
forward. In the Nsambya CHBC experience, these measures have somehow reduced the 
turnover of the community volunteers over the years. Indeed, a recent analysis of data on the 
volunteers showed that 46% of them have served the Nsambya CHBC model since the 
volunteer programme started, 11 years ago. From interactions with colleagues operating 
similar programmes, this duration may be slightly longer than observed for many similar 
programmes in and around Kampala. Perhaps, it is time to review the label “volunteer” in this 
context. 
 Apart from the primary function of linking the department to the communities in the 
catchment area, over the years, community involvements have indeed extended the reach of 
the model significantly. Additionally, it has been observed that as more communities got 
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sensitized and engaged the level of stigma also reduced considerably. From the community 
perspective, the volunteers can be seen as the ‘front-liners’ of the model.  
 
While in the communities, the multidisciplinary team supervises the volunteers, carries out 
advocacy, does VCT and provider initiated HIV counselling and testing. The team also 
supports the satellite or outreach clinics, which were designed to decentralize basic services 
to the communities and thus promote geographical access to services at the periphery. Of 
note, when the outreach clinics are utilized they ease congestions as well as reduce waiting 
times at the ambulatory clinics at the department. The community activities often target 
pregnant women, OVC, men and groups considered hard to reach.  
 
Figure 14: Renovation of Ggaba outreach clinic for decentralization of HIV/TB services into the 
communities (work-in-progress) 
 
Figure15: Inauguration of Ggaba outreach clinic, an important outreach facility for surrounding 
communities. 
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6.0. History and evolution of the Tukula Fenna Project 
6.1. Background of Tukula Fenna Project 
Associazione Casa Accoglienza alla vita “Padre Angelo” or “HOUSE FOR LIFE, 
Father Angelo” is an Italian Health NGO and a partner to the Home Care Department of 
Nsambya Hospital. Prior to its registration as an NGO in 2009, “HOUSE FOR LIFE” 
together with other Italian partners; in particular, PENTA Foundation and University of 
Padova, Department of paediatrics worked to establish the children’s HIV programme at 
Nsambya Hospital, Home Care Department in 2003. That collaboration was established 
through a memorandum of understanding (MoU) aimed at supporting the hospital in the 
fight against HIV particularly in children and adolescents, orphans and vulnerable children 
(OVC) and their families in Kampala and three surrounding districts (Mukono, Wakiso and 
Mpigi). The programme was then called the “PCP Project” because the initial intervention 
was providing Cotrimoxazole prophylaxis against Pneumocystis Carinii pneumonia (PCP). 
As more resources including expertise became available over the years, the project evolved 
into a full-blown HIV programme for infants, children and adolescents as well as their 
families and caretakers. The name “PCP” became inappropriate and was replaced by “Tukula 
Fenna”, which in Luganda means “growing up together”. The TFP provides comprehensive 
HIV care, treatment and PSS and operates at the Home Care department of Nsambya 
Hospital, Ggaba Parish Outreach Clinic and 3 other outreach clinics in and around Kampala. 
To date, approximately 2,100 infants, children and adolescents have ever been enrolled into 
care, about 1140 are active in care and about 60%  are receiving antiretroviral therapy (ART) 
Figure 16 below is a flow chart showing the number enrolled into care, those active in care, 
those on ART, lost to care and deaths, since the project started.   
6.2. CORE Project Activities and Services include: 
i. HIV education, counselling and testing of infants, children and adolescents 
ii. enrolment of infants, children and adolescents into the programme 
iii. screening children for TB and enrolling positive ones into the TB programme 
iv. provision of Isoniazid prophylaxis to HIV infected children after screening to 
exclude active TB 
v. provision of Septrin prophylaxis for all HIV positive children 
vi. provision of nutritional supplements for all children in care 
vii. psychosocial support for children and their families and caretakers 
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viii. antiretroviral therapy (ART) for medically eligible children 
ix. monthly clinical and laboratory follow up of the children 
x. home visits for defaulter tracing, monitoring adherence to ART and anti TB 
treatment, family therapy support, adherence support counselling and psychosocial 
support for Orphans and Vulnerable Children 
xi. in-patient care (paying medical bills of children admitted to Nsambya Hospital) 
whose caregivers cannot afford 
xii. workshops for children and guardians to provide health education on a wide range 
of health issues and promote adherence to ART 
xiii. early infant diagnosis (EID) and 
xiv. adolescents’ transition clinic activities  
xv. research studies 
 
The literature review has shown that there are relatively few paediatric HIV services in 
Uganda, translating into limited access for children and vulnerable populations like orphans 
and vulnerable children (OVCs). In comparison to adults, HIV-infected children are an 
underserved and understudied population [205-207].  
6.3. Aims of the Tukula Fenna Project:  
To contribute to paediatric HIV services in Uganda, and conduct research studies in 
children and adolescents infected with HIV to improve their management.  
6.4. Objectives of the Tukula Fenna Project: 
To provide comprehensive and quality paediatric HIV services, for HIV-infected 
infants, children and adolescents and their families in four districts in Uganda, 
including Kampala, Mukono, Wakiso and Mpigi and 
To conduct relevant HIV-related research studies that can inform and improve 
operations and contribute to scientific knowledge in the field of HIV paediatric 
management in a resource-limited setting (Uganda). 
6.5. Research 
The types of research are detailed below:   
6.5.1. Operational research: 
This operational research focused on the following broad themes: 
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 Retention in care,  
 Survival on ART, 
 Attrition and LTFU, 
 Treatment failure, 
 Dried blood spots (DBS) and virological outcomes among children on ART: potential 
for operationalization of virological monitoring using DBS in resource-limited 
settings 
 
6.5.2. Specific study on HIV-EBV co infections in children and adolescents in the Tukula 
Fenna Project 
7.0. Objectives of this thesis: 
7.1. Main objective: 
To contribute to improvement of paediatric HIV management through operational 
research in the context of a community home –based care model, in a resource-limited 
setting (Kampala, Uganda) 
7.2. Specific objectives 
 a) To explore factors associated with treatment failure among children receiving ART in two 
ART programmes one in Mozambique and the other in Uganda (Paper 4) 
b) To investigate attrition and lost to follow up and their baseline predictors among children 
and adolescents in a community home-based care ART programme in Uganda (Paper 2) 
c) To examine the effects of the Nsambya Community Home-Based Care Model on National 
HIV and Tuberculosis management and health system strengthening in Uganda (Paper 1) 
d) To compare retention and survival among HIV-infected children and adolescents in two 
different ART delivery models in Kampala; the Nsambya Community Home-based Care of 
Nsambya Hospital, and the Facility-Based Family-Centred Approach of the Makerere 
University-Johns Hopkins University Research Collaboration (Paper 3)  
e) To explore HIV-EBV co infection in children and how it influences HIV disease 
progression and optimization of care (Paper 5),  
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g) To investigate the relationships between viral loads measured from dried blood spots and 
clinical and immunological treatment failure criteria among ART-experienced HIV-infected 
children in Uganda (Paper 6) 
7.3. Research questions: 
a) What are the factors and reasons associated with treatment failure among children 
receiving ART in ART programmes in Mozambique (Beira) and Uganda (Kampala)? 
b) What are the baseline predictors of attrition and lost to follow up among children and 
adolescents in the Nsambya community home-based care ART programme in Uganda? 
c) What are the effects of the Nsambya Community Home-Based Care model on National 
HIV and Tuberculosis management and health systems strengthening in Uganda? 
 d) Among HIV-infected children and adolescents on ART, are there any differences in 
retention and survival between the Nsambya Community Home-based Care model of 
Nsambya Hospital and the Facility-Based Family-Centred Approach of the Makerere 
University-Johns Hopkins University Research Collaboration? 
e) What are the effects of HIV-EBV co infection on HIV disease progression in children and 
optimization of care and treatment?  
g) In using dried blood spots to measure viral loads among ART-experienced HIV-infected 
children in Uganda, what relationships emerge between virological outcomes and clinical 
treatment failure criteria on one hand, and immunological treatment failure criteria on the 
other?  
 
8.0 Methodology: 
This section provides an overview of the methods sections of the six studies. Additional 
details are provided under the methodology of each study.  
Generally, the studies were observational, specifically, retrospective cohort studies, except 
for study 5, which was a cross-sectional study (please see Paper 5). Except for studies 3 and 4 
that involved two centres, all the studies were conducted at the Home Care Department of 
Nsambya Hospital in Kampala, Uganda. 
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Apart from the chart reviews, literature reviews provided context for the studies. That was 
complemented by review of documents such as monthly and annual programme activity 
reports and other relevant documents. 
Study subjects were mainly HIV-infected children and adolescents enrolled in the TFP for 
periods related to the individual studies. The only exception was study 1, which included 
adults in the Nsambya CHBC, where the TFP operates. 
 Two main tools were used for data collection; patients’ files and the databases. Paper 2 
provides detail description of the data collection system and tries to answer data-related 
questions such as, who collects data?, what type of data are collected?, how are the data 
collected and when are the data collected?.  
The outcomes for the operational research were: a) retention in care, b) attrition and 
LTFU, c)  survival on ART,  d) treatment failure  and  e) operationalizing  the use of Dried 
blood spots for viral load measurements in children in a resource-limited setting. 
Rationale for selected themes for operational research 
The selected themes have direct bearings on implementation as well as potentials to 
contribute to improvement of HIV paediatric management in the project setting. 
The statistical methods, ethical clearance and funding sources were detailed in each study. 
 
Figure 17: Simplified conceptual framework of thesis showing progression from literature reviews 
through implementation of the TFP and research to findings of the thesis. 
The TFP used a schema derived from the WHO and Ugandan ART guidelines for the 
implementation of interventions. The schema is presented in Figure 18 below. 
Literature!reviews!!
TFP!
Operational!Research!
Findings!(papers)!
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Figure 18: Schema for implementation of HIV/ ART programmes at Nsambya Home Care Department 
(Nsambya Hospital, Kampala). This schema was applied in the TFP 
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9.0. Results: original papers as chapters of this thesis: 
All the papers have been placed in the Appendix 
9.1. Chapter 1: Nsambya Community Home-Based Care complements National HIV and 
Tuberculosis management in Uganda, and contributes to health systems strengthening 
9.2. Chapter 2: Attrition and LTFU among children and adolescents on ART in a 
community home-based care programme in Kampala, Uganda 
9.3. Chapter 3: Survival and retention in care of children and adolescents on ART in two 
different ART delivery models in Kampala; Community Home-Based Care and Facility-
Based Family-Centred Approach 
9.4. Chapter 4: Treatment failure among cohorts of children on ART in Uganda and 
Mozambique, 
9.5. Chapter 5: Epstein-Barr Virus load in children infected with Human 
Immunodeficiency Virus type 1 in Uganda. 
9.6. Chapter 6: Virological outcome from dried blood spots testing among ART-
experienced HIV-infected children routinely monitored with clinical and immunological 
criteria in Uganda  
"
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9.7. Abstracts presented at international conferences and year of publication: 
 
9.7.1. Abstracts published in 2013: 
1. Poster #: (P_47): Baseline predictors of attrition and loss to follow-up among 
children and adolescents in a community home-based care HIV programme in 
Uganda, accepted for a poster display at the 5th International Workshop on HIV 
Paediatrics, 28 – 29 June 2013, Kuala Lumpur, Malaysia: Authors: Massavon 
William1§2, Lundin Rebecca1, Costenaro Paola1, Nabachwa Sandra2, Penazzato 
Martina1, Kayiwa Joshua5 , Namisi P. Charles2, Ingabire Resty2,  Tumwine K. James3, 
Nannyonga Musoke Maria2, Morelli Erika1, Bilardi Davide1, Kalibbala Daniel2, 
Mazza Antonio4, Giaquinto Carlo1 
 
2.  Abstract #: 2428251: Operational Challenges of Isoniazid Preventive Therapy 
Following WHO 2011 Recommendations For Children Living With HIV/AIDS: 
The Case Of Uganda" accepted by for oral presentation at the 17th ICASA 
conference in Cape Town, South Africa, 7-11 December, 2013. Authors: Costenaro 
P, Lundin R, Massavon W, Giaquinto C, Nabachwa S M, Kizito S, Alowo A, Morelli 
E, Nannyonga M, Namisi C, Bilardi D, Mazza A and Penazzato M 
 
3. Abstract #: 2427977: Survival And Retention Among HIV-infected Children and 
Adolescents in a Community Home-Based Care and a Facility-Based Family-
Centred Approach in Kampala, Uganda: A Cohort Study, accepted as a Poster 
Display, at the 17th ICASA Conference, 7 – 11 December 2013, Cape Town, South 
Africa. Authors: Massavon W12, Barlow-Mosha L3, Mugenyi L5, McFarland W6, 
Gray G,7 Lundin R1, Costenaro P1,  Nannyonga M M2, Penazzato M1, Bagenda D3,8, 
Namisi P C2,Wabwire D3, Mubiru M3, Kironde S2, Bilardi D1, Mazza A4,Fowler 
MG3,9, Musoke P3, Giaquinto C1. 
 
 
4. Poster #: P_13: Virological outcomes of dried blood spots testing of combination-
ART experienced HIV-infected children routinely monitored with clinical and 
immunological criteria in Uganda. Accepted as a poster display at the 5th 
International Workshop on HIV Paediatrics in Kuala Lumpur, Malaysia, 28-29 June 
2013. Authors: Costenaro P, Lundin R, Petrara MR,  Penazzato M, Massavon W, 
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Kizito S, Nabachwa S, Nannyonga M, Morelli E, Bilardi D, Mazza A , Zanchetta M, 
Giaquinto C , De Rossi A. 
 
9.7.2. Abstracts published in 2012 
 
1. Abstract #: P-01:  Implementing the 2011 WHO Intensified Case Finding and 
Isoniazid Preventive Therapy Algorithm in children and adolescents in a 
resource-limited setting: a programme perspective, accepted for poster 
presentation at the 13TH Annual Conference of the Uganda Society of Health 
Scientists, Silver Springs Hotel, Kampala, Uganda, 21-22 June, 2012. Authors: 
Massavon W, Costenaro P, Nannyonga M, Nabachwa S, Namisi CP, Penazzato M, 
Kizito S , Bbaale Kusiima J, Nantongo R, Morelli E, Bilardi D, Mazza A, Giaquinto 
C. 
 
2. Abstract #:P_07: Nsambya Community/Home-Based Care Model: 
complementing national HIV and TB Management and contributing to Health 
Systems Strengthening in Uganda, accepted for poster presentation at the 6TH 
International Workshop on HIV Treatment, Pathogenesis and Prevention Research in 
Resource Limited Settings (INTEREST) in Mombasa, Kenya, 8-11 May 2012. 
Authors: Massavon W1§2, Nannyonga M M2, Namisi C2, Ingabire R2, Nsubuga M2, 
Kalibbala D2, Penazzato M1, Kizito S2, Sozzi F2, Criel B3, Tumwine JK4, , Morelli E1, 
Bilardi D1, Mazza A5, Costernaro P1, Giaquinto C1. 
 
3. Abstract #: P_27:  Feasibility and challenges of Isoniazid Preventive Therapy 
and Intensified Case Finding in the paediatric HIV care package in a low-income 
setting, accepted for poster presentation at the 2012 International AIDS Society (IAS) 
HIV Paediatric Workshop in Washington DC (USA), July 20-21. Authors: Costenaro 
P, Penazzato M, Franceschetto G, Massavon W, Nabachwa S M, Morelli E, Kizito S, 
Nannyonga M, Namisi C, Bilardi D, Mazza A and Giaquinto C. 
 
 
4. Abstract #: 8594: Validation of WHO 2010 immunologic criteria in predicting 
paediatric first-line antiretroviral treatment (ART) failure in ART- experienced 
children in Uganda: CD4 is a poor surrogate for virologic monitoring of paediatric 
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ART failure. Accepted for poster exhibition XIX International AIDS Conference in 
Washington D.C. (USA), 22-27 July 2012. Authors:  Linda Barlow-Mosha1, Peter 
Mudiope1, William Massavon4, Danstan Bagenda1, Enid Kabugho1, Monica Etima1, 
Mary Glenn Fowler1, 3, Maria Nannyonga 4, Carlo Giaquinto5, Philippa Musoke1,2. 
 
5. Abstract #: 6970: Integration of legal service aid into HIV/AIDS service delivery, 
the experience of Nsambya Home Care, Uganda, was selected for presentation in 
the poster exhibition at the XIX International AIDS Conference  held in Washington, 
D.C. (USA), 22-27 July 2012. Authors: R.Kamahoro Ingabire1, C. Giaquinto2, 
W.Massavon1&2, A.Mazza3, M. Nannyonga Musoke1, I.Owomugisha4, E. Morelli2, D. 
Bilardi2, Costenaro P2, M. Penazzato2. 
 
6. Abstract #: A-452-0408-10719: Management of acute malnutrition using plump 
nut among HIV infected and exposed children in Uganda. Accepted as poster 
presentation at the XIX International AIDS Conference held in Washington, D.C. 
(USA), 22-27 July 2012. Authors: Nalutaaya AJ1, Musoke I1, Namisi CP1, Massavon 
W1&2, Giaquinto C2, Nannyonga MM1, Mazza A3, Morelli E2, Bilardi D2, Costernaro 
P2, Penazzato M2. 
 
9.7.3. Abstracts published in 2011: 
 
1. Abstract #:1.2-038: Retention in care of children and adolescents in an HIV 
programme in Kampala, Uganda: the impact of a multifaceted approach. 
Accepted as a poster and presented at the 7TH ECTMIH in Barcelona, 3-6 Oct 2011. 
Authors: Massavon W1,2, Nannyonga M2, Penazzato M1, Nabachwa S2, Kayiwa JA3, 
Namisi CP2, Morelli E1, Bilardi D1, Mazza A4, Giaquinto C1. 
 
2. Abstract #:MOPE258: Dynamics of Epstein-Barr virus in HIV-1-infected 
children in Uganda. Accepted for oral presentation at the 6TH IAS Paediatric HIV 
Workshop in Rome, Italy, July 15-16, 2011. Authors: Petrara MR1, Penazzato M2,3, 
Massavon W3, Nabachwa S4, Nannyonga M4, Mazza A 3,5, Zanchetta M6, Giaquinto 
C2,3 , De Rossi A1,6. 
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3. Abstract #:P_90: The challenges of Isoniazid Preventive Therapy (IPT) and 
Intensified Case Finding (ICF) algorithm implementation in the Paediatric HIV 
care package. Accepted as a poster and presented at the Paediatric HIV Workshop in 
Rome (Italy), July 15-16, 2011. Authors: Costenaro P, 2 Penazzato M, 2 Morelli E, 2 
Massavon W, 3 Nabachwa S M, 3 Namisi C, 3 Nantie R C, 3 Nannyonga M, 2 Bilardi 
D, 4 Mazza A, 2 Giaquinto C. 
 
4. Abstract #:P_52: Treatment failure in children living in resource-limited 
settings: the experience from two paediatric cohorts from Beira (Mozambique) 
and Kampala (Uganda). Accepted as a poster and presented at the Paediatric HIV 
Workshop in Rome (Italy), 15-16 July, 2011. Authors: Costenaro P, Penazzato M, 
Lundin R, Rossi G, Massavon W, Patel D, Nabachwa S, Franceschetto G, Morelli E, 
Bilardi D, Nannyonga Musoke M, Atzori A, Putoto G, Mastrogiacomo ML, Mazza A, 
Giaquinto C. 
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10.0. Synopsis: 
This section focuses on the operational aspects of the findings and relevant observations that 
contribute in developing the complete picture of this thesis, and covers the following 
components: 
a) CHBC and paediatric HIV management in a resource-limited setting  
b) Missing data and the operational setting 
c) ART and the potential protective effect against EBV-related lymphoproliferative disorders 
in HIV-EBV co infected children 
d) Operationalization of the use of DBS in Viral load monitoring in HIV-infected children in 
low and middle-income countries 
e) LTFU in an HIV programme: some operational interpretations and 
f)) TFP: contributing to national AIDS response and health systems strengthening 
10.1. Community Home-Based Care and Family-Centred Approach in paediatric HIV 
management in a resource-limited setting: potentially powerful synergies 
Implementing the TFP within the existing CHBC model for adults promotes the concept of 
family-centred approach (FCA). The literature shows that FCA builds family support for 
adherence and promotes retention in care , and enhances family uptake of HIV services 
including voluntary counselling and testing (VCT) prevention of mother to child transmission 
(PMTCT) and early infant diagnosis [208, 209]. Despite these benefits, inherent barriers in 
implementation have not encouraged the realization of the full potentials of FCA within the 
TFP. They include patient information systems that are not synchronized for families, which 
translates into different clinic appointments days for children and adolescents and their care 
givers or parents, difficulties in arranging care for a family unit and tracking family members 
missing appointments 
What are the possible solutions? 
- Ensuring complete and regularly updated patients’ contact information, 
-Synchronizing health information of family members as a unit, 
-Arranging same-day clinical appointments for the family members as a unit 
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-Arranging ‘snow-ball’ tracking of family members missing appointments, to promote 
retention in care. By this concept, family members and friends in the social networks of 
patients work with health workers to help track other family members who have defaulted. 
Family-centred approach (FCA) functioning optimally within a community home-based care  
is feasible and could lead to powerful synergies to provide and enhance HIV services uptake 
and treatment outcomes for families with benefits for children and adolescents in resource-
limited settings [210-213]. 
10.2. Missing data and the operational setting 
Although capturing laboratory and clinical data in line with national monitoring guidelines 
may be considered a proxy for quality of care [214], this may not always be the case because 
of missing data. Apart from the data related challenges described in Paper 2 [215],  other 
reasons for missing data in our programme included: 
-variables either not measured due to lack or defective equipment, for example weight and 
height, or the variable may be measured but data not captured in patients’ medical records or 
transferred to the electronic databases for storage and future analysis, 
-lack of expertise for instance WHO clinical staging by less qualified staffs, 
-Observations from Paper 2 show that, changes in treatment guidelines that do not require 
routine measurements of some variables (e.g. baseline CD4 and viral loads), may lead to 
missing data [215], 
-Policy decisions may compromise data collection and lead to missing data, affect data 
quality, reporting and programme evaluation. For instance, in times of financial crises, 
laboratory investigations were often stopped, or done selectively which led to missing data 
over time, 
-As clinic days get busier with increasing patient numbers staffs often forget or omit 
recording variables in some of the patients, 
- Some patients have been on ART for many years and often have two or more versions of 
their paper-based medical files. Some of the files may not be available, particularly in 
retrospective record reviews, where access to medical records may be selective .This could 
lead to potential bias [216, 217]. 
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-Furthermore, it is expected that with time, some adolescents will transfer to adults’ 
programmes, and as paediatric ART services gradually expand nationwide, some children 
and adolescents will transfer to other sites for different reasons. Currently, health information 
systems are disjointed; this could mean that, as patients transfer out, their baseline 
characteristics at ART initiation may not be available to the receiving sites. Patients should 
be able to move with their health information to facilitate continuity of care as well as 
verification when needed at the receiving facilities [218].   
10.3. ART and the potential protective effect against EBV-related lymphoproliferative 
disorders in HIV-EBV co infected children 
As demonstrated by the literature, children co infected with HIV and EBV have a higher risk 
of developing EBV-related lymphoproliferative disorders. In paper 5, we found that 
recipients on ART had relatively lower levels of EBV DNA, suggesting possible suppression 
of replication of EBV in HIV-EBV co infected children on ART. This means that, ART 
theoretically could protect against the development of EBV-related lympho-proliferative 
disorders in such children. For that to happen, HIV-EBV co infected children will require 
early detection and ART initiation as well as close monitoring over time.  
10.4. Operationalization of the use of DBS in Viral load monitoring in HIV-infected 
children in low and middle-income countries 
For a longtime, children on ART in low and middle-income countries were monitored using 
clinical and immunological criteria. That was primarily due to the prohibitive cost of viral 
load testing and lack of expertise in such settings. In paper 6, we demonstrated that 
virological measurements were feasible from dried blood spots (DBS), in line with the 
literature [219, 220]. Generally, filter papers are relatively cheap, DBS is easy to process, 
store, package and ship to distant laboratories with the expertise and resources to conduct 
virological testing on such children. The associated potentials are many and make the use of 
DBS cost-effective. This simple technique could expand and improve the quality of 
paediatric HIV care and treatment, particularly, early detection of treatment failure, the need 
for switching and possible resistant viral strains testing in resource-limited settings [221, 
222]. 
10.5. LTFU in an HIV programme: some operational interpretations 
Poor quality of care and long distances to health facilities are important determinants of 
LTFU particularly in remote rural areas of Uganda [223]. This situation may encourage 
internal migration to seek HIV and other medical services in the urban areas. 
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Among patients loss to follow up (LTFU), a common theme that emerged from home visit 
reports, counsellors’ reports, quarterly ART reports, was “relocation to original village” after 
some improvement in health conditions. This suggests some internal migration for health care 
services, especially for children and adolescents who have less choice compared to adults. 
LTFU may therefore be partially explained by ‘internal migration for health care’ because of 
the disproportionate distribution of health facilities, with the majority concentrated in urban 
settings. As an example, Kampala has about 30% of all HIV facilities in the country [78, 
224], while the majority of Ugandans are rural dwellers. Hence, to promote geographical and 
universal access, there is urgent need for greater and more effective decentralization of 
paediatric ART services within primary health care facilities at the district and sub-district 
levels in the general health system.   
 
10.6. Tukula Fenna Project: contributing to national AIDS response and health systems 
strengthening in Uganda 
The TFP (TFP) can be seen as a contribution to the Uganda national AIDS response as it 
helps in expanding access to paediatric HIV services in Uganda. The project is one of the 
relatively few HIV paediatric programmes providing comprehensive care, treatment, PSS 
including orphans, and vulnerable children (OVC) support in the country. All the services are 
free of charge owing to external financial support. Findings from research studies from the 
project add to knowledge in the field of paediatric HIV management in a resource-limited 
setting. 
As shown earlier, the TFP was integrated and implemented within an existing community and 
home-based care model that was originally designed for adults at the home care department 
of Nsambya Hospital. In terms of contributions to the health system, the TFP provided 
additional funding from external sources, particularly from Italian partners and donors such 
as House for Life, Father Angelo (Italian NGO), PENTA Foundation and CARAP. The 
project also supported health infrastructure development. Examples include the new building 
for the Home Care Department (Figure 12), the TB clinic to strengthen integrated HIV-TB 
management (Figure 13) and the renovation and upgrading of the Ggaba Outreach Clinic 
(Figure 14). It also provided additional HRH, as well as transportation and logistic support 
for clinical services and community-based activities like outreaches and home visiting.   
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HRH management followed common policy guidelines facilitated by administrative and 
operational integration. In addition, administrative and operational integration encouraged 
common approaches to health worker trainings, supervisions and appraisals. The measures 
have been described in detail in paper 1 [111]. 
Decentralization of basic HIV services is a cardinal feature of the Nsambya community and 
home-based care (CHBC) model. Decentralized services include VCT, ART refills, 
collection of laboratory specimens and PSS through outreach clinics in the communities. This 
approach seems to have promoted geographical access to HIV services at the periphery of the 
health system. In the Nsambya CHBC model, community volunteers play ‘frontline roles’ in 
terms of home visiting, tracking of defaulting patients in the communities and sensitizing and 
mobilizing communities to access HIV and TB services. To that extent, the TFP has worked 
closely and supported community volunteers with bicycles and mobile phone lines to 
motivate as well as facilitate their work.  
Conclusions: 
-Strengthening FCA in the Nsambya CHBC model could generate powerful synergies to 
improve uptake of HIV, TB and other medical services for families as units with benefits for 
children and adolescents; 
 -Improving data management systems could have potentially positive impacts on programme 
outcomes and reporting, 
-Apart from bringing in additional resources to the Home Care Department of Nsambya 
Hospital, the TFP adopted an integrated approach to the implementation of HIV paediatric 
care, treatment and PSS within the existing Nsambya CHBC model. That is quite atypical of 
projects and the approach avoided the creation of a parallel health system and contributed to 
health systems strengthening. 
-although the TFP implementation approach may not have been a perfect arrangement, for 
over a decade, the project provided comprehensive HIV care, treatment and PSS for children 
and adolescents, including OVCs free of charge. Certainly, over a decade of free services 
may have removed part of the financial barriers and promoted access to HIV services for this 
underserved population.  To this end, the TFP can be considered as an important contribution 
to the Uganda national AIDS response in terms of expanding access to paediatric HIV 
services and indirectly contributing to health systems strengthening in the country.  
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11.0. Conclusions from thesis; paper by paper: 
Paper 1 
The Nsambya CHBC complements national HIV and TB management efforts, and resulted in 
more positive outcomes when compared to the national averages. This approach may hold the 
potential for chronic disease management in resource-limited settings. Scaling up CHBC 
could have wider positive impacts on the management of not only HIV and TB, but also other 
chronic diseases as well as the general health system. A long-standing “faith-based 
solidarity” among international donors and partners has been pivotal to the survival and 
evolution of the Nsambya CHBC. 
Paper 2 
Overall, attrition  and  LTFU were relatively high  among children and adolescents in  the 
Tukula project. Not receiving ART was the single factor significantly associated with 
attrition in the cohort, while both baseline BMI z-scores and receipt of ART were protective 
against LTFU among HIV positive children and adolescents enrolled in the TFP. Efforts 
should be made to initiate ART among all paediatric patients as soon as possible, and to 
provide aggressive follow-up for those not yet receiving ART. Orphans  need more 
nutritional  support  to reduce the burden of malnutrition  and improved access to early ART, 
which could also promote growth responses in this vulnerable and understudied group. 
Paper 3 
Irrespective of model of care, children receiving ART had better retention in care and 
therefore long-term survival. Encouragingly, if children were on ART, then their survival was 
as good, if not slightly better, in the CHBC compared to the FBFCA. Based on our 
observations, substantial improvement in child survival can be achieved in either a 
community-based or a family-care model as long as HIV- infected children are identified 
early and begun on ART. To ensure this occurs, early identification of HIV infected children 
requires strong linkages of pregnant HIV- infected women to PMTCT services; active 
tracking to ensure all HIV exposed infants receive Polymerase Chain Reaction-based early 
infant diagnosis. Additionally, rapid early initiation of ART among HIV infected infants and 
children are essential. We anticipate the move to early initiation of ART in all HIV-infected 
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children and adolescents in resource-limited settings, irrespective of their CD4 cell counts, 
will improve survival. 
Among ART patients in both models, attrition was significantly associated with model of 
care, mild immunosuppression and being underweight. In the CHBC, attrition was 
significantly associated with CD4 cell count, WHO clinical stages III-IV and absence of 
ART. 
Paper 4 
In conclusion, our data reinforce the need for simplification of more effective clinical and 
immunological criteria for prompt recognition of cART treatment failure. Children presenting 
with advanced disease and TB co-infection should be targeted for closer and more sensitive 
monitoring of treatment response. This should  be matched with a constant provision of 
appropriate antiretroviral drugs and with optimization of first line drugs and treatment 
sequencing. Supply of new paediatric formulations for second line regimens and drug 
optimization should be considered  as critical milestones  to allow scaling up of early cART 
and reduction of treatment failure in children. 
Paper 5 
In conclusion, HIV-1, inducing microbial translocation and a state of persistent immune 
activation, may lead to EBV replication and expansion of EBV-infected B-cells, thus 
increasing the EBV-DNA load. Super-infection by both types of EBV in HIV-1 infected 
subjects may represent an additional risk for the onset of EBV-related malignancies. ART, by 
limiting HIV-1 replication, microbial translocation and related immune activation, may 
prevent super-infection by both EBV types and keep EBV viremia down, thus reducing the 
risk of EBV-associated lymphomas. 
Paper 6 
In our cohort immunological and clinical criteria as per WHO 2010 guidelines poorly predict 
the presence of a viral load greater than either 1000 cp/ml or 5000 cp/ml (whole blood)  from 
DBS.  The low sensitivity and positive predictive values for immunological and/or clinical 
failure confirm those reported by literature [225] This finding further supports the WHO 
recommendations that VL monitoring should be implemented and used to earlier identify 
cases of treatment failure  [226].  
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This study provides data on virological outcome in a program setting among children on 
cART routinely monitored by clinical and immunological criteria alone. We confirm that VL 
monitoring using DBS is feasible in LMIC. Studies are needed to improve the accuracy of 
viral load determination from DBS to increase test accuracy and detect early virological 
failure.  
 
11.1. Policy implications of thesis findings  
Scaling up CHBC could have wider positive impacts on the management of not only HIV and 
TB, but also other chronic diseases as well as the general health system. 
In this thesis and in line with the literature, Early ART initiation was associated with 
improved survival and retention  in both community-based and facility-based approaches.   
ART is potentially protective against EBV-related lymphoproliferative disorders in HIV-
EBV co infected children. This calls for early ART initiation in such children. 
Operationalization of the use of DBS in Viral load monitoring in HIV-infected children in 
low and middle-income countries is feasible and should be encouraged to improve the quality 
of paediatric HIV management in such settings. 
The low ART coverage among children calls for urgent,  greater and more effective 
decentralization of paediatric ART services within primary health care services at the district 
and sub-district levels in the general health system in Uganda. 
Children presenting with advanced HIV disease and TB co-infection should be targeted for 
closer and more sensitive monitoring of treatment response. 
Orphans need more nutritional support to reduce the burden of malnutrition and improved 
access to early ART, which could also promote growth responses in this vulnerable and 
understudied group 
 
11.2. Further research 
-The CHBC model demonstrates the potential for chronic disease management in resource-
limited settings, further studies could validate this potential. 
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-Community involvement has been shown to improve HIV and TB treatment outcomes. Yet 
there are no clear tools to objectively measure community engagements. 
-There is urgent need for studies to improve the accuracy of viral load determination from 
DBS to improve detection of early virological failure.  
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Abstract: 
Community Home-Based Care (CHBC) has evolved in resource-limited settings to 
 
fill the unmet needs of people living with HIV/AIDS (PLHA).We compare HIV and 
tuberculosis (TB) outcomes from the Nsambya CHBC with national averages in 
Kampala, Uganda.  This retrospective observational study compared HIV and TB 
outcomes from adults and children in the Nsambya CHBC, with national averages 
from 2007-2011.  Outcomes included numbers of HIV and TB patients enrolled into 
care, retention, loss to follow up (LTFU) and mortality among patients on 
antiretroviral therapy (ART) at 12 months from initiation; new smear-positive TB 
cure and defaulter rates, and proportion of TB patients tested for HIV. Chi-square test 
and trends analyses were used to compare outcomes from Nsambya CHBC with 
national averages.  By 2011, approximately 14,000 PLHA had been enrolled in the 
Nsambya CHBC, and about 4,000 new cases of TB were detected and managed over 
the study period. Overall, retention and LTFU of ART patients 12 months after 
initiation; proportion of TB patients tested for HIV, and cure rates for new smear- 
positive TB scored higher in the Nsambya CHBC compared to national averages.  The 
findings show that Nsambya CHBC complements national HIV and TB management, 
and resulted in more positive outcomes. 
Keywords: Community Home-Based Care, Nsambya, HIV/AIDS, TB, Health 
 
Systems Strengthening, Resource-limited Settings, Sub-Saharan Africa, Uganda 
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Background 
In the wake of the human immunodeficiency virus (HIV) epidemic in Sub-Saharan 
 
Africa (SSA), alternative service delivery models like the Community Home-Based 
 
Care (CHBC) [1-6] have evolved to fill the gap left by over-stretched and under- 
 
resourced health systems. CHBC includes any form of care (physical, psychosocial, 
palliative and spiritual) given to the sick and the affected in their own homes and care 
extended from the hospital or health facility to their homes through family 
participation and community involvement [7, 8]. CHBC provides for the unmet needs 
 
of the large and growing population of PLHA in many resource-limited settings [7, 9, 
 
10]. However, the effects of CHBC on national HIV and TB outcomes have not been 
 
examined in detail. 
 
In Uganda, the first CHBC programmes were established in 1987 in response to 
increasing numbers of acutely ill HIV/AIDS patients leading to congestion of hospital 
wards, increased staff workload and excessive pressure on infrastructure. Three 
different organizations pioneered this approach:  Kitovu Mobile HIV programme, The 
AIDS Support Organization (TASO) and Nsambya Hospital Home Care Department; 
popularly known as Nsambya Home Care (NHC). TASO was started by local people, 
whereas, Kitovu Mobile and Nsambya Home Care were pioneered by catholic 
missionary sisters from Ireland. 
 
 
 
HIV and TB present important public health problems and health systems challenges 
for the country. According to the 2011/12 Uganda AIDS Commission Progress 
Report, Uganda has a generalized HIV epidemic and prevalence has increased from 
6.4% in 2004 to 7.3% in 2011[11] . Uganda is also one of the 22 high-burden 
 
countries with respect to TB [12], and the 2012 WHO Global TB Control Report, 
 
shows that Uganda had a TB prevalence of 183 (95-298) and an incidence rate of 
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193(156-234) per 100, 000 population respectively. In the same report, 53% of TB 
 
patients tested positive for HIV  [13].  To deal with the dual epidemics, the ministry 
 
of health (MoH) developed national policy guidelines for the integrated management 
of TB/HIV co infection. The guidelines aim among other things, to reduce the burden 
of both diseases, by improving detection, quality of care and promoting access 
through decentralization of services to the lower levels of the health systems, where 
the majority of the population lives [14]. 
 
 
 
 
The Ugandan guidelines for scaling up ART [15] outline a primary care approach and 
 
make provisions for a CHBC model, in line with the WHO framework for action on 
 
CHBC in resource-limited settings[7]. This encourages synergies in the 
 
implementation of interventions for both HIV and TB. By mandate, CHBC is 
expected among other functions to provide palliative care, pain management, 
implement HIV-related interventions and serve as a bridge to extend HIV care, 
treatment and psychosocial support services beyond the traditional health facilities to 
the large and growing population of PLHA in their homes and communities [16] . 
 
Clearly, CHBC is consistent with the designed national response, and as a service 
delivery model, it could promote integrated management of the dual epidemics in 
Uganda and other settings with similar problems [17-20]. 
 
 
 
In this paper, we describe the Nsambya CHBC; examine the results and their effects 
on national HIV and TB outcomes, and their contribution to health systems 
strengthening in Uganda. Additionally, we highlight some challenges and recommend 
practical steps to strengthen implementation of CHBC in a resource-limited setting. 
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Methods 
Study design, setting and population 
 
This retrospective observational study compared HIV and TB outcomes from the 
Nsambya CHBC with national averages reported by the National TB and Leprosy 
Programme (NTLP) and the National AIDS Control Programme (NACP) over five 
years (2007-2011). The study was conducted at St. Raphael of St. Francis Hospital 
(Nsambya Hospital), Home Care Department in Kampala, Uganda. Nsambya Hospital 
is a Faith-based Private-Not-For-Profit facility owned by the Catholic Archdiocese of 
Kampala and accredited by both the ministry of health (MoH) and the Uganda 
Catholic Medical Bureau (UCMB). It is a general tertiary referral hospital with a bed 
capacity of 361, and involved in research and training of postgraduate doctors, nurses, 
midwives and laboratory technicians. 
The  study population consisted of adults and children receiving HIV and TB care, 
treatment and psychosocial support services over the study period. 
 
 
Description of CHBC 
NHC was established to extend basic health services into patients’ homes, to reduce 
pressure on hospital workers and infrastructure and encourage family members to 
participate in the care of their relatives.  This service was also intended to promote 
early hospital discharge, follow-up after discharge and community involvement. What 
started as a team of three health workers providing palliative care to patients in their 
homes has evolved into a specialized HIV and TB Centre. NHC has a catchment area 
stretching across four districts in and around Kampala, and covers approximately 21 
km in radius.  The estimated population of the catchment area  was about 4 million in 
2012 [21] . Over the years, NHC has evolved into a CHBC with the development of 
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community components, which include community engagements, a community-based 
volunteer programme, community outreach programmes and outreach clinics. 
The Nsambya CHBC is a blend between facility-based care and home-based care with 
the community serving as an important intermediary. It employs task shifting to 
overcome some of the shortages in the workforce, and uses home visits and outreach 
clinics to get services closer to patients. In addition, psychosocial support services 
help patients to deal with some of the challenges posed by HIV positive status, and 
poverty in accessing healthcare in poor-resource settings.  The pillars of the CHBC 
and how they function, patient enrolment practice,  tracking of defaulters and other 
interventions have been described in detail  in a previous study [22]. 
 
 
 
Programmes implemented with CHBC 
Prior to implementing programmes with the CHBC, donors and partners made 
concerted efforts to operate within existing national policy guidelines as much as 
possible. That understanding paved the way for establishing a framework of 
administrative and operational integration among donors and partners aimed at 
coordinating resources, promoting efficiency and avoiding measures that could 
potentially damage the health system. 
Within that framework, several closely related programmes were implemented with 
the CHBC: HIV prevention education, counselling and testing, ART, HIV chronic and 
palliative care, TB treatment, Intensified TB Case Finding (ICF) and Isoniazid 
Preventive Therapy (IPT). The programmes were vertical owing to the weak state of 
the general health system, and the approach can be considered as a contextualized 
solution [23-26]. Nonetheless, the Nsambya CHBC has extensive and important 
 
functional linkages to the general health system and all the relevant stakeholders. For 
instance, the MoH supports the TB clinic within the Nsambya CHBC to function as a 
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national referral facility that provides TB treatment for the public, participates in 
surveillance activities and national TB-HIV studies. The various interrelationships of 
the Nsambya CHBC are  illustrated in Figure 1, and the key players, processes and 
 
linkages to the observed outcomes are summarized in Figure 2. 
 
 
 
 
The Nsambya CHBC was funded mainly by non-governmental initiatives through a 
long-standing faith-based solidarity, and minimal support from the MoH. The faith- 
based solidarity also provided vital technology and technical assistance to achieve a 
common goal. The goal was to provide comprehensive HIV care, treatment and 
psychosocial support services for HIV-infected patients and their families and 
affected communities. Services were generally free of charge; however, adults paid a 
user fee of 1,000 Uganda shillings, the equivalent of 38 cents of a US dollar at the 
time of this study, per visit. 
 
 
Data collection 
 
 
Data from routine programme activities, programme reports, patients’ records, HIV 
and TB registers at NHC were collected for the study. Country-level data were 
obtained from the NACP and NTLP reports as well as from global HIV and TB 
reports. Some of the data were incomplete from the three institutions in the study. 
Consequently, the analyses were limited to periods with complete data, and that has 
been provided under the results section. 
 
 
Statistical methods and data analysis 
 
 
Primary study outcomes included the proportions of ART patients retained in care, 
LTFU and mortality at 12 months from ART initiation, proportion of TB patients 
tested for HIV, and cure and defaulter rates for new smear-positive cases. Secondary 
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outcomes included HIV-TB co infection and ART status among defaulters, and bed 
occupancy rate for HIV-related hospital admissions within 12 months of starting the 
CHBC. Bed occupancy rate was determined from a hospital report (unpublished). 
The data were analyzed with Microsoft Excel programme version 2007, and STATA 
version 12.  Chi-square tests were used to determine the differences and trends 
between the mean outcomes from the Nsambya CHBC and national outcomes. In 
addition, Chi square test and Fisher’s exact test were used to determine differences in 
the proportions of TB defaulters co infected with HIV, not co infected, receiving 
ART, and not on ART. 
The Uganda National Council for Science and Technology granted ethical approval 
for the study (UNCST Ref: HS 1383). The relevant authorities waived informed 
consent. 
 
 
Results 
 
 
Effect on HIV patient outcomes 
 
 
It is estimated that about 14,000 PLHA and their families have been enrolled in the 
Nsambya CHBC since its inception in 1987. Overall, about 91.6% were adults, 67.7% 
were females and 8.4% were children. From January 2009 to December 2011, on 
average, 90% (89%-91%) of the Nsambya CHBC patients on ART  were retained in 
care, 12 months after ART initiation, compared to 83.3% (83.2%-83.4%) for the 
national average. The difference was significant (Chi-square =60.3, p<0.001) and the 
trends were significantly different (chi-square for trend=26.8, p<0.001), with the 
Nsambya CHBC having more positive trends than National (Table 1 and Figure 3). 
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The Nsambya CHBC recorded an average LTFU rate of 5.7% (4.9%-6.4%) for ART 
 
patients 12 months after initiation, compared to the national figure of 8.7% (8.6%- 
8.8%). Overall, LTFU differed significantly (Chi-square =95.8, p<0.001), as well as 
the trends (chi-square for trend=95.7, p<0.001), with the Nsambya CHBC having a 
significantly decreasing trend compared to the national trend (Table 1 and Figure 4). 
 
 
 
 
The proportion of ART patients that died, 12 months after ART initiation was 5.4% 
(4.7%-6.1%) for the Nsambya CHBC and 4.6% (4.5%-4.7%) for the national figure. 
Overall, the difference in mortality (Chi-square = 38.9, p<0.001) and the trends were 
significant (chi-square for trend= 35.8, p<0.001). However, the trend was 
significantly decreasing under the Nsambya CHBC compared to the National (Table 1 
 
and Figure 5). 
 
 
 
Effect on TB patient outcomes 
 
 
Approximately 4,000 new TB cases were detected and managed from 2007 to 2011. 
Adults constituted 92.3%, females 51.0%, and children 7.7% of the cases. On 
average, 95% of TB patients from the Nsambya CHBC were tested for HIV as against 
 
72% for the national value. From 2007 to 2010, the Nsambya CHBC recorded an 
average cure rate of 54.6% for new smear-positive TB patients, while the figure for 
the national average was 30.8%. The difference was significant (Chi-square =21.2, 
p=0.001), but there was no difference in the trends (chi-square for trend=3.0, p=0.083, 
 
Table 2 and Figure 6). New smear-positive TB defaulter rates were 10.1% and 10.7% 
 
for the Nsambya CHBC and National respectively. The difference was not significant 
(Chi-square =2.1, p=0.541) and the trends did not differ (chi-square for trend=0.02, 
p=0.877), Table 2 and Figure7. 
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Overall, there were 110 TB defaulters, 54.5% (60/110) were enrolled in care in the 
Nsambya CHBC and the rest were referrals from other facilities. Majority of the TB 
defaulters were HIV-TB co infected (72%, p<0.001), and included all the TB 
defaulters enrolled in care in the Nsambya CHBC, who accounted for 76% (p<0.001) 
of all the HIV-TB co infected defaulters. Overall, minority of the TB defaulters were 
receiving ART (39%), and when stratified by source of patients, the proportions were 
similar: 38% versus 42%, (p=0.769) for Nsambya CHBC patients and referrals 
respectively (Table 3). 
 
 
Effect on bed occupancy 
 
The immediate impact of the Nsambya CHBC was a remarkable reduction in bed 
occupancy from an average of three months to two weeks for HIV/AIDS-related 
hospital admissions in 1987, within 12 months of starting the CHBC; long before 
ART became publicly accessible in the country (data not presented). 
 
Discussion 
Overall, the core findings from this study demonstrate that the Nsambya CHBC 
complements national HIV and TB management, and resulted in a higher proportion 
of ART patients retained in care and a lower LTFU rate, 12 months after initiation. 
We believe the higher retention in care and lower LTFU rates seen among the ART 
patients could be revealing the results of 25 years of evolution of the Nsambya 
CHBC, from preparing PLHA for death in the pre-ART era to keeping them alive 
through ART and long-term follow up measures. The process entailed regular review 
of CHBC design to make it sensitive to some key challenges faced by patients while 
seeking health care. That translated into additional psychosocial support services such 
as the OVC support programme, food supplements to help with food insecurity, 
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economic empowerment,  particularly of adolescents through sponsorships for 
vocational trainings, and  some caregivers  to enable them deal with poverty and other 
negative impacts of HIV/AIDS [22]. Other factors include strategies such as tracking 
 
of defaulting patients, community involvements, task shifting to community 
 
volunteers, nurses, counsellors and social workers [27], and using outreaches to 
 
promote geographical access to some services. Furthermore, the evolutionary process 
involved the adoption of measures  that have contributed to health system 
strengthening, as a stronger health system [5] is crucial for effective service delivery. 
 
 
We think that, the slightly higher mortality rate seen among Nsambya CHBC patients 
on ART might be due to improved tracking of patients considered “lost to follow up”. 
Indeed, a variable proportion of ART patients labelled as “lost to care” were actually 
dead upon tracking, and that observation is consistent with the literature [28-30]. Our 
 
mortality rate may also be reflecting improved documentation and reporting of deaths 
from the communities by community volunteers, who are residents of the 
communities. Overall, the mortality trend was reducing much more in the Nsambya 
CHBC, as depicted in Figure 5. 
 
We also found that a higher percentage of TB patients were tested for HIV in the 
Nsambya CHBC and the average cure rate for new smear-positive TB patients was 
higher than the national average.  However, the defaulter rates were similar. Various 
factors may explain the higher proportion of TB patients tested for HIV and the 
improved TB cure rates in the Nsambya CHBC. The Nsambya CHBC has a TB clinic 
and a laboratory for various tests including sputum microscopy on the same premises 
as the main HIV clinic. That structural arrangement coupled with training of health 
workers on policy guidelines for the integrated management of HIV-TB co infection 
may have strengthened management of the two diseases. That arrangement may also 
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have raised awareness among health workers and patients as well as facilitated 
screening of TB patients for HIV and vice versa. Moreover, patients see the 
arrangement as convenient and cost-saving to have HIV and TB screening and 
treatment at the same facility [31]. The high TB defaulter rate was unexpected, 
 
particularly when compared to LTFU among ART patients in the Nsambya CHBC. 
Nevertheless, that finding might be linked to the overall small proportion of TB 
defaulters started on ART (table 3), which is in keeping with the literature [32, 33]. In 
 
addition, TB patients referred to receive treatment but not enrolled in the Nsambya 
CHBC could not be tracked because of disjointed health information systems and 
logistic challenges. This observation could be reflecting a wider problem, and calls for 
early initiation of ART in all HIV-TB co infected patients in line with the recent 
revisions of the treatment guidelines [34, 35], and concerted efforts to track all TB 
 
patients receiving treatment in the Nsambya CHBC. 
 
The remarkable reduction in bed occupancy was feasible because of early discharge 
from hospital, home-based care provided by outreach staffs, and support from family 
members and friends of patients and community involvements. Studies from Uganda 
[36, 37] and elsewhere in SSA [38, 39] reported high HIV-related hospital 
 
admissions, sometimes to the exclusion of non-HIV patients in the 1990s and early 
2000s. Undoubtedly, the  reduction in bed occupancy translates into freeing up beds 
for non-HIV patients, decreased workload on health workers and reduced pressures on 
health infrastructure, all of which have gains for the health system [26]. There may 
 
also be gains for the patients and their caregivers from the shorter stays, such as 
overall costs. With the advent of ART, the reduction in bed occupancy has been 
sustained, as the health conditions of many HIV patients improved and relatively 
fewer patients were admitted to hospital and for shorter durations, in line with the 
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literature [40-42]. Over the years, community involvements seem to have raised 
 
awareness about HIV and reduced stigma to some extent, as reported by some 
patients, their caregivers as well as community volunteers, some of whom are expert 
patients. These positive effects could contribute to the building blocks for chronic 
disease management in resource-limited settings, particularly, where the default 
healthcare delivery models were not designed for chronic disease management [16] . 
 
 
We have observed some of the positive impacts of home visits and the various forms 
of psychosocial support, including lessons on self-management on patient outcomes, 
and believe they could go beyond HIV and TB management to benefit patients with 
other chronic conditions such as diabetes and hypertension, to mention a few [43]. 
 
Yet, that scenario may be dictated by additional funding and other resources to scale 
up, policy guidelines for regulation and the political commitment to support and 
sustain the approach, as well as a change in the mind-sets of programme coordinators 
and managers. Currently, CHBC is largely a ‘donor-partner’ funded initiative 
operating on a miniature scale [8, 44], compared to the existing HIV and TB disease 
 
burdens and unmet needs. 
 
 
 
 
 
Impact of long standing faith-based solidarity 
 
To a large extent, the findings from the Nsambya CHBC illustrate what could be 
achieved when  a common goal  is backed by some form of ‘solidarity’; in this case, 
‘a complex and powerful long standing faith-based solidarity’ involving international 
donor-partnerships and local partners. To accomplish the common goal for the 
solidarity, a wide range of resources and several programmes were envisaged. 
Somehow, the donors and partners directly or indirectly, supported most of the 
essential pillars of health system strengthening [45, 46] through funding, drugs, 
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equipment, materials, infrastructure development and vital technologies like 
electronic databases to support health information systems. The donor- partnership 
synergies also provided technical assistance to build and maintain systems; train, 
supervise, monitor and evaluate performance against set standards periodically. Thus, 
gradually developing some of the needed systemic capacities [47], as well as a viable 
 
service delivery mechanism over time. It is estimated that, at the time of this study, 
the existing key donors and partners had each supported the Nsambya CHBC for at 
least eight years covering different periods  or with some overlap, and the oldest 
partner for over 25 years and on-going.  This ‘longevity of faith-based solidarity’ has 
been pivotal to the survival, evolution and expansion of the Nsambya CHBC. 
 
 
Administrative and operational integration 
 
One of the important achievements of the Nsambya CHBC was the establishment of 
administrative and operational integration among donors and partners. The measures 
allow some resources to be pooled together; utilized after collective decisions and 
accounted for in a transparent manner. Administrative and operational integration 
have facilitated and somehow harmonized implementation of some common policy 
guidelines. For instance, there are common policy guidelines for human resources for 
health management in place. In practice, they translate into common procedures for 
advertising vacancies, standardized selection criteria and the use of Ugandan national 
salary scales. This avoids disparities in salaries and working conditions for health 
workers with similar qualifications and experiences, but working on different 
programmes. The measures have reduced duplication, minimized wastage and 
administrative costs, poaching of health workers, and seem to have promoted 
efficiency and synergies with better programme outcomes. 
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Positive ‘spill over’ effects 
Even though, the original goal of the Nsambya CHBC was to provide care, treatment 
and psychosocial support for PLHA and their families, with time, the additional 
resources from the HIV programmes appear to have benefited other programmes and 
the general health system. Notably, TB control, nutritional support for children, OVC 
support including sponsorships for vocational training and support for caregivers [22]. 
 
These positive “spill over” effects are consistent with findings from studies  in 
 
Ethiopia and Malawi [48] and elsewhere [25, 26,  49] globally. 
 
 
 
 
Challenges to be addressed 
 
Despite the achievements of the Nsambya CHBC, some important challenges remain, 
and they can be viewed from the level of CHBC, from that of the implementing 
organization, donor-partner demands and preferences and the general health system. 
Documentation and data capturing from community activities need to improve in 
order to contribute to operational research in the future. The referral networks linking 
the communities to the outreach clinics and to the department and hospital require 
strengthening in order to be effective. Community volunteers play vital roles in the 
referral networks, but they may not be adequately resourced to function effectively. 
Budgeting must also be clear and stable in order for programmes to be designed in a 
feasible manner and implemented consistently. This can be difficult to manage with 
multiple  donors  and  partners  providing  varying  portions  of  funds  over  varying 
periods. Supplies such as drugs and medical products are also received on a variable 
basis from a range of sources. In order to prevent waste and actively identify areas of 
both overage and shortage, efficient and timely recording systems for supplies are 
essential. 
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Although, the Nsambya CHBC has an organizational know-how in place that could be 
extended to benefit other health problems other than HIV and TB, some donors and 
partners prefer to fund only specific aspects of the programmes. That state of affairs, 
creates some difficulties among the donor-partner relationships, and somehow does 
not contribute to the realization of the full potentials of CHBC. With respect to the 
general health system, referral networks are generally fragile, operational guidelines 
lack visibility, and the disjointed nature of health information systems makes it a 
daunting task tracking patients lost to care, especially when they relocate to different 
cities, towns or villages. 
 
 
 
We  recommend  the  following  steps  for  the  relevant  authorities  to  consider  in 
strengthening and expanding implementation of CHBC programmes: 
i. Government co-funding and political commitment to scale up CHBC and 
ensure continuity of support in the face of changes in the donor-partner 
relationships, 
 
ii. Streamlining the existing patient tracking system to make it sensitive for 
tracking all patients in care in the Nsambya CHBC, 
 
iii. Strengthening of the referral networks through national guidelines and 
resource allocation as well as research and, 
 
iv. A critical assessment of how the CHBC models impact on the general health 
system. 
 
 
 
Limitations of study 
Potential limitations of this study include issues with documentation (incomplete 
data), availability and data quality. Consequently, we believe the reported number of 
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patients ever enrolled in the Nsambya CHBC could be an underestimation, possibly 
due to missing data from worn out paper-based registers, before electronic databases 
became available. To deal with missing data , we relied on reported data from the 
NACP and NTLP, presented in global HIV and TB reports for the comparisons, 
whenever possible. That meant, only periods with available reported data could be 
compared. These limitations were accommodated for, by providing the periods for the 
various analyses in the text under results. 
Data on the average bed occupancy rate was from a secondary source (unpublished 
hospital report) which did not provide the standard deviation for the mean reported. In 
addition, portions of the relevant paper-based registers for 1987-88 hospital 
admissions have worn out over the years, resulting in missing data. Therefore, the 
primary data could not be accessed for analyses. 
We also recognize that the national averages level off diversity in data and their 
sources and therefore believe that, the observed differences in outcomes may not be 
due solely to the CHBC approach but possibly some other factors, which we were 
unable to explore. 
 
 
 
Conclusions 
 
We conclude that, the Nsambya CHBC complements national HIV and TB 
management efforts, and resulted in more positive results for several HIV and TB 
outcomes, when compared to the national averages. The findings could be reflecting 
the results of 25 years of evolution of the Nsambya CHBC, from preparing PLHA for 
death in the pre-ART era, to keeping them alive through life-prolonging ART and 
long-term follow up measures. A process that  entailed regular review of the 
approach, community involvements, additional interventions to mitigate some of the 
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negative impacts of HIV/AIDS, while adopting measures and strategies that have 
contributed to health system strengthening in the country. This approach may hold the 
potential for chronic disease management in resource-limited settings. Scaling up 
CHBC could have wider positive impacts on the management of not only HIV and 
TB, but also other chronic diseases as well as the general health system. A complex 
and powerful long-standing “faith-based solidarity” among international donors and 
partners has been pivotal to the survival and evolution of the Nsambya CHBC. 
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Figure 1: Nsambya Community Home-Based Care and linkages to the general health system, 
stakeholders and communities. 
 
NGO: non-governmental organization; CBO: community-based organizations; FBO: faith based 
organizations; UGANET: Uganda network on law, ethics and HIV/AIDS; OVC: orphans and vulnerable 
children; TB: tuberculosis; ICF/IPT: intensified case finding and Isoniazid preventive therapy; ART: 
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Figure 3: Trends for ART patients retained in care, 12 months after initiation, Nsambya CHBC and 
National (2009-2011) 
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Figure 4: Loss to follow up trends for Nsambya CHBC and National (2009-2011) 
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Figure 5: Mortality trends after 12 months of ART initiation, Nsambya CHBC and National (2009- 
2011) 
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Figure 6: Trends for new smear-positive TB cure rates, Nsambya CHBC and National (2007-2010) 
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Figure 7: Trends for new smear-positive TB defaulter rates, Nsambya CHBC and National (2007- 
2010) 
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Table 1: comparison of HIV treatment outcomes from the Nsambya CHBC with National 
averages, 12 months after ART initiation, Kampala, (2009-2011) 
 
Year National 
 
% (n/N) 
Nsambya CHBC 
 
% (n/N) 
Overall chi-square 
 
P - value 
Chi-square for 
trend P - value 
 
Retained in care 
 
2009 82.5 (252155/305642) 83.4 (2946/3532)  
2010 83.6 (310435/371334) 92.5 (4352/4705) <0.001 <0.001 
2011 83.9 (386693/460898) 94.0 (5185/5516)   
Loss to follow up 
2009 9.1 (27813/305642) 8.7 (307/3532)   
2010 8.7 (32306/371334) 5.4 (254/4705) <0.001 <0.001 
2011 8.2 (37794/460898) 3.0 (166/5516)   
Mortality     
2009 5.4 (16505/305642) 7.8 (276/3532)   
2010 4.5 (16710/371334) 5.3 (249/4705) <0.001 <0.001 
2011 3.9 (17975/460898) 3.0 (166/5516)   
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Table 2: comparison of new smear-positive TB cure and defaulter rates from the Nsambya 
CHBC with National averages, Kampala, (2007-2010) 
 
Year National 
 
% (n/N) 
Nsambya CHBC 
 
% (n/N) 
Overall chi- 
square 
 
P - value 
Chi-square for 
trend 
 
P - value 
 
New smear-positive TB cure rates 
 
2007 30.7 (6540/21303) 35.6 (99/278)  
2008 27.5 (6261/22766) 56.1 (165/294) 0.001 0.083 
2009 30.0 (6934/23113) 55.8 (168/301)   
2010 34.9 (8186/23456) 71.0 (171/241)   
New smear-positive TB defaulter rates 
2007 15.1 (3217/21303) 14.0 (39/278)   
2008 11.2 (2550/22766) 11.2 (33/294) 0.541 0.877 
2009 11.5 (2658/23113) 8.3 (25/301)   
2010 5.1 (1196/23456) 7.0 (17/241)   
- 34 - 
 
 
 
Table 3: Comparison of TB defaulters (adults and children) receiving treatment in the 
Nsambya CHBC by HIV-TB co infection and ART status, Kampala, (2007-2010) 
 
Characteristic Referred patients 
 
N=50 
NCHBC patients 
 
N=60 
Total 
 
N=110 
Fisher’s exact/ 
Chi square- 
tests 
 
P - value 
 
HIV-TB co infected 
 
n(%) n(%) 
 
Yes 19(38) 60(100) 79(72) <0.001* 
 
No/unknown 31(62) 0 (0) 31(28) 
 
HIV-TB co infected on ART 
 
Yes 8(42) 23 (38) 31(39) 0.769** 
No 11(58) 37(62) 48(61)  
* Fisher’s exact test, ** Chi square test 
 
 
 
 
 
 
Data sources: 
 
1.   Global AIDS Response Progress Report, Uganda AIDS Commission April 2012, Kampala, 
 
2.   Status of Antiretroviral Therapy Services in Uganda. Quarterly ART Reports for October- 
December 2010, 
 
3.   Status of Antiretroviral Therapy Services in Uganda. Quarterly ART Reports for January- 
June 2011, 
 
4.   Status of Antiretroviral Therapy Services in Uganda. Quarterly ART Reports for October- 
December 2011, 
 
5.   CDC Uganda Quarterly Reports; October- December 2009, 
 
6.   CDC Uganda Quarterly Reports; October- December 2010, 
 
7.   CDC Uganda Quarterly Reports; October- December 2011, 
 
8.   Annual Health Sector Performance Report. Financial Years 2009/10, Ministry of Health, 
Uganda, Kampala, 
 
9.   Annual Health Sector Performance Report. Financial Years 2010/11, Ministry of Health, 
Uganda, Kampala, 
 
10. WHO Report 2011: Global TB Control, 
- 35 - 
 
11. WHO: TB_notification_2012-06-11.csv, 
 
12. WHO: TB_outcomes_2012-06-15.csv, 
http://www.who.int/tb/country/data/download/en/index.html 
 
13. Nsambya Home Care TB registers 
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Figure captions and legends 
1.Figure 1: Nsambya Community Home-Based Care and linkages to the general 
health system, stakeholders and communities 
 
Legend:   NGO: non-governmental organization; CBO: community-based organizations; FBO: 
faith based organizations; UGANET: Uganda network on law, ethics and HIV/AIDS; OVC: 
orphans and vulnerable children; TB: tuberculosis; ICF/IPT: intensified case finding and 
Isoniazid preventive therapy; ART: antiretroviral therapy; PMTCT: prevention of mother to 
child transmission; EID:  early infant diagnosis 
 
 
2. Figure 2: Illustration of the key players in the Nsambya CHBC model, the vital 
components and linkages to outcomes 
 
Legend: Conceptual framework of the Nsambya CHBC, the context within which it 
operates and functional connections to all stakeholders including beneficiaries 
 
3. Figure 3: Trends in retention in care (12 month's after ART initiation): Nsambya 
 
CHBC versus National (2009-2011) 
 
Legend: NHC=NCBHC, Y- on x-axis of the graph represents year 
 
4. Figure 4: Trends in Loss-to-follow up : Nsambya CHBC versus National (12 month's 
after ART initiation), 2009-2011 
Legend: NHC=NCHBC, Y-on x-axis represents year 
 
 
 
5. Figure 5: Trends in mortality at 12 months after ART initiation: Nsambya CHBC 
versus National (2009-2011) 
Legend: NHC=NCHBC, Y-on x-axis represents year 
 
 
6. Figure 6: Trends in new smear positive TB cure rates: Nsambya CHBC versus 
National (2007-2010) 
 
 
Legend: NHC=NCHBC, Y-on x-axis represents year 
 
 
7. Figure 7: New smear positive TB defaulter trends: Nsambya CHBC versus National 
(2007-2010) 
 
 
Legend: NHC=NCHBC, Y-on x-axis represents year 
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Abstract 
 
Background: We examine attrition and loss to follow-up (LTFU) and their baseline predictors among HIV-infected 
children and adolescents in a Community Home-Based Care (CHBC) model in Kampala (Uganda). 
 
Methods: We conducted a retrospective cohort analysis of attrition and LTFU and their predictors among children 
and adolescents aged 0-20 years  in the Tukula Fenna  project. The project operates at the Home Care Department 
of Nsambya Hospital and four outreach  clinics, located in Kampala and three surrounding districts in Uganda. The 
project uses community home-based care   to   provide free Antiretroviral Therapy (ART), other medical treatment 
as necessary, nutritional support, psychosocial support, and home visits. Kaplan-Meier curves were used to assess 
attrition and LTFU, and multivariate Cox proportional hazard regression models were used to identify their predictors. 
 
Results: 1162 children and adolescents with confirmed positive HIV status were enrolled in the Tukula Fenna 
project between October 2003 and August 2012. Over this period, 5.34% (62) of patients died 37.61% (437) were LTFU, 
and overall attrition was 42.94% (499). This resulted in overall incidence of death of 18 per 1000 person-years, of LTFU 
of 126 per 1000 person-years, and of attrition of 144 per 1000 person-years. The single factor significantly associated 
with overall attrition among the 1162 patients was absence of ART (HR: 0.11, 95% CI: 0.09,0.14). Both baseline BMI 
z-score (HR: 0.96, 95% CI: 0.91, 1.00) and receipt of ART (HR: 0.12, 95% CI: 0.10, 0.15) were significantly negatively 
associated with LTFU among all 1162 patients in this cohort. 
 
Conclusion: Not receiving ART was the single factor significantly associated with overall attrition. Both baseline 
BMI z-scores and receipt of ART were protective against LTFU among HIV positive children and adolescents enrolled 
in the Tukula Fenna project. Orphans need more nutritional support and improved access to early ART initiation. 
 
Keywords: Attrition;  LTFU;  Retention;  Children;  Adolescents; 
CHBC; Nsambya; Uganda 
 
Introduction 
 
The availabilty and rapid scaling up of Antiretroviral Therapy (ART) 
programmes for infants and children with Human Immunodeficiency 
Virus (HIV) infection in Low-Middle Income Countries (LMIC) has 
enabled many to survive and grow into adolescents and adults [1- 
3]. However, retention in care of children and adolescents with HIV 
remains a major operational challenge requiring innovation and 
creativity [4-6]. Particularly, challenges associated with data collection 
systems may influence   reporting of important outcomes such as 
attrition and loss to follow-up (LTFU) in these settings. 
 
Various approaches have been employed to improve retention in 
HIV programmes in LMIC with varying degrees of success [7-9]. A 
number of studies have documented improved retention in care as well 
as better clinical outcomes using community-based  or Community 
Home-Base Care (CHBC) models in Malawi, Haiti and  elsewhere 
[10-14]. In general, CHBC includes any form of care (physical, 
psychosocial, palliative and spiritual) given to the sick and the affected 
in their own homes and care extended from the hospital or health 
facility to their homes through family participation and community 
involvement [15,16]. Home delivery of HIV counselling and testing, 
defaulter  tracking,  adherence  counselling  and  monitoring  in  the 
home have also been shown to be associated with improved retention 
in care [8,17]. Other studies have demonstrated  positive impacts of 
psychosocial support  services on retention  in HIV programmes  in 
LMIC [18,19]. 
 
Thus, home delivery of basic HIV services, community-based or 
CHBC approaches seem to improve retention in care. However, the 
majority of the   studies cited above were conducted  in adults, and 
little is known about  retention of children and adolescents from such 
approaches in LMIC. In this paper, we examine attrition  and LTFU 
and their baseline predictors among children and adolescents in the 
Nsambya CHBC HIV service delivery model in Kampala, Uganda. 
 
Methods 
 
Study design 
 
This retrospective cohort  study utilized data routinely collected 
from the Tukula Fenna project between October 2003 and August 2012. 
 
Study setting 
 
According to the United Nations Children’s Fund, by 2010, AIDS 
orphans  accounted  for  39% of  all  children  orphaned  in  Uganda 
[20]. Approximately half of the patients in the Tukula Fenna project 
are  orphans  and  recipients  of Orphans  and  Vulnerable  Children’s 
(OVC) support. The Tukula Fenna project operates at the Home Care 
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Department of St. Raphael of St. Francis Hospital (Nsambya Hospital) 
and four outreach clinics, located in Kampala and three surrounding 
districts in Uganda. Nsambya Hospital is a tertiary referral hospital in 
the Nsambya area of Kampala. Although Nsambya Hospital is a private- 
not-for-profit   facility, all paediatric HIV services are free of charge 
due to external support from international  partners (House for Life, 
Father Angelo,  Paediatric European Network for Treatment of AIDS 
Foundation and the US President’s Emergency Plan For AIDS Relief ) 
and local support from the Ugandan Ministry of Health. 
 
The Tukula Fenna project started in 2003 and provides standard 
and comprehensive HIV services for infants, children and adolescents 
within the framework of the Nsambya CHBC model. The components of 
the Nsambya CHBC framework include monthly on-site appointments 
either at the Home Care Department  or at the four outreach clinics 
added to decentralize Voluntary Counselling and Testing (VCT), ART 
refills and  Prevention  of Mother-To-Child  Transmission  (PMTCT) 
and   Early  Infant   Diagnosis  (EID)  services.  Other   components 
include a nutritional support clinic, home visits, psychosocial support 
workshops and services provided by a multidisciplinary outreach team 
(counsellors, social workers, nurses and sometimes clinicians) and an 
adolescents’ transition clinic to prepare adolescents and their caregivers 
for a smooth transition  to adults’ HIV care. The outreach team also 
works with community volunteers and community leaders to identify 
OVC for support, as well as  sensitize and mobilize communities to 
access HIV services. 
 
Study population 
 
The study included all infants, children and adolescents aged 0-20 
years enrolled in the Tukula Fenna project between October 2003 and 
August 2012 with confirmed HIV infection and with a valid enrollment 
date. 
 
Pre-ART care package 
 
Patients were enrolled into  care after VCT either at the Home 
Care Department or at the outreach clinics or as referrals from various 
sources, such as other hospitals or centres, community  HIV testing 
sites, and self-referrals. Infants and children less than 18 months  of 
age known or suspected to be HIV-exposed were diagnosed through 
HIV-1 DNA polymerase chain reaction test. Other services included 
cotrimoxazole  prophylaxis,  multivitamins   supplements,   screening 
for tuberculosis (TB), and Isoniazid Preventive Therapy (IPT) as 
prophylaxis and treatment for latent TB, and treatment of opportunistic 
infections. Laboratory evaluation involved 6-monthly CD4 cell counts 
and percentages and full blood counts and other tests as necessary. 
Nutritional status was assessed through monthly age-appropriate 
anthropometric  measurements (weight, height and mid upper arm 
circumference) taken and recorded by attending nurses or nutritionists 
at the nutritional support clinic. 
 
In   terms   of  psychosocial  support,   paediatric  patients  and 
their  care givers received   various forms of counselling and  social 
services, including  monthly  food incentives, free medical services, 
and  sponsorships   for  basic  and  vocational  education   for  some 
orphans  and  vulnerable  children.     Other  forms  of  psychosocial 
support included children and adolescents’ peer- support groups and 
quarterly psychosocial support workshops for paediatric patients and 
their  caregivers. Peer-support  groups consisted of 5-10 children  or 
adolescent peers carefully selected to form a group. The group provided 
an atmosphere of belonging which enabled children and adolescents 
to share life experiences related to being HIV positive, including peer- 
counselling on adherence to clinical appointments and medications. In 
addition, drama performances by some of the adolescents in the project 
were used to further educate and sensitize paediatric patients on HIV 
prevention, positive living and other themes from time to time. 
 
The quarterly psychosocial support workshops provided 
opportunities  for further interactions between health care providers 
and  paediatric patients  and  their  caregivers outside  the traditional 
health facilities. Discussion topics commonly included nutrition, 
adherence  issues, self-management in HIV/AIDS and age-appropriate 
sexual and reproductive health issues. Sometimes psychosocial support 
entailed initiating child protection procedures involving legal assistance 
for OVC, when necessary. 
 
Patients have been followed up through regular monthly visits since 
starting the project, either at the outreach clinics or at the Home Care 
Department. As part of the follow up process, pre-ART patients were 
home visited to map their homes for future visits, assess psychosocial 
issues that could affect adherence during pre-ART preparations, and 
evaluate the need for other psychosocial support  services. Home 
visiting provided vital first hand  impressions about the homes and 
family settings of the children and adolescents visited. The strategy was 
also used to track defaulters. 
 
ART care package 
Generally, ART care was an “add-on” to the pre-ART care package 
described above. All eligible patients and their care givers were taken 
through two to three weeks of pre-ART preparations before starting 
ART. Issues with disclosure, drug stock-outs and other logistic 
challenges may have delayed ART initiation. Follow up visit schedules 
for clinical evaluation and laboratory tests for ART patients were 
similar to pre-ART patients. Additional  tests were performed anytime 
if clinically required. 
Generally, patients on ART had a more aggressive tracking through 
phone calls and home visits, when they missed appointments or when 
treatment failure was suspected. Such patients received additional 
adherence support counselling and other forms of support depending 
on the needs and available resources. For example, health care providers 
also made efforts to build family support for therapy. In special cases, 
the outreach team delivered ART and food supplements to patients in 
their homes to promote adherence and improve treatment outcomes. 
Such special cases usually involved orphans and vulnerable children 
with little or no social support networks. Although such services were 
usually provided on a monthly basis, the frequencies depended largely 
on the needs and available resources. 
 
Data collection system 
 
Data collection involved different categories of health workers, 
different types of data and data collection tools, and selective linkage 
of data from paper-based registers and patient files to an electronic 
database, all of which were associated with challenges. 
 
Patient  data  were  routinely  collected  by  attending  clinicians, 
nurses, counsellors, social workers, laboratory staffs and data clerks 
at all five locations and recorded in physical patient files and registers 
or pre-designed reporting  templates. Data collected included socio- 
demographic information, clinical records, laboratory tests and results 
and information  on counselling and other psychosocial support 
services including OVC support, workshops and home visits. Data were 
collected during  the clinics, counselling sessions, workshops, home 
visits and community-based  activities, where community  volunteers 
played important roles in data collection, through monthly reports. 
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Although large amounts of data were collected, owing to design 
and  limited capacity, it was mainly quantitative  socio-demographic 
data, clinical records and laboratory data that were selectively entered 
into an electronic database by trained staffs. Such data were stored in 
password protected Microsoft Access files and updated on a monthly 
basis (Microsoft Corporation, Virginia, USA). 
 
Generally, data collection was associated with many operational 
challenges, particularly documentation and capturing laboratory data. 
Ordering laboratory tests and receiving results entailed a complex chain 
of activities often involving about three different categories of staffs and 
a number of intermediate steps. Not all the players and intermediate 
steps were effectively coordinated, resulting in missing data at various 
points along the chain, which in turn may influence reporting. 
 
Outcome measurements and statistical analysis 
 
Outcomes  of interest  were death,  LTFU, and  attrition.  Among 
patients receiving ART, LTFU was defined as no patient contact for 
more than 3 months before the end of the study period among patients 
who had not died or transferred out of care; patients not receiving 
ART were considered LTFU after 6 months with no patient contact. 
Attrition was defined as LTFU and death combined. Time to attrition 
was calculated as the difference between date of last patient visit, date 
of patient transfer to other treatment  center, or date of death and date 
of first patient visit. One day of follow-up was added for patients with a 
recorded first visit but no other recorded visits or death. 
 
Baseline characteristics were compared between groups using 
Pearson’s Ȥ2 for comparisons between two binomial categorical variables 
and Kruskal Wallis tests for comparisons between categorical variables 
with two or more categories. In addition to gender, comparisons were 
made by age category (0-2, >2-5, >5-10, >10-15, and >15-20 years), 
orphan status, whether or not the child had initiated ART, and whether 
or not the child had recorded CD4 values within one year before to one 
month  after ART initiation. Kaplan-Meier estimates of death, LTFU, 
and attrition  were calculated. The logrank test was used to compare 
Kaplan-Meier estimates of attrition  between children receiving ART 
and those not receiving ART. 
 
Multivariable Cox proportional hazard regression models were 
used to identify predictors of LTFU or attrition among all children in 
the cohort and among the subset of patients receiving ART. Models were 
adjusted for baseline characteristics including gender, orphan  status, 
age, BMI, CD4 count and percent, whether or not ART was received, 
initial ART regimen and year of ART initiation. CD4 count and percent 
were only included in the model among the subset of patients receiving 
ART, as three quarters of the full cohort were missing CD4 data while 
fewer (55%) were missing CD4 data among the subset of children on 
ART. Multiple imputation by chained equations (MICE) was used to 
estimate missing covariate values in all models. Data were analyzed in 
Stata version 12.0 (Stata Corporation, College Station, TX, USA). 
 
Ethical approval 
 
The Uganda National Council for Science and Technology granted 
ethical approval (Ref #: HS 1021) for the study. 
 
Results 
 
Baseline patient characteristics 
 
Between October 2003 and August 2012, 1498 patients were 
enrolled in the Tukula Fenna project. Of the 1498 enrolled, 1162 patients 
had confirmed positive HIV status. Total follow-up was 3466 person- 
years, median follow-up time from enrollment was 24.97 months (IQR 
6.21-65.61), and median follow-up time from ART initiation was 36.57 
months (IQR 17.48-61.24) among the 625 patients who initiated ART. 
 
Baseline characteristics for these 1162 patients stratified by gender 
are summarized in Table 1. Significant differences were found between 
age categories in orphan status, with higher proportions of orphans in 
the >5-10 and >10-15 years groups (38.10% and 36.80%, respectively) 
than  in  the  0-2 (5.02%), >2-5 (17.47%), or  >15-20 (2.60%), p for 
trend<0.01) years age groups. In addition, median BMI z-score was 
lower among children>5-10 and >10-15 years old (-2.39 and -2.40 versus 
-0.81, -0.97, and -1.50 than those 0-2, >2-5, and >15-20, respectively, p 
for trend<0.01). Initiation of ART and timing and make-up of initial 
ART regimens also differed by age category, with a higher percentage 
of children receiving ART in the >5-10 and >10-15 years age groups 
(33.92% and 30.40% versus 13.76%, 19.84%, and 2.08% than those 0-2, 
>2-5, and >15-20 years, respectively, p for trend<0.01). Children in the 
>2-5 years age group made up a large percentage of ART recipients only 
in 2009-2010 (31.55% versus 16.33%, 13.29%, 17.44%, and 14.85% in 
2003-2004, 2005-2006, 2007-2008, 2011-2012, respectively). On  the 
other hand, those in the 0-2 years age group made up a large percentage 
of ART recipients only in 2011-2012 (28.71% versus 4.08%, 10.49%, 
13.37%, and 11.76% in 2003-2004, 2005-2006, 2007-2008, and 2009- 
2010, respectively, p for trend<0.01). Orphans in this cohort were older 
(median  age 8.77 years versus 4.36 years for non-orphans,  p<0.01, 
28.05% and 28.33% of non-orphans  in 0-2 and >2-5 years age groups, 
respectively versus 5.02% and 17.47% of orphans, p<0.01), had lower 
BMI z-scores (median -2.40 versus -1.53 among non-orphans, p<0.01), 
and  were less likely to receive ART (51.3% orphans  received ART 
versus 59.5% non-orphans,  p=0.02). In addition to orphan status and 
age, children receiving ART differed from those not on ART by CD4 
z-score, with a lower median CD4 z-score (-0.18) among ART recipients 
than among non-recipients (1.28, p<0.01). Patients missing CD4 count 
data were more often orphans, (62.9% orphans versus 52.2% among 
those with CD4 data, p=0.01) and younger (median 6.27 years versus 
7.21 years among those with CD4 data, p=0.02). They also weighed less 
(median BMI z-score -1.93 versus -1.36 among those with CD4 data, 
p<0.01), and were much less likely to receive ART (39.4% received ART 
versus 96.6% of those with CD4 data, p<0.01). 
 
Attrition and loss to follow-up 
 
Throughout the entire study period, 5.34% (62) of patients died, 
37.61% (437) were LTFU, and overall attrition was 42.94% (499). This 
resulted in overall incidence of death of 18 per 1000 person-years, of 
LTFU of 126 per 1000 person-years, and of attrition of 144 per 1000 
person-years. At 12, 24, and 36 months  after enrollment,  mortality 
was 4.13%, 4.65%, and 4.99%, LTFU was 21.34%, 26.76%, and 29.52%, 
and overall attrition  was 25.47%, 31.41%, and 34.51%, respectively. 
Attrition,  LTFU and  mortality  were lower among  the 625 patients 
receiving ART, with 12, 24, and 36 month mortality of 1.60%, 2.08%, 
and 2.24%, LTFU of 3.84%, 7.04%, and 8.48%, and overall attrition of 
5.44%, 9.12%, and 10.72%. Figure 1 shows the Kaplan-Meier failure 
curves for death, LTFU, and attrition throughout  the duration of the 
study among all 1162 patients. While mortality ceases to increase after 
the first year or so, LTFU and overall attrition continue to increase after 
12 months, albeit at a slower rate. 
 
Predictors of attrition and loss to follow-up 
 
Cox proportional  hazards ratios for attrition  and  LTFU among 
all patients and those receiving ART are shown in (Table 2 and 3), 
respectively. The single factor  significantly associated with  overall 
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Table 1: Baseline characteristics of 1162 children enrolled in Tukula Fenna HIV programme between October 2003 and August 2012, by gender. 
 
 Overall Male Female  p-value for difference¥ 
n=1162 (100.00%) n=562 (48.36%) n=600 (51.64%) 
Orphaned*, n (%) (n=891)1 538 (60.38) 259 (59.82) 279 (60.92) 0.74 
Age in years, median (IQR) 6.52 (7.31) 6.26 (7.15) 6.82 (7.40) 0.41 
Age group categories, n (%)    0.72 
0-2 years 213 (18.33) 103 (18.33) 110 (18.33)  
>2-5 years 247 (21.26) 125 (22.24) 122 (20.33)  
>5-10 years 380 (32.70) 184 (32.74) 196 (32.67)  
>10-15 years 302 (25.99) 138 (24.56) 164 (27.33)  
>15-20 years 20 (1.72) 12 (2.14) 8 (1.33)  
CD4 count± z-score, median(IQR), (n=293)2 -0.13 (1.61) -0.06 (1.72) -0.18 (1.44) 0.47 
CD4 percent± z-score, median(IQR), (n=228)3 -0.21 (1.56) -0.33 (1.63) 0.00 (1.61) 0.06 
WHO clinical stage, n (%), (n=1158)4    0.28 
I/II 983 (84.89) 468 (83.72) 515 (85.98)  
III/IV 175 (15.11) 91 (16.28) 84 (14.02)  
BMI z-score, median (IQR), -1.74 (2.85) -1.74 (2.88) -1.73 (2.81) 0.21 
(n=999)5     
Receiving ART, n (%) 625 (53.79) 302 (53.74) 323 (53.83) 0.97 
Initial ART regimen by key component, n (%) (n=625)6     
NNRTI-based 591 (94.56) 284 (94.04) 307 (95.05) 0.58 
PI-based 28 (4.48) 16 (5.30) 12 (3.72) 0.34 
Including d4t 180 (28.80) 91 (30.13) 89 (27.55) 0.48 
Including ZDV 407 (65.12) 200 (66.23) 207 (64.09) 0.58 
Year starting ART, n( %), (n=625)7    0.3 
2003/2004 49 (7.52) 20 (6.31) 29 (8.66)  
2005/2006 143 (21.93) 72 (22.71) 71 (21.19)  
2007/2008 172 (26.38) 80 (25.24) 92 (27.46)  
2009/2011 187 (28.68) 101 (31.86) 86 (25.67)  
2011/2012 101 (15.49) 44 (13.88) 57 (17.01)  
* Child considered orphaned if either mother or father was reported deceased at baseline 
± CD4 count and percent results from within 1 year prior to or 1 month after ART initiation 
¥ Pearson’s chi square or Kruskal Wallis chi square tests used, as appropriate 
1 missing orphan status for 271 (23.32%) of children 
2 missing CD4 count for 869 (74.78%) of children 
3 missing CD4% for 934 (80.38%) of children 
4 missing WHO stage for 4 (0.00%) of children 
5 missing BMI z-score for 163 (14.03%) of children 
6, 7 missing information on initial ART regimen and year starting ART for 537 (46.21%) of children 
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Figure 1:  Kaplan-Meier  failure  curves  for  death,  LTFU, and  attrition 
throughout the duration of the study among all 1162 patients. 
0 12 24 36 48 60 72 84 96 108 
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Figure 2: Kaplan-Meier failure curves for overall attrition among those 
patients receiving and not receiving ART. 
 
attrition among 1162 eligible patients was absence of ART (HR: 0.11, 
95% CI: 0.09, 0.14). Both BMI z-score (HR: 0.96, 95% CI: 0.91, 1.00) 
and receipt of ART (HR: 0.12, 95% CI: 0.10, 0.15) were significantly 
negatively associated with LTFU among all 1162 patients in this cohort. 
Figure 2 shows the Kaplan-Meier failure curves for attrition  among 
children who were receiving ART and those who were not yet on ART. 
Attrition  was significantly higher  among  those  not  receiving ART 
(logrank Ȥ2=516.27, p<0.01). In the subgroup of 625 patients receiving 
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 All patients (n=1 162) Patients receiving ART 
(n=625) 
 Hazard ratio 
(95% confidence 
intervals) 
p-value Hazard ratio 
(95% confidence 
intervals) 
p-value 
Male 1.15 (0.94-1.40) 0.09 0.98 (0.66-1.47) 0.94 
Orphaned 1.11 (0.85-1.45) 0.74 1.06 (0.63-1.76) 0.84 
Baseline age in 
months 
1.00 (1.00-1.00) 0.7 1.00 (1.00, 1.01) 0.35 
Baseline BMI z- 
score 
0.97 (0.93-1.03) 0.09 1.01 (0.89-1.13) 0.91 
Baseline CD4 count± 
z-score 
- - 0.90 (0.63-1.26) 0.52 
Baseline CD4 per- 
cent± z-score 
- - 1.03 (0.71-1.49) 0.89 
Receiving ART 0.11 (0.09-0.14) <0.01 - - 
Initial ART regimen     
NNRTI-based - - Reference  
PI-based - - 0.89 (0.34-2.30) 0.8 
Including d4t - - 0.72 (0.32-1.62) 0.43 
Including ZDV - - 0.87 (0.42-1.83) 0.72 
Year starting ART     
2003/2004 - - 0.76 (0.29-2.03) 0.59 
2005/2006 - - 0.52 (0.22-1.27) 0.15 
2007/2008 - - 0.68 (0.26-1.75) 0.42 
2009/2010 - - 0.73 (0.33-1.64) 0.45 
2011/2012 - - Reference  
 
 
Table 2: Cox proportional hazard ratio of risk of attrition* among 1162 children en- 
rolled in Tukula Fenna HIV programme and 625 receiving ART  between October 
2003 and August 2012. 
Table 3: Cox proportional hazard ratio of risk of loss to follow-up* among 1162 
children enrolled in Tukula Fenna HIV programme and 625 receiving ART between 
October 2003 and August 2012. 
 
 All patients (n=1 162) Patients receiving ART 
(n=625) 
 Hazard ratio 
(95% confidence 
intervals) 
p-value Hazard ratio (95% 
confidence inter- 
vals) 
p-value 
Male 1.12 (0.94-1.34) 0.21 0.89 (0.68-1.44) 0.95 
Orphaned 1.03 (0.81-1.30) 0.82 1.03 (0.65-1.63) 0.9 
Baseline age in 
months 
1.00 (1.00-1.00) 0.68 1.00 (1.00, 1.01) 0.41 
Baseline BMI 
z-score 
0.96 (0.91-1.00) 0.04 1.02 (0.92-1.01) 0.69 
Baseline CD4 
count± z-score 
- - 0.88 (0.61-1.26) 0.48 
Baseline CD4 
percent± z-score 
- - 1.03 (0.72-1.48) 0.86 
Receiving ART 0.12 (0.10-0.15) <0.01 - - 
Initial ART regi- 
men 
    
NNRTI-based - - Reference  
PI-based - - 0.87 (0.36-2.07) 0.75 
Including d4t - - 0.69 (0.32-1.48) 0.34 
Including ZDV - - 0.85 (0.42-1.70) 0.64 
Year starting ART     
2003/2004 - - 0.98 (0.39-2.47) 0.96 
2005/2006 - - 0.69 (0.30-1.59) 0.39 
2007/2008 - - 0.75 (0.30-1.87) 0.54 
2009/2010 - - 0.75 (0.35-1.63) 0.47 
2011/2012 - - Reference  
*Attrition defined as death or no contact prior to August 7, 2012 for at least 6 
months among children not receiving ART and for at least 3 months among those 
receiving ART 
± Baseline CD4 count and percent results from within 1 year prior to or 1 month 
after ART initiation 
*Loss to follow-up defined as no contact prior to August 7, 2012, excluding any 
deaths, for at least 6 months among children not receiving ART and for at least 3 
months among those receiving ART 
± Baseline CD4 count and percent results from within 1 year prior to or 1 month 
after ART initiation 
 
ART, no  baseline characteristics were significantly associated with 
either attrition or LTFU. 
 
Missing data 
 
High percentages of children were missing CD4 data 74.78% (CD4 
count)  and  80.38% (CD4%). In  addition,  46.21% of ART regimen 
information, 23.32% of data on orphan status and 14.03% of data on 
BMI z-score were missing. 
 
Discussion 
 
We found that among children and adolescents receiving HIV care 
through the Tukula Fenna project, overall incidence of death was 18 
per 1000 person-years, of LTFU was 126 per 1000 person-years, and 
of attrition  was 144 per 1000 person-years. Not receiving ART was 
the single factor significantly associated with overall attrition among 
the 1162 patients studied, while both baseline BMI z-score and receipt 
of ART were significantly negatively associated with LTFU among all 
patients in this cohort. The higher rate of LTFU and relatively lower 
death rate observed in this study are  in line with the literature, and 
most likely due to considerable misclassification of LTFU, that is, many 
deaths among patients considered LTFU [21,22]. We also think that the 
high LTFU rate may be due in part to delays in obtaining and entering 
data, such that patients considered LTFU may actually have unrecorded 
visits or  unrecorded  deaths. A considerable proportion  of attrition 
occurred during the first 12 months or so after enrolment into care, 
which is consistent with the literature [23,24] and depicted in Figure 
1. Potential explanations include patient factors, such as enrolling into 
 
care with comorbidities and advanced disease, providers factors such 
as delayed linkage to care and or failure of timely initiation of ART in 
eligible patients, and health system factors such as stock-outs of drugs 
and poor geographical access to HIV paediatric services. 
 
Our data also support studies that have demonstrated  that ART 
is protective against LTFU and attrition. That is illustrated by lower 
rates of  deaths,  LTFU and attrition   among patients receiving ART, 
compared to those not receiving ART (Figure 2) over the study period 
[4,25]. Children  on ART may enjoy better overall health including 
improved growth responses [26-28], better enabling them to come in 
for their scheduled visits. There may also be greater motivation on the 
part of caregivers to promote retention in care as part of promotion of 
adherence to ART, such that children not on ART would not receive the 
extra attention paid to those on ART. Studies have also demonstrated 
that healthy HIV infected children have a lower risk of attrition [29,30] 
compared to sick and malnourished children and may explain the 
protective effect of baseline BMI z-scores against LTFU observed in the 
current study. Additionally, as described under the ART care package, 
the existing patient tracking system seems to favour those receiving 
ART, compared to pre-ART patients, due to rationing  of resources. 
Every effort should be made to initiate ART as early as possible among 
HIV positive paediatric patients, as well as streamline linkage to care 
and tracking of HIV positive children not yet receiving ART in order to 
improve retention rates among this sub-group. 
 
There were notable variations in the timing, proportions and trends 
in ART initiation  with respect to  the age categories. For instance, 
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children in the age group >2-5 years made up a large percentage of ART 
recipients only in 2009-2010, while those in 0-2 years constituted a 
large proportion of ART recipients mainly in 2011-2012. It is important 
to recognize that patients in this study have been enrolled from 2003- 
2012 and many changes have occurred over the period in terms of 
general access, treatment  protocols, and in particular,   eligibility for 
ART among children, following the serial revisions of the treatment 
guidelines. Thus, the observed trends could be reflecting increasing 
access with improvements in some services overtime, and increasing 
eligibility for  ART associated with  the  serial revisions [31-35] of 
the guidelines (Table 1). In addition to the changes in the treatment 
guidelines, PMTCT / EID, programmes were introduced in the project 
in 2011 and may explain the observed peak in ART initiation among 
the 0-2 year age group by 2011-2012. 
 
We also saw differences between orphans and non-orphans in terms 
of age, nutritional  status and receipt of ART. Ophans were generally 
older, more malnourished  and were less likely to receive ART. This 
finding could mean that, despite food incentives and the community 
home-based care approach, some orphans have late or limited access to 
ART with resultant poor growth responses. Additionally, and perhaps 
more importantly, this finding may be reflecting issues related to 
custody of some orphans in our setting. Studies conducted in Uganda 
and elsewhere in sub-Saharan Africa have shown that most orphans 
are cared for by grandmothers and or older siblings who generally have 
little or no formal education and usually have no training or financial 
support  for the care and management  of People Living With HIV/ 
AIDS (PLHA) [36-39]. Furthermore, sometimes depending on the 
socio-cultural events in the lives of the caretakers, some orphans may 
have to change caretakers and or relocate to different dwelling places. 
These scenarios and unreliable addresses or telephone contacts make 
it quite difficult tracking some orphans in the communities to provide 
them with psychosocial supports services in real-time. There is urgent 
need to strengthen the orphans and vulnerable children’s programme to 
indentify and support such children and promote their access to health 
care and linkage to the nutritional support clinic. 
 
Missing data was an important challenge in this study, and the main 
reasons have been described under the data collection system. Further 
to that, certain patient characteristics seem to be at play in explaining 
the observed trends. For example, patients missing CD4 count data were 
more often orphans, younger, in poorer health (more malnourished) 
and were much less likely to receive ART. These patient characteristics 
were found to be associated with attrition in the literature [24,30,40] 
and may partly explain our observations. Alternatively, this finding 
could be reflecting poor access to HIV services among these categories 
of patients. 
 
Limitations of this study include using routine programmatic 
data that are based on observational information for research, issues 
with data collection, missing data and their potential impacts on the 
study outcomes. Some of the challenges with observational data are 
that, they may not be designed to answer specific research questions, 
and operational definitions may not be universal, making it difficult 
to compare some outcomes from different studies. In addition, the 
scope of observational data may predispose to bias, which in turn 
could limit the extent to which results can be extrapolated. The current 
analysis has revealed important  gaps in data collection, fragmented 
and uncoordinated data collection tools and selective linkage of mainly 
quantitative data from the clinics and laboratory into the electronic 
database. These challenges translate into poor data capturing and 
missing data for some variables, including those related to attrition and 
LTFU. Missing data about reason for exiting the programme may also 
contribute to these rates, as some patients considered lost to follow-up 
may have transferred to other facilities or tested negative for HIV after 
an initial positive test and terminated from care. Other studies from 
similar LMIC have documented the negative impacts of incorrect or 
missing contact information on LTFU and attrition rates [21,41]. 
 
Multiple Imputation  by Chained  Equations  (MICE) was used 
to estimate missing covariate values in all models in this study. 
Additionally, differences in baseline characteristics were all adjusted 
for, in order to minimize any potential confounding. 
 
We believe that regular training of data collecting staffs, simplifying 
and streamlining data collection tools, together with regular updates 
of patient information  could improve the data capturing system and 
minimize  missing data.  In  addition,  including  qualitative data  on 
home visits, psychosocial support services and orphans and vulnerable 
children support in the electronic databases would facilitate analysis 
and usage of such data for research. Such a measure would explore the 
value of qualitative data and show how they may contribute to explain 
outcomes such as attrition and LTFU in this under studied population. 
Despite the limitations, we believe that our findings remain valid and 
relevant. 
 
Conclusion 
 
Overall, attrition  and  LTFU were relatively high  in  this  study. 
Not receiving ART was the single factor significantly associated with 
attrition in this cohort, while both baseline BMI z-scores and receipt 
of ART were protective against LTFU among HIV positive children 
and adolescents enrolled in the Tukula Fenna project. Efforts should 
be made to initiate ART among all paediatric patients as soon as 
possible, and to provide aggressive follow-up for those not yet receiving 
ART. Orphans  need more nutritional  support  to reduce the burden 
of malnutrition  and improved access to early ART, which could also 
promote growth responses in this vulnerable and understudied group. 
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Abstract 
 
We describe factors determining retention and survival among HIV-infected children 
and adolescents engaged in two health care delivery models in Kampala, Uganda: one 
a community home-based care (CHBC), and the other a facility-based family-centred 
approach (FBFCA). This retrospective cohort study reviewed records from HIV- 
positive children age 0 to 18 years engaged in the two models from 2003 to 2010 
focussing on retention/loss to follow-up, mortality, use of antiretroviral therapy 
(ART), and clinical characteristics. Kaplan Meier survival curves with log rank tests 
were used to describe and compare retention and survival, stratified by model of care 
and age. Overall, 1,623 children were included, 90.0% (1460/1623) from the CHBC. 
Children completed an average of 4.2 years of follow-up (maximum 7.7 years). 
Median age was 53 (IQR: 11-109) months at enrolment. In the CHBC, retention 
differed significantly between those on ART and patients not receiving ART (log- 
rank test, adjusted, p<0.001). Comparing patients on ART in both models, there was 
no significant difference in long-term survival (log-rank test, p=0.308, adjusted, 
p=0.489), while retention was higher in the CHBC; 94.8% versus 84.7% in the 
FBFCA (log-rank test, p<0.001, adjusted p=0.006). Irrespective of model of care, 
children receiving ART had better retention in care and survival. 
Key words: Antiretroviral therapy, HIV care, children, adolescents, retention, 
survival, Uganda 
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Background 
Sub-Saharan Africa (SSA) is home to the vast majority of infants, children, and 
 
adolescents living with HIV and morbidity and mortality remain high [1-3]. For 
 
example, mortality among HIV-infected children has been measured at 4.3% per year 
 
in East Africa and 8.3% in West Africa [4,5]. A recent meta-analysis conducted in 
 
SSA reported a higher risk of early death among perinatally infected children [6]. 
 
Studies have also shown that substantial proportions of children and adolescents 
initiate treatment in SSA with advanced disease (46.3%-72.0%), and comorbidities 
such as TB (5.7%-34.0%) and malnutrition (33%-54%) that tend to be associated 
with early mortality and poor clinical outcomes [7-10]. 
 
 
 
 
Significant child mortality can be averted if antiretroviral therapy (ART) is started 
 
early [11-14]. However, despite overwhelming evidence demonstrating the benefits of 
 
ART, in practice high mortality and loss to follow up persist among HIV-infected 
children and adolescents in care in the resource-limited settings of SSA. In addition to 
scarce resources for programmes for children, the situation is compounded by a 
combination of factors including late HIV diagnosis, missed opportunities to initiate 
ART, health care programmes not tailored to the needs of the infected child and their 
family, and logistic bottlenecks in implementation of care and treatment programmes 
[15,16]. Initiation of ART even among children known to be eligible may be missed. 
 
For instance, in a study of ART-eligible children in The Gambia, only 32.7% started 
 
ART, 47.1% were lost to follow-up, and 13.5% died before initiating ART [17]. 
 
 
 
Retention in care while awaiting ART eligibility can also be a challenge. As an 
illustration, retention varied from 71% to 95% and 62% to 93% at 12 and 24 months, 
respectively, among children and adolescents in ART programmes in several 
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countries of SSA [18]. A prior study in Uganda showed that even with frequent CD4 
 
monitoring, HIV-infected  children experienced significant clinical events while 
 
ineligible for ART according to the 2006 WHO  guidelines [19]. Another study in 
 
Uganda showed that mortality was highest among HIV-infected children under two 
 
years [20]. Given this situation, it is important to assess factors that determine 
 
survival and retention in care among HIV-infected children and adolescents in care in 
resource-limited settings. 
 
 
The present study focuses on retention and survival in two different ART delivery 
models for HIV-infected children and adolescents in Kampala, Uganda. One is a 
facility-based, family-centred approach (FBFCA) adopted by the mother to child 
transmission (MTCT)-Plus programme of the Makerere University-Johns Hopkins 
University (MU-JHU) Research Collaboration. The other is a community home-based 
care (CHBC) implemented by the children’s HIV programme of the Home Care 
Department of Nsambya Hospital. The American Academy of Paediatrics defined 
family-centred care as based on the understanding that the family is the child’s 
primary source of strength and support [21]. Beyond that, the family provides an 
 
enabling environment for using index HIV patients to reach other infected and 
affected family members, build family support for therapy and chronic care, integrate 
other medical needs for the family and thus enhance uptake of HIV and other medical 
services for the family as a unit [22].  In general, CHBC includes any form of care 
 
(physical, psychosocial, palliative and spiritual) given to the sick and the affected in 
their own homes and care extended from the hospital or health facility to their homes 
through family participation and community involvement [23,24]. 
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Factors that determine retention and survival of HIV-infected children and 
adolescents in these health care models are not well understood. The present study 
therefore aims at identifying factors that determine these outcomes for the CHBC of 
Nsambya Hospital and the FBFCA of MU-JHU. We also examine pre-ART deaths 
among children and adolescents in the CHBC to compare mortality rates prior to and 
after ART initiation and to ascertain whether children experiencing mortality prior to 
initiating ART had met the 2010 WHO [25] or the 2011 updated United States (US) 
 
[26] treatment guidelines  for initiating ART or not. 
 
 
 
 
Methods 
 
Study design, setting, and population 
 
This retrospective cohort study covered eight years of records review (2003 to 2010) 
from two facilities implementing HIV paediatric programmes in Kampala, Uganda. 
They included the children’s HIV programme of the Home Care Department of 
Nsambya Hospital, which uses community home-based care (CHBC) and the MTCT- 
plus programme of MU-JHU Research Collaboration, which adopts a facility-based 
family-centred approach (FBFCA). Prior to the study, all children in the FBFCA had 
been initiated on ART, thus the record review at the FBFCA involved only children 
on ART. The facilities are both private-not-for-profit, but differ in service delivery 
approaches, including catchment areas and enrolment practices. The study population 
included all HIV positive infants, children and adolescents aged 0-18 years, enrolled 
 
in both programmes over the study period. Services are generally free of charge under 
both models. 
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Description of health care models 
The FBFCA of MU-JHU Collaboration was established in 2003 with funding from 
Columbia University. Its catchment area includes Kampala and Wakiso districts and 
covers approximately 20 km radius from Mulago hospital in Kampala. Enrolment into 
the FBFCA occurred between 2003 and 2005 and targeted all HIV-infected family 
members as a unit. However, HIV- infected pregnant women in PMTCT served as the 
starting point for identifying other infected family members such as infants, children 
and spouses or partners to be enrolled into care. Eligibility of the women included 
being pregnant, testing HIV positive, attendance of PMTCT clinic, disclosure of HIV 
status to spouse or partner, willingness to be home visited and living within 20 km 
radius from Mulago Hospital. The FBFCA offered comprehensive HIV care, 
including early infant diagnosis (EID), treatment and psychosocial support services, 
other medical services, and routine follow up to eligible women and their families. All 
children enrolled in the study had been initiated on ART prior to the study start date, 
in contrast to the CHBC. The programme has a uniform design that has been 
implemented in many countries. Although funding ended in December 2011, the 
families continue to be followed in a family care approach with funding from the US 
President's Emergency Plan for AIDS Relief (PEPFAR). 
 
 
The CHBC also started in 2003 and it integrates facility-based care with home-based 
care using community involvements as important linkages to decentralize HIV 
services. It has a catchment area covering four districts: Kampala, Wakiso, Mukono 
and Mpigi within 21 km radius from Nsambya hospital. In contrast to the FBFCA, 
children and adolescents in the CHBC were identified directly for participation.  The 
components of the CHBC, details of enrolment practice, pre-ART care and ART care 
packages, as well as  patient tracking system have been described in an earlier work 
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[27].  The CHBC was funded by international donors and partners, and indirectly 
 
supported by PEPFAR. 
 
 
 
Both health care models share some common elements such as providing additional 
support including nutritional supplements, patient education, and counselling of 
patients and their caregivers. Additionally, peer support groups for both adults and 
children have been developed to promote emotional support. Other components of 
psychosocial support include financial assistance for income generating activities, a 
music, dance and drama group and home visiting to track defaulting patients. 
Furthermore, the FBFCA trains peer- educators to provide support and help in the 
clinics. 
 
 
Clinical and laboratory follow up 
Patients were followed up routinely using similar appointment systems, standard 
guidelines and procedures. Generally, children on ART had monthly clinic visits 
under both models, while visits for pre-ART patients depended on their clinical 
conditions and varied between one month under the CHBC and 3-6 months under the 
FBFCA. Initiation of ART was based on the Ugandan National ART guidelines that 
are adopted from the WHO guidelines [25,28-30]. The latter have changed over time, 
 
especially with the more recent move in 2013 to initiate treatment in all children 
 
under 5 years of age, irrespective of clinical or immune status [11]. During visits, 
 
patients were evaluated clinically using WHO clinical staging, age, weight, height, 
ART status, and laboratory investigations like haemoglobin levels and 6-monthly 
CD4 cell counts to monitor response to therapy. Adherence to clinical appointments 
was assessed using appointment schedules, while adherence to medication was 
assessed by caregivers and self-reports in addition to pill counts.  Apart from ART, 
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patients in care received universal Cotrimoxazole prophylaxis for opportunistic 
infections, and secondary prophylaxis for cryptococcal meningitis. In addition, 
patients in the CHBC received isoniazid preventive therapy (IPT) for prophylaxis and 
treatment of latent TB infection. 
 
 
Study outcomes 
 
The main study outcomes were:  a) retention in care, b) deaths among patients on 
ART, and c) pre-ART deaths (deaths before ART initiation) among patients in the 
CHBC programme. Death was ascertained through medical records and verbal 
autopsies carried out by trained community volunteers and counsellors. Retention was 
defined as the proportion of patients known to be alive (either, by patient record 
review or by telephone calls or home visits) and in care at the end of the follow up 
period. We defined loss to follow up (LTFU) as 90 days or more (if on ART) and 180 
days or more (if not on ART) without contact since the last clinic appointment. 
Attrition included deaths and LTFU. Known transfers to continue ART or care at 
other facilities were not considered as attrition. 
 
 
 
Statistical analysis 
We analysed factors that determined retention and mortality among children and 
adolescents enrolled in the two HIV service delivery models described above. We 
used frequency distributions, medians, and interquartile range (IQR) to describe 
baseline characteristics and compared these using Chi-square and Wilcoxon Rank- 
Sum tests, respectively. The baseline characteristics included age groups (at 
enrolment), gender, CD4 cell counts, CD4 per cent, growth responses (weight-for-age 
and height-for-age z-scores), WHO disease stages, ART status, and age at ART 
initiation. Because of differences in baseline characteristics in the two study groups, 
all analyses were adjusted for age at ART initiation, CD4 per cent, CD4 cell counts, 
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proportions on ART, nutritional status and WHO clinical staging using Cox 
regression. In addition, Cox regression was used to determine factors associated with 
attrition among patients on ART in both models, and among patients in the CHBC 
separately, in unadjusted and adjusted analyses. Kaplan Meier curves with log-rank 
tests were used to describe and compare retention and survival, stratified by model of 
care as well as by age groups. Data on CD4 cell count and CD4 per cent were log 
transformed because of skewed distribution. Finally, we used Chi-square test to 
examine the number and proportions of children dying prior to ART initiation in 
terms of whether they met or did not meet the 2011 US or 2010 WHO guidelines for 
initiating ART. All statistical testing was two-sided and conducted at the 5% 
significance level. Data from both programmes were extracted from databases, 
merged and analysed with Intercooled STATA software version 12. 
 
 
Ethical clearance was approved by the MildMay Institutional Review Board and 
Ethics Committee, and the study was registered by the Uganda National Council for 
Science and Technology (UNCST, ref#: HS 1021). The relevant committees waived 
informed consent. The study was funded by the University of Padova, Department of 
Paediatrics and supported by Casa Accoglienza alla vita padre Angelo. 
 
 
 
 
Results 
Baseline characteristics 
 
Overall, 1,623 infants, children, and adolescents were included in the analyses, 90.0% 
(1460/1623) were in the CHBC (Table1). There were slightly but not significantly 
more females compared to males. At enrolment, 47.1% in the CHBC and 38.9% in the 
FBFCA were over 60 months of age (p=0.097). Baseline median CD4 cell counts 
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were 393 cells/mm3 in the CHBC versus 727 cells/mm3 in FBFCA (p <0.001) and 
median CD4 per cents were 5.8 % in CHBC versus 17.0% in FBFCA (p <0.001). By 
WHO clinical staging, 86.4% and 96.9% were in stages I-II in the CHBC and 
FBFCA, respectively, versus 13.6% and 3.1% in stages III-IV in the CHBC and 
FBFCA respectively (p<0.001). ART was initiated among 30.2% in the CHBC model 
compared to 100% in the FBFCA (p<0.0001). Median age at ART initiation was 91.0 
months for children in the CHBC versus 45.9 months in the FBFCA (p <0.001). In 
terms of growth response, 37.4% in the CHBC versus 16.9% in the FBFCA had 
weight-for-age z-scores of -2SD (p<0.001), while 55.7% in the CHBC versus 69.7% 
in the FBFCA had height-for-age z-scores of >-2SD, (p=0.001). 
 
 
Retention in care 
An overall average of 4.2 years of follow-up was observed (maximum 7.7 years). 
Retention in care was substantially and significantly higher among children on ART 
compared to those not on ART within the CHBC model (p<0.001, adjusted, p<0.001). 
A total of 266 children were lost to follow-up, all were within the CHBC model 
(18.2%) with only two (0.5%) on ART lost to follow-up. Among children on ART, 
retention was higher in the CHBC (94.8%, 95% CI: 92.7% - 96.8%) compared to 
(84.7%, 95% CI: 79.1% - 90.2%, p=0.001, adjusted p=0.006) in the FBFCA (Figures 
1A and 1B). 
 
 
 
Factors associated with attrition among children and adolescents on ART in both 
models 
In univariate analysis, attrition was significantly associated with model of care (HR: 
 
0.40, 95%CI: 0.23-0.70, p=0.002); mild immunosuppression (HR: 4.17, 95% CI: 
 
1.31-13.31, p=0.016); severe immunosuppression (HR:3.14, 95% CI: 1.10-8.94, 
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p=0.032); age at ART initiation (HR:0.74, 95% CI: 0.61-0.90, p=0.003); and weight- 
for–age z-scores of >-2SD (HR: 0.40, 95% CI: 0.21-0.77, p=0.006). 
At multivariate modelling, the risk of attrition was significantly associated with model 
of care (HR: 0.29, 95% CI: 0.12-0.70, p=0.006) with the CHBC model promoting 
retention; mild immunosuppression (HR: 4.66, 95% CI: 1.21-17.98, p=0.026); and 
weight-for-age z-scores of >-2SD (HR: 0.31, 95% CI: 0.15-0.65, p=0.002, Table 2). 
 
 
Factors associated with attrition among children and adolescents in the CHBC (30% 
on ART) 
At univariate analysis, the risk of attrition in the CHBC  was significantly associated 
with age group 36-59 months (HR: 0.46, 95% CI: 0.33-0.64, p<0.001); age group 60+ 
months (HR: 0.44, 95% CI: 0.35-0.56, p<0.001); CD4 cell count (HR: 0.85, 95% CI: 
0.78-0.93, p<0.001); CD4 per cent (HR: 0.80, 95% CI: 0.66-0.96, p=0.016) and 
severe immunosuppression (HR: 1.87, 95% CI: 1.44-2.43, p<0.001). The risk of 
attrition was also significantly associated with WHO clinical stages III-IV (HR: 1.84, 
95% CI: 1.47.-2.29, p<0.001); weight-for-age z-scores of >-2SD (HR: 0.76, 95% CI: 
 
0.62-0.93, p=0.007); height-for-age z-scores of >-2SD (HR: 0.69, 95% CI: 0.56-0.84, 
p<0.001) and  receipt of ART (HR: 0.06, 95% CI: 0.04-0.09, p<0.001). 
At multivariate analysis, the risk of attrition was significantly associated with CD4 
cell count (HR: 0.84, 95% CI: 0.74-0.95, p=0.006); WHO clinical stages III-IV (HR: 
1.94, 95% CI: 1.34-2.80, p<0.001), and receipt of ART (HR: 0.04, 95% CI: 0.02-0.08, 
p<0.001, Table 3). 
 
 
 
Retention stratified by age groups 
 
When retention was stratified by age groups among children and adolescents in the 
two models, the difference was only significant in the age group 12 -35 months 
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(P=0.015) and borderline in age group 36 -59 months (P=0.06). This means that age 
has a confounding effect on retention in care (Figure 2). 
 
 
Mortality on ART 
 
There was no significant difference in survival of children and adolescents receiving 
ART between the two models (Figure 3A, p=0.308, adjusted p=0.489). However, 
there was a significant difference between pre-ART deaths (deaths that occurred 
before ART initiation) and deaths among ART patients in the CHBC, (Figure 3B: log- 
rank test p=0.001, adjusted p=0.001). Overall, 34 children died while on ART, 4.8% 
(21/441) within the CHBC and 8.0% (13/163) within the FBFCA. The estimated time- 
point mortality for ART patients in the CHBC were 1.9% at 12 months, 5.9% at 60 
months, and 5.9% at 96 months. For the FBFCA, estimated time-point mortality at 12, 
60, and 96 months were 1.2%, 8.3%, and 9.3%, respectively. 
 
 
 
 
Survival stratified by age groups 
 
When survival was stratified by age groups in the two models, there was no 
 
significant difference, except a borderline effect for age group 36-59 months (log rank 
test: p=0.060, Figure 4). Thus, there was not enough evidence to suggest that age had 
a confounding effect on survival. 
 
 
 
Pre-ART Mortality 
 
Sixty deaths were recorded among children in the CHBC who were not on ART 
(Table 4). Most were known to have met the 2011 US (81.7%) and the 2010 WHO 
(80.0%) treatment initiation guidelines. All recorded infant deaths (under 12 months) 
were among those who had met both treatment guidelines before they died. 
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Discussion 
 
We found that by far the most significant factor determining retention in care among 
infants, children, and adolescents with HIV was being on ART. Once on ART, there 
was no difference in survival between the CHBC and FBFCA. In addition to ART 
initiation directly promoting survival [31-33], we observed a substantial indirect 
 
survival effect by ART dramatically enhancing retention (Figure 1B). The CHBC 
model therefore stands to improve child survival greatly if ART is initiated early. 
Furthermore, patients can benefit from ancillary interventions to promote health and 
well-being such as food supplements, adherence counselling, and psychosocial 
support  also effective only if retained in the programmes [34-36]. Of note, the CHBC 
 
and FBFCA models reach two different populations of HIV-infected children (Table 
 
1). The FBFCA engages the children at or nearer to birth, whereas the CHBC attempts 
to find them in the communities, thus complementing each other. Operational 
synergies between the two models could result in a wider reach and greater ART 
coverage among HIV-infected children and adolescents. 
 
 
 
We also observed that the majority of the pre-ART deaths occurred in children and 
adolescents who had met the 2011 US and the 2010 WHO treatment guidelines but 
did not initiate therapy for various reasons. This finding illustrates the failure of 
timely initiation of ART, which in turn may be linked to programmes that are not 
tailored to meet the needs of the infected child and family. For instance, at the time of 
this study, there were no PMTCT/EID services within the CHBC. That scenario, 
coupled with delayed HIV diagnosis, drug stock-outs, logistic challenges and fragile 
linkages to ART initiation and psychosocial support services may have resulted in 
considerable LTFU and deaths (Figures 1B and 3B) between testing and initiating 
care and treatment [37-40] in the CHBC. There is urgent need for concerted efforts to 
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ensure timely initiation of ART in children and adolescents in the CHBC. To that 
effect, simplification of treatment guidelines to universal treatment regardless of 
disease stage would not only help such efforts, but also eliminate missed opportunities 
to initiate ART, while awaiting eligibility criteria to be met [3]. 
 
 
 
 
We also saw that nearly one out of every five deaths occurred in children and 
adolescents who had not yet met either guideline for initiation. As shown by the 
literature, significant clinical events do occur in HIV-infected children and 
adolescents even before meeting the previous guidelines [19,20]. Our data therefore 
 
support the 2013 WHO consolidated guidelines recommending early ART initiation 
 
for children less than five years old regardless of CD4 cell count [41]. However, the 
 
new guidelines may not address substantial mortality for children over five. Given the 
number of deaths we observed in children over five who had not met the guidelines, 
coupled with substantial LTFU when not on ART, we believe the benefits of early 
ART outweigh the risk of delayed ART for this older group as well. We therefore 
endorse extending initiation of ART to all HIV-infected children and adolescents 
irrespective of their CD4 cell counts as a means to avert child deaths. 
 
 
 
Among patients on ART in both models, retention was higher in the CHBC. Factors 
that may explain this observation include decentralized voluntary counselling and 
testing and ART refills involving outreach clinics within the communities. In 
addition, ART patients in the CHBC have a ‘priority’ tracking system within the 
clinics compared to patients not receiving ART, due to scanty resources [27]. 
 
However, the ‘priority’ tracking may not have promoted retention of children not on 
 
ART. This disparity calls for an integrated approach towards patients tracking. 
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Although all the children were on ART in the FBFCA and retention was relatively 
stable, the services were not decentralized. Hence, we believe that geographical 
access may have been a barrier to retention over time. We also think that 
socioeconomic factors and education level of caretakers may have contributed to the 
differences in retention. 
 
 
 
We also noted that, age was a confounder for retention but not survival (Figures 2 and 
 
4). Indeed, when retention was stratified by age groups, more children in the CHBC 
than in the FBFCA were retained in the age groups 12 -35 months and 36-59 months. 
Many of the children in the FBFCA in those age groups were ‘graduates’ of the 
PMTCT programme and were exposed to single dose Nevirapine (sd NVP) for 
PMTCT and were on NVP-based first line ART regimens. Studies from Uganda and 
elsewhere have shown that, exposure to sd NVP during PMTCT and initiating NVP- 
based first line ART regimens in HIV-infected children was associated with 
suboptimal clinical outcomes [42-45] and may partly explain this observation. 
 
Additionally, maternal health issues could be contributory factors.  On the contrary, 
the CHBC had no PMTCT programme and most probably had more non NVP- 
exposed children for those age groups and thus better outcomes on ART.  For the age 
group 5 years plus, retention was not different between the two models, as they were 
either far removed from exposure or were never exposed to sd NVP. 
 
 
 
Additionally, we found that among patients receiving ART, attrition was significantly 
associated with model of care, mild immunosuppression and being more underweight 
(Table 2), whereas in the CHBC, the risk of attrition was significantly associated with 
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CD4 cell count, WHO clinical stages III-IV and absence of ART (Table 3). These 
 
findings have been described consistently in the literature [10,13,27]. 
 
 
 
 
In terms of growth responses, we saw that children in the CHBC were significantly 
more underweight, whereas, those in the FBFCA were significantly more stunted with 
some overlap. Although, it is well recognized that HIV infection in children 
compromises growth responses, in Uganda, 39% and 16% of all children less than 5 
years are stunted and underweight respectively, demonstrating that important non- 
HIV contributors to stunting and wasting exist, in particular high background rates of 
TB and other coinfections, food insecurity and malnutrition  [46,47]. Children in the 
 
FBFCA were relatively younger, mainly enrolled through PMTCT/ EID programmes 
and were all on ART. Thus, the observed growth responses could be related to 
complications of perinatal HIV infection, younger age as well as background factors. 
In contrast, children in the CHBC were older and only 30% were on ART. In an 
earlier study [27], we noted that about 46% of the patients in the CHBC were orphans 
 
and majority were malnourished, older, and less likely to receive ART. We therefore 
think that these factors could be contributing to the observed growth responses in that 
cohort. 
We note potential limitations to our data and conclusions. First, the data were 
observational and based on programmatic information. Second, the two programmes 
should be interpreted in the context of reaching different populations of children and 
the direct comparisons are cautious. Patients were not randomized to receive one or 
the other model, but rather circumstances (such as distance to facilities) dictated what 
options were available. Third, some aspects of the interventions were shared by both 
models, such as guidelines for initiating ART and nutritional support and could be 
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potentially confounding. Fourth, the high level of loss to follow-up among patients 
not on ART in the CHBC leaves much doubt on the final disposition of the children in 
that programme. We expect that many of the children lost to care may have died; 
however, the characteristics of those who died and those who may have accessed care 
elsewhere are not known [48-50]. Additionally, there were differences in the study 
 
population sizes, proportions in age groups and baseline characteristics, all of which 
could be potential confounders. Consequently, the analyses were adjusted, including 
stratification of retention and survival by model of care and age groups, in order to 
minimize any potentially confounding effects. 
We also acknowledge that our findings reflect data from programmes in one urban 
setting in East Africa, and therefore may not be generalizable to family–centred 
approach and community home-based care models in other settings. Despite the 
limitations, we firmly believe that our findings remain valid and relevant. 
 
 
 
Conclusion 
 
We conclude that, irrespective of model of care, children receiving ART had better 
retention in care and therefore long-term survival. Encouragingly, if children were on 
ART, then their survival was as good, if not slightly better, in the CHBC compared to 
the FBFCA. Based on our observations, substantial improvement in child survival can 
be achieved in either a community-based or a family-care model as long as HIV- 
infected children are identified early and begun on ART. To ensure this occurs, early 
identification of HIV infected children requires strong linkages of pregnant HIV- 
infected women to PMTCT services; active tracking to ensure all HIV exposed infants 
receive Polymerase Chain Reaction-based early infant diagnosis. Additionally, rapid 
early initiation of ART among HIV infected infants and children are essential. We 
anticipate the move to early initiation of ART in all HIV-infected children and 
- 19 -  
adolescents in resource-limited settings, irrespective of their CD4 cell counts, will 
improve survival. 
Among ART patients in both models, attrition was significantly associated with 
model of care, mild immunosuppression and being underweight. In the CHBC, 
attrition was significantly associated with CD4 cell count, WHO clinical stages III-IV 
and absence of ART. 
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Table1:Baseline characteristics of HIV-infected children and adolescents in a community 
home-based care model and a facility-based family-centred approach, Kampala, Uganda, 
2003-2010 
 
Characteristic  Community- 
based home care 
approach 
N = 1, 460 
Facility-based 
family-centred 
approach 
N = 163 
Total 
N = 1,623 
P values 
  n (%) n (%) n (%)  
Age (months) 
< 12 
  
371 (25.4) 
 
54 (33.1) 
 
425 (26.2) 
 
0.097 
12 – 35  228 (15.6) 21 (12.9) 249 (15.3)  
36 – 59  173 (11.9) 23 (14.1) 196 (12.1)  
60+  688 (47.1) 65 (38.9) 753 (46.4)  
Gender      
Female  746 (51.1) 87 (53.4) 833 (51.3) 0.581 
Male  714 (48.9) 77 (46.6) 790 (48.7)  
Cd4count& percent 
Median CD4 (IQR) 
Median CD4 % (IQR) 
 393 (51 – 762) 
5.8 (0.1 – 16.9) 
727 (442 - 1348) 
17.0 (10.0 – 25.0) 
438 (78 - 824) 
8.1 (0.2 – 18.1) 
<0.001 
<0.001 
Level 
immunosuppression 
CD4 
Not significant 
of 
by 
 
 
 
 
273 (24.4) 
 
 
 
 
39 (25.0) 
 
 
 
 
312 (24.4) 
 
 
 
 
0.424 
Mild  122 (10.8) 21 (13.5) 143 (11.1)  
Advanced  131 (11.6) 12 (7.7) 143 (11.1)  
Severe  605 (53.5) 84 (53.8) 689 (53.5)  
On ART      
Yes  441 (30.2) 163 (100) 604 (37.2) <0.001 
No  1019 (69.8) 0 (0.0) 1019 (62.8)  
Age at ART initiation (months) 
Median (IQR) 91.0 (48.9 – 135.5) 45.9 (6.5 – 85.0) 78.6 (34.0 – 124.6) <0.001 
WHO clinical staging 
I – II  1258 (86.4) 157 (96.9) 1415 (87.5) <0.001 
III – IV  198 (13.6) 5 (3.1) 203 (12.5)  
Growth response     
Weight for Age 
 -2SD 430 (37.4) 24 (16.9) 454 (35.2) <0.001 
>-2SD 719 (62.6) 118 (83.1) 837 (64.8)  
Height for Age     
 -2SD 508 (44.3) 43 (30.3) 551 (42.8) 0.001 
>-2SD 639 (55.7) 99 (69.7) 738 (57.2)  
  
 HR‡ (95% CI) P  HR‡ (95% CI) P 
Model of care      
FBFCA 
CHBC 
1 
0.40 (0.23 – 0.70) 
 
0.002 
 1 
0.29 (0.12 – 0.70) 
 
0.006 
Age (months)      
< 12 1   1  
12 – 35 0.73 (0.31 – 0.70) 0.465  1.95 (0.39 – 9.89) 0.419 
36 – 59 0.29 (0.09 – 0.87) 0.028  1.63 (0.18 – 15.17) 0.664 
60+ 0.43 (0.22 – 0.85) 0.015  3.19 (0.27 – 37.03) 0.354 
 
Female 
 
1     
Male 1.13 (0.64 – 1.99) 0.675    
 
CD4 † 
 
0.86 (0.69 – 1.06) 
 
0.162    
CD4 % † 1.00 (0.57 – 1.77) 0.992    
 
Table 2: Factors associated with attrition among HIV-infected children and adolescents on 
ART  in a community home-based care model and a facility-based family-centred approach, 
Kampala, Uganda, (2003-2010) using Cox regression 
Characteristic Unadjusted 
(Univariate analysis) 
Adjusted* 
(Multivariate analysis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gender 
 
 
 
Cd4count & percent 
 
 
 
Level of 
immunosuppression 
by CD4 
Not significant 1 1 
Mild 4.17 (1.31 – 13.31) 0.016 4.66 (1.21 – 17.98) 0.026 
Advanced 0.87 (0.16 – 4.73) 0.868 0.89 (0.09 – 9.12) 0.921 
Severe 3.14 (1.10 – 8.94) 0.032 3.16 (0.81 – 12.39) 0.099 
Age at ART initiation 
Months† 0.74 (0.61 – 0.90) 0.003 0.67 (0.31 – 1.44) 0.309 
WHO clinical staging 
I – II 1 
III – IV 1.52 (0.68 – 3.38) 0.309 
Growth response 
Weight for Age 
 -2SD 1 1 
>-2SD 0.40 (0.21 – 0.77) 0.006 0.31 (0.15 – 0.65) 0.002 
Height for Age 
 -2SD 1 
>-2SD 0.54 (0.28 – 1.03) 0.060 
‡ Hazard of attrition;  † Log transformed due to skewed data; 
*Only factors significant at univariate or borderline were considered into multivariate 
  
Table 3: Factors associated with attrition  among HIV-infected children and adolescents in 
the CHBC model, Kampala, Uganda (2003-2010) using Cox regression 
Characteristic Unadjusted 
(Univariate analysis) 
Adjusted* 
(Multivariate analysis) 
 
 
ART 
HR‡ (95% CI) P HR‡ (95% CI) P 
No 
Yes 
Age (months) 
1 
0.06 (0.04 – 0.09) <0.001 
1 
0.04 (0.02 – 0.08) <0.001 
< 12 1 1 
12 – 35 0.85 (0.65 – 1.10) 0.218 2.18 (0.97 – 4.92) 0.060 
36 – 59 0.46 (0.33 – 0.64) <0.001 1.65 (0.74 – 3.69) 0.225 
60+ 0.44 (0.35 – 0.56) <0.001 1.38 (0.63 – 3.01) 0.418 
Gender 
Female 1  
Male 1.11 (0.93 – 1.33) 0.243 
Cd4count & percent 
CD4 † 0.85 (0.78 – 0.93) <0.001 0.84 (0.74 – 0.95) 0.006 
CD4 % † 0.80 (0.66 – 0.96) 0.016   
Level of 
immunosuppression 
by CD4 
Not significant 1 
Mild 0.99 (0.66 – 1.49) 0.968 
Advanced 0.89 (0.59 – 1.34) 0.590 
Severe 1.87 (1.44 – 2.43) <0.001 
Age at ART initiation 
Months† 0.85 (0.66 – 1.10) 0.209 
WHO clinical staging 
I – II 1 
III – IV 1.84 (1.47 – 2.29) <0.001 1.94 (1.34 – 2.80) <0.001 
Growth response 
Weight for Age 
 -2SD 1 
>-2SD 0.76 (0.62 – 0.93) 0.007 
Height for Age 
 -2SD 1 
>-2SD 0.69 (0.56 – 0.84) <0.001 0.81 (0.60 – 1.09) 0.162 
‡ Hazard of attrition;  † Log transformed due to skewed data; 
*Only factors significant at univariate or borderline were considered into multivariate 
  
Table 4: Deaths among children and adolescents in community home-based care who were not on 
ART classified according to whether the US 2011 or WHO 2010 initiation guidelines were met or 
not , Kampala, Uganda, 2003-2010. 
 
 
 
Age group for 
 
US (months) 
 
 
N 
US CDC 
guidelines1 for 
ART met 
Age group for 
WHO 
(months) 
 
 
N 
WHO 
guidelines2 for 
ART met 
<12 11 11 (100%) <12 11 11 (100%) 
12-35 13 10 (76.9%) 12-24 9 9 (100%) 
36-59 4 3 (75.0%) 24-59 8 5 (62.5%) 
60+ 32 25 (78.1%) >60 32 23 (71.9%) 
Overall 60 49 (81.7%) Overall 60 48 (80.0%) 
 
 
Source: WHO and US treatment guidelines 
 
1. US CDC 2011 criteria for ART initiation: <12 months all should be on ART; 12 – 35 months if CD4 
 
<1000 or <25%; 36 – 59 months if CD4 <750 or <25%; 60+ months if CD4 <500. 
 
2. WHO 2010 criteria for ART initiation: <12 months all should be on ART; 12 – 24 months all should 
be ART; 24 – 59 months if CD4 <750 or <25%; 60+ months if CD4 <350. 
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Figure  1:  Retention  in  care,  HIV-infected  children  and  adolescents  in  a  facility-based  family 
centred approach (FBFCA) and a community home-based care (CHBC) model, on and not on 
ART, Kampala, Uganda, 2003-2010 
Fig 1A: FBFCA (all on ART) versus CHBC (on 
ART) 
Fig 1B: CHBC (on ART) versus CHBC (not on 
ART) 
 
 
 
 
Community home-based care(on ART) 
Community home-based care(not on ART) 
 
Facility-based family-centered approach (all on ART) 
Community home-based care (on ART) 
 
Log rank test: P = 0.001 
Adjusted: P=0.006 
Log-rank test: P<0.001 
Adjusted: P<0.001 
 
 
 
Number at risk 
0 12 24 36 48 60 72 84 96 
Time (months) 
 
 
Number at risk 
0 12 24 36 48 60 72 84 96 
Time (months) 
FB(all on ART)  163 139 7 
HB(on ART)  441 250 38 
HB(on ART)  441 250 38 
HB(not on ART) 1019 155 14 
 
Legend: Figure 1 compares retention among patients on ART in the two models, and it was 
higher in the CHBC. 
  
P
er
ce
nt
 re
ta
in
ed
 in
 c
ar
e 
P
er
ce
nt
 re
ta
in
ed
 in
 c
ar
e 
0.
00
 
0.
25
 
0.
50
 
0.
75
 
1.
00
 
0.
00
 
0.
25
 
0.
50
 
0.
75
 
1.
00
 
P
er
ce
nt
 re
ta
in
ed
 in
 c
ar
e 
0.
25
 
0.
50
 
0.
75
 
P
er
ce
nt
 re
ta
in
ed
 in
 c
ar
e 
0.
25
 
0.
50
 
0.
75
 
0.
00
 
1.
00
 
0.
00
 
1.
00
 
Figure 2: Retention stratified by age group among HIV-infected children and adolescents in a CHBC 
and a FBFCA in Kampala, Uganda (2003-2010) 
 
 
<12 months 12-35 months 
 
 
 
 
 
Facility-based family-centered approach (all on ART) 
Community home-based care (on ART) 
Facility-based family-centered approach (all on ART) 
Community home-based care (on ART) 
 
Log rank test: P = 0.664 Log rank test: P = 0.015 
 
 
 
 
Number at risk 
0 12 24 36 48 60 72 84 96 
Time (months)  
Number at risk 
0 12 24 36 48 60 72 84 96 
Time (months) 
FB(all on ART)   54 43 0 
HB(on ART)   38 10 0 
FB(all on ART)   21 15 0 
HB(on ART)   66 35 5 
 
36-59 months 60+ months 
 
 
 
 
 
Facility-based family-centered approach (all on ART) 
Community home-based care (on ART) 
Facility-based family-centered approach (all on ART) 
Community home-based care (on ART) 
 
Log rank test: P = 0.060 Log rank test: P = 0.245 
 
 
 
 
Number at risk 
0 12 24 36 48 60 72 84 96 
Time (months)  
Number at risk 
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Legend: Figure 2 stratifies retention by age groups in the two models. Age groups 12-35months and 36- 
59 months appear to be confounders for retention. 
  
Figure 3: Survival on anti-retroviral therapy (ART), HIV-infected children and adolescents 
in a facility-based family-centred approach (FBFCA) and a community home-based care 
(CHBC) model, Kampala, Uganda, 2003-2010 
 
Fig 3A: FBFCA (all on ART) vrs CHBC   (on ART) Fig 3B: CHBC (Pre -ART) vrs CHBC (on ART) 
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Legend: Fig 3A compares survival trends among children and adolescents on ART in both models, and 
shows that they were not significantly different. On the other hand, Fig 3B shows that survival trends 
differed significantly between patients on ART in the CHBC and those not receiving ART (pre-ART). 
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Figure 4: Survival stratified by age group among HIV-infected children and adolescents in a CHBC and a 
FBFCA in Kampala, Uganda (2003-2010) 
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Legend: Figure 4 stratifies survival by age groups in the two models. Apart from a borderline effect for 
age group 36-59 months (p=0.060), there was not enough evidence to suggest that age had a 
confounding effect on survival in the two models. 
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1 
2 
3 ABSTRACT 
4 
5 Background. Delays detecting treatment failure and switching to second line combination antiretroviral 
6 
7 therapy (cART) are often observed in HIV-infected children of low-middle income countries (LMIC). 
8 
9 Methods.  An observational  study included HIV-infected  children attending the Beira Central Hospital 
11 
12 (Mozambique) and the St. Raphael of St. Francis Nsambya Home Care (Uganda) evaluated clinical and 
13 
14 immunological failure according to WHO 2006 guidelines. Baseline predictors for cART failure and for 
15 
16 drug substitution were explored in unadjusted and adjusted Cox proportional hazard models. 
17 
18 Results.  218 of 740 children with at least 24 weeks follow-up experienced treatment failure (29% 95%CI 19 
20 
21 [26-33]),  with  crude  incidence  of  20.0  events  per  100  person-years   (95%CI  17.5-22.9).  Having 
22 
23 tuberculosis co-infection or WHO stage 4, or starting a non-triple cART significantly increased risk of 
24 
25 failure. 
26 
27 202 of 769 (26.3%) children receiving cART substituted drug(s), with crude incidence of 15.4 events per 
28 
29 100 person-years (95% CI 13.4-17.7). Drug toxicity (18.3%), drug availability (17.3%) and tuberculosis 
31 
32 drugs interaction (52, 25.7%) were main reported reasons while only 9 (4%) patients switched cART for 
33 
34 clinical  or  immunological  failure.  Children  starting  lamivudine-zidovudine-nevirapine   or  lamivudine- 
35 
36 stavudine-efavirenz  or lamivudine-zidovudine-efavirenz  were more likely to substitute drugs. Increased 
37 
38 substitution was found in children with mild immunosuppression  and tuberculosis co-infection at cART 39 
40 
41 initiation as well as poor adherence before drug substitution. 
42 
43 Conclusions. Considerable delay in switching to second line cART may occur despite an observed  high 
44 
45 rate of failure. Factors including WHO clinical stage and tuberculosis co-infection should be evaluated 
46 
47 before starting cART. Toxicity and drug adherence should be monitored to minimize drug substitution in 
48 
49 LMIC. 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
Randomized trials were conducted to evaluate the optimal first antiretroviral regimen for reducing the risk 
of  treatment  failure.  Findings  from  the  P1060  trial  reported  an  increased  risk  of  failure  starting  a 
nevirapine (NVP)-based cART in infants and young children (13, 22, 23). This was not confirmed by the 
PENPACT1 trial, where no difference in clinical and virological outcomes were shown between NNRTI 
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1 
2 
3 
4 
5 
6 
7 Background: 
8 
 
 
MANUSCRIPT 
9 The global scaling up of treatment and care for people living with HIV (PLWH) has led to a 43% decline 
11 
12 in new HIV paediatric infections since 2003, with 330,000 newly infected children in 2011. Despite the 
13 
14 efforts to expand access to combination antiretroviral therapy (cART), only 28% of eligible children have 
15 
16 received it (1). Expansion of early HIV diagnosis coverage, prompt cART initiation and better retention 
17 
18 in care remain major goals (2, 3) and the lack of laboratory monitoring frequently observed in low and 19 
20 
21 middle-income  countries  (LMIC)  should not represent  a barrier to cART distribution  in children  (4). 
22 
23 However, optimization of the clinical management of PLWH and prompt diagnosis of treatment failure 
24 
25 are becoming more and more critical in the context of life-long treatment and limited drug availability. 
26 
27 Although virological failure is widely considered the gold standard to detect treatment failure, clinical and 
28 
29 immunologic parameters are often the only criteria available in LMIC (5, 6). CD4 cell monitoring has 
31 
32 been  shown  to  be  a  poor  predictor  of  virological  failure  in  treatment  experienced  children  (7-9), 
33 
34 particularly  when  severely  immune-compromised  (10).  Studies  in LMIC  have  reported  high  rates  of 
35 
36 virological suppression in children up to 5-6 years after treatment initiation (11, 12), however treatment 
37 
38 failure rates of 10-34% were observed among children after two to three years of cART (13-18). Program 39 
40 
41 reports suggest that only a small proportion of patients on treatment are receiving a second line therapy, 
42 
43 an estimated 4% of adults and 1-14% of children (16, 18-20). Delays in detecting treatment failure and 
44 
45 switching  to  second  line  therapy  lead  to  the  development  of  HIV  drug-resistance,  compromising 
46 
47 subsequent  regimens  (6, 21).  This  is particularly  relevant  for  children,  due  to the  lack  of paediatric 
48 
49 formulations. 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
December 2009 at the Beira Central Hospital (HCB) in Mozambique and the Nsambya Home care (NHC) 
department   of   St.   Raphael   of   St.   Francis   Hospital   in   Uganda.   Two   Italian   non-governmental 
organizations, Doctors with Africa Cuamm (Mozambique) and Associazione Casa Aiuto alla Vita Padre 
Angelo (Uganda), partnered with these hospitals to provide pediatric HIV care. 
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1 
2 
3 and PI-based regimens in older children (24). Data to inform the most durable NRTI backbone in the 
4 
5 context of a triple therapy is still limited. Conflicting results were reported concern the use of abacavir 
6 
7 (ABC) as first line regimen: Green et al. suggested that abacavir (ABC) may be preferable to zidovudine 
8 
9 (AZT) combination with lamivudine (3TC) (25), while poorer early virological outcomes were recently 
11 
12 observed  in  children  starting  ABC/3TC-based  first  line  regimens,  compared  to  d4T/3TC  (26,  27). 
13 
14 Identifying  optimal  regimens  is particularly  relevant  for children  with HIV/TB  co-infection  living in 
15 
16 LMIC, where  NVP  is  widely  preferred  to  EFV  or  a  triple  NRTI-based  regimen,  due  to  its  better 
17 
18 acceptability and relatively low cost (28). 19 
20 
21 Drug   substitution   is  often   required   to  optimize   antiretroviral   treatment   (19,   29).   Results   from 
22 
23 observational  studies estimate a probability of cART discontinuation  or modification  ranging between 
24 
25 2.8-20%  in adults  of LMIC  (19,  30-34).  A randomized  study  conducted  in children  shows  a cART 
26 
27 switching/discontinuation   rate  up  to  29%  (24).  Acute  and  chronic  toxicity,  drug  intolerance,  poor 
28 
29 adherence and treatment failure remain the major determinants of cART modification (35-38). Drug costs 
31 
32 and/or stock outs due to challenges in adequately forecasting and maintaining an effective supply chain 
33 
34 have been cited as further reasons for cART discontinuation in LMIC (31, 33). 
35 
36 The aim of this study is to estimate the rate and predictors of cART treatment failure in two pediatric 
37 
38 cohorts from Mozambique and Uganda during a five years follow-up period, and to explore the rate of 39 
40 
41 and factors associated with drug-substitution. 
42 
43 
44 
45 Methods. 
46 
47 Setting and study design. 48 
49 We conducted  a retrospective  cohort study among children starting cART between January 2005 and 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
self-reported number of doses was more or less than 95% of expected monthly number of doses. HIV 
related clinical events were diagnosed with or without biological confirmation, depending on lab facilities 
available, while  immunodeficiency was classified as mild, advanced and severe according to the WHO 
2006 thresholds (39). For the treatment failure analysis the period of follow-up was from cART initiation 
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1 
2 
3 Both  programs  provided  HIV  counseling  and  testing,  cotrimoxazole  prophylaxis,  cART,  laboratory 
4 
5 investigations and management of opportunistic infections. Infants and children under 18 months of age, 
6 
7 known or suspected to be exposed to HIV, were diagnosed through HIV-1 DNA testing. Patients were 
8 
9 considered eligible for cART according to WHO 2006 guidelines (39). 
11 
12 Laboratory examinations including full blood count, liver function tests, creatinine and CD4 count were 
13 
14 required before starting cART, as well as a chest x-ray and acid fast bacilli (AFB) testing to exclude TB if 
15 
16 suspected.  In  the  absence  of  contraindications,  written  consent  was  collected  when  enrolling  in  the 
17 
18 programme and before starting cART. Throughout the study, patients were switched to second line cART 19 
20 
21 when treatment failure was identified following WHO 2006 guidelines (39). 
22 
23 The study was approved by the Uganda National Council for Science and Technology and the Nsambya 
24 
25 Hospital and HCB ethics committees (Uganda) and by the Gabinete Do Director Gerar , Ministerio Da 
26 
27 Saudè of HCB (Mozambique) . 
28 
29 
30 
31 
32 Data collection. 
33 
34 In Mozambique, data were collected from clinical charts and paper registries and entered in the hospital's 
35 
36 electronic patient database system. Similarly, in Uganda, routine clinical data were recorded in paper- 
37 
38 based patient files and registries and entered into an electronic interface by trained staff. 39 
40 
41 Children  were examined  at least monthly  during the first six months  of cART  and then every  three 
42 
43 months  in  Mozambique,  while  in  Uganda  monthly  visits  were  maintained  throughout  the  follow-up 
44 
45 according to the project design. Weight and height were measured at every clinic visit. Full blood count, 
46 
47 liver function tests and glucose assays were performed every 6 months, and CD4 counts every 6 to 12 
48 
49 months. Adherence to cART was assessed at every follow-up visit and defined as “good” or “poor” if the 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
modifications. All analyses were conducted in R version 2  (R Development Core Team, Vienna, Austria) 
and Stata version 12.0 (Stata Corporation, College Station, TX, USA). 
For  both  treatment  failure  and  drug  substitution  analyses,  frequency  distributions  and  median  and 
interquartile range (IQR) were used to describe baseline patient characteristics. Baseline characteristics of 
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1 
2 
3 up to the treatment failure outcome, while follow-up was from treatment initiation to first cART drug 
4 
5 substitution  for drug substitution  analysis.  For children  without treatment  failure  or drug-substitution, 
6 
7 follow-up was censored at date of death, loss to follow up (LTFU, defined as missing follow-up visits for 
8 
9 more than 6 months),  transferred to other clinic, confirmed HIV-negative or aged more than 18 years old, 
11 
12 last CD4 measurement, or last anthropometric or adherence record, whichever occurred latest. 
13 
14 
15 
16 Endpoint Definitions  and Study Population. 
17 
18 Drug-substitution was defined as substitution of one or more drugs of the first antiretroviral regimen for 19 
20 
21 any reason. Reasons for drug substitution were classified retrospectively from the inspection of what was 
22 
23 reported  by  clinicians  in  patient’s  clinical  charts.  Clinical  and  immunological  failure  were  defined 
24 
25 according to the WHO 2006 criteria, using CD4 measurements and WHO disease stage from at least 24 
26 
27 weeks after cART initiation (39). Treatment failure, when both clinical and immunological failure were 
28 
29 observed, was considered to occur at the earliest of the two events. 
31 
32 For analysis of treatment failure, only children with at least 24 weeks of follow-up post-cART initiation 
33 
34 were included to ensure sufficient time for treatment response. 
35 
36 For analysis of cART drug substitution, children who received an ABC component in their initial cART 
37 
38 regimen  were  excluded,  as  first  line  ABC  treatment  was  systematically  administered  to  children 39 
40 
41 diagnosed with active TB and all patients initially on ABC were routinely switched to EFV once the TB 
42 
43 infection cleared. 
44 
45 
46 
47 Statistical analyses. 48 
49 In this intent-to-treat analysis, all children were included from cART initiation, regardless of subsequent 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
later (p 0.01 and <0.01, respectively) than children included in the study. 
Treatment failure analyses 
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1 
2 
3 interest were gender, age at treatment initiation, Body Mass Index (BMI, weight(kg)/height2(m)) for age 
4 
5 z-score, WHO disease stage, initial cART treatment regimen (also by most potent component), adherence 
6 
7 to cART, CD4 count and percent, and immunodeficiency  classification.  All descriptive  analyses were 
8 
9 stratified by hospital. Differences on all key variables at baseline between these strata were determined 
11 
12 using Pearson’s chi-squared test for categorical variables, the t-test for difference in means for baseline 
13 
14 BMI for age z-score, and the Wilcoxon rank sum test for all other continuous variables. 
15 
16 Unadjusted Cox proportional hazards models were used to determine the odds of treatment failure and 
17 
18 cART  drug  substitution.  The  following  variables  were  considered  in  a  multivariate  adjusted  Cox 19 
20 
21 proportional hazards model of treatment failure: cART treatment regime, age, adherence, gender, country 
22 
23 of treatment, baseline disease stage, immunodeficiency  status, and BMI for age z-score. The following 
24 
25 variables  were  considered  in a multivariate  adjusted  Cox  proportional  hazards  model  of cART  drug 
26 
27 substitution: cART treatment regime, adherence, classification of immunodeficiency status, WHO disease 
28 
29 stage, and age group. A backward selection procedure was used to create these adjusted models with a 
31 
32 variable being included in the model if it resulted in an improvement in the model fit as defined by the 
33 
34 Akaike Information Criterion (AIC). 
35 
36 
37 
38 
39 
40 
41 Results 
42 
43 Between January 2005 and December 2009, 1075 HIV-infected  children less than 15 years old began 
44 
45 cART in HCB and NHC. Two hundred and thirteen (20%) children were excluded from the study due to 
46 
47 missing data (table 1). Children excluded from both treatment failure and drug substitution analyses were 
48 
49 more likely to be Ugandan (p<0.01), female ( p=0.049), younger (p<0.01) and enrolled and starting cART 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
an overall follow-up of 1499 person/years. Throughout the study period, 202 (26%, 95% C.I. 23-30%) 
patients  substituted  treatment,  with median time to substitution  of 9.69 months  (IQR 25.82).  Overall 
incidence of substitution was 15.4 events per 100 person-years (95% CI 13.4-17.7). Reported reasons for 
substitution included any toxicity (37, 18.3%), of which 3 were d4T toxicity (1.5%), 25 (12.4%) AZT 
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1 
2 
3 Among 862 children eligible for analysis, 740 children (492 from Mozambique and 248 from Uganda) 
4 
5 with at least 24 weeks of follow-up were included for a total of 1088.5 person/years of follow-up. At the 
6 
7 time of data collection, 24/740 (3.24%) children died, 68 (9.19%) were LTFU, 7 (0.95%) were transferred 
8 
9 to other clinic and 1 (0.14%) was confirmed HIV-negative. A total of 218 treatment failure events (29% 
11 
12 95%CI [26-33]) occurred, with a crude incidence rate of 20.0 events per 100 person-years (95%CI 17.5- 
13 
14 22.9).  Median  time  to  treatment  failure  was  379  days  (IQR  229-649).  Immunological  failure  alone 
15 
16 occurred in 100 (46%) children  while clinical failure alone was found in 116/218  (53%) cases. Two 
17 
18 children (1%) had concomitant clinical and immunological failure. Baseline characteristics are shown in 19 
20 
21 table 2. 
22 
23 The adjusted Cox proportional  hazards model of treatment failure with the lowest AIC included age, 
24 
25 treatment type and baseline disease stage. Incidence rates and crude and adjusted relative hazards from 
26 
27 the model are shown in table 3. 
28 
29 Patients with TB and those with other WHO stage 4 defining diseases were significantly more likely to 
31 
32 experience treatment failure (HR 2.27, 95%CI 1.5-3.4, p <0.001 and HR 1.57, 95%CI 1.02-2.4, p 0.04, 
33 
34 respectively) compared to children with WHO stage 3 disease without TB.  As expected, starting cART 
35 
36 with an unconventional  regimen  (not containing  an NRTI backbone  in combination  with EFV, NVP, 
37 
38 LPV/r, or ABC) was also significantly associated with risk of treatment failure (HR 3,37, 95%CI 1.12- 39 
40 
41 11.89, p=0.03). 
42 
43 
44 
45 Drug substitution analysis. 
46 
47 Among 862 eligible children, 4 with unknown ART regimen and 89 who received ABC in their initial 
48 
49 cART regimen were excluded from the cART drug substitution analysis. The remaining 769 children had 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
immunological  cART  failure,  with a crude  incidence  rate  of 20.0  events  per 100 person  years.  Our 
findings appear in line with evidence from the literature referring on immunological  failure (16-18) . 
Considering that virological failure tends to precede clinical and immunological failure, this figure could 
underestimate a greater impact of virological failure. 
10 
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1 
2 
3 toxicity and 9 (4.5%) NVP toxicity, clinical and immunological failure (9, 4.5%), drug availability (35, 
4 
5 17.3%), drug interaction (1, 0.5%), provider preference for a better option (32, 15.8%), simplification 
6 
7 associated with non-adherence (4, 2%), caregiver health problem (1, 0.5%) and TB drugs interaction (52, 
8 
9 25.7%). Among the 9 patients with drug substitution for clinical or immunological failure, median time to 
11 
12 substitution  was  26.65  months  (IQR  23.95).  Reasons  for substitution  were  unknown  for  31 (15.3%) 
13 
14 children.  Baseline characteristics are provided in table 4. 
15 
16 The adjusted Cox proportional hazards model of cART drug substitution with the lowest AIC included 
17 
18 age, adherence, treatment type, immunodeficiency status, and baseline disease stage. Incidence rates and 19 
20 
21 crude and adjusted relative hazards from the model are shown in table 5. 
22 
23 Drug substitution was significantly more likely among patients starting treatment with 3TC-AZT-NVP 
24 
25 (HR  3.29,  95%CI  2.27-4.76,  p  <0.001),  3TC-d4T-EFV  (HR  3.22,  95%CI  2.02-5.13,  p  <0.0001)  or 
26 
27 3TC+AZT+EFV  and (HR 1.74, 95%CI 1.03-2.95,  p=0.037)  compared  to those starting on 3TC-d4T- 
28 
29 NVP. Drug substitution was also more likely among mildly immunosuppressed patients (HR 2.23, 95%CI 
31 
32 1.24-4.02, p <0.01) compared to those with severe immunodeficiency, in infants (HR 2.74, 95%CI 1.54- 
33 
34 4.90, p <0.01) compared to children 5 years, in children with TB (HR 3.38, 95%CI 2.28-5.01, p<0.0001) 
35 
36 compared to those with WHO stage 3 or 4 disease without TB or those with stage 1 or 2 disease, and 
37 
38 among those with good treatment adherence  before drug substitution  (HR 0.53, 95% CI 0.37-0.77,  p 39 
40 
41 <0.001) compared to those with poor adherence. 
42 
43 
44 
45 
46 
47 Discussion. 48 
49 In  this  study,  a  notable  proportion  (29%)  of  HIV  positive  children  experienced   clinical  and/or 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
drugs, particularly for NVP and LPV/r (42). Development of better options for TB co-treatment appears 
to be critical to prolong effectiveness of first line regimens. 
As expected, unconventional regimens were associated with treatment failure compared to triple cART 
(37). Treatment  failure was not different  between PI-based  and NNRTI-based  regimens,  however  the 
http://mc.manuscriptcentral.com/jpids 
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1 
2 
3 Over a 5 year period, among the 202  patients who substituted cART only 4% switched to second line 
4 
5 regimen due to treatment failure after a median time of 26.65 months, indicating a significant delay in 
6 
7 switching to second line despite the high rate of failure retrospectively observed in the cohort. Several 
8 
9 studies reported low proportion of children on second-line  cART in LMICs (19, 20). Our switch rate 
11 
12 appears even lower than those observed  by Davies et al (16) and by two other observational  studies 
13 
14 showing  that around 14% children switched to second-line due to clinical and/or immunological failure 
15 
16 (17, 18). Reasons explaining the alarming gap between a recognized clinical and/or immunological failure 
17 
18 and the initiation of a second line cART were not well identified. In our programme we hypothesize that 19 
20 
21 limited  availability  and  costs  of  second  line  drugs  may  be  major  barriers  to  second  line  therapy. 
22 
23 Furthermore  the trade-off  that clinicians are facing when considering  the limited options for children 
24 
25 failing first line and the risk of maintaining them on a failing regimen can be very challenging and may 
26 
27 result in further delays in switching to second line cART. Under-diagnosis of treatment failure may also 
28 
29 have contributed to the low rate of switching observed.   It should be noted that in the drug substitution 
31 
32 analysis reasons for switching may be misclassified, as these data were collected retrospectively and are 
33 
34 based on clinician report. 
35 
36 
37 
38 WHO clinical stage 4 and TB co-infection at cART initiation were significantly associated with treatment 39 
40 
41 failure.  Poor  clinical  status  has  been  observed  to  negatively  affect  treatment  response,  in  particular 
42 
43 malnutrition and chronic diarrhea independently increase the risk of treatment failure as much as baseline 
44 
45 low immunity,  high VL and younger age (15-17).  As suggested  by Hermans  et al (40, 41),   TB co- 
46 
47 infection may impair immune recovery after cART initiation in adults.  In addition, poor adherence may 
48 
49 occur as a result of high pill burden, and interaction with rifampicin may affect the bioavailability of HIV 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
100 person years  and 95% of these were for causes other than treatment failure. This figure is consistent 
with  previous  observational   studies  among  HIV  positive  children  (17,  24,  43)  living  in  LMIC. 
Toxicity/intolerance was one of the main reasons reported for substitution (18.3%), mostly related to AZT 
toxicity (12.4%), as reported in other studies (17, 38, 44). Due to high prevalence of HIV/TB co-infection 
 
12 
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1 
2 
3 validity of this finding may be questionable considering that only a few children were receiving a PI- 
4 
5 based regimen at the time of the study. Few randomized trials investigated the most effective first-line 
6 
7 cART regimen in HIV-positive children. The P1060 trial (13, 23) showed an increased risk of virological 
8 
9 failure in children (<3 years) on NPV-based cART, regardless of PMTCT exposure, however this was not 
11 
12 confirmed by the PENPACT trial conducted in older children of high income countries (24). Due to the 
13 
14 nature of our cohort’s age and lack of reliable PMTCT exposure data, our observational  retrospective 
15 
16 findings  are not comparable to those from either controlled trial. 
17 
18 
19 
20 
21 Determining  when to switch  to second  line cART  is a critical  decision  in settings  where virological 
22 
23 monitoring  is not available.  Although evidence shows that viral load (VL) is not essential to identify 
24 
25 treatment failure (34), using clinical and immunological parameters leads to delays in switching to second 
26 
27 line therapy (17), resulting in longer exposure to failing regimens which contributes to development of 
28 
29 drug-resistant HIV strains (6). In our study reasons for delays to cART switching were not completely 
31 
32 clarified, in particular we were unable to understand if clinicians didn’t switch cART in children with 
33 
34 recognized  treatment  failure  or  if  clinical/immunological  criteria  were  too  complicated  to  recognize 
35 
36 treatment failure. Earlier cART initiation and VL monitoring are currently recommended by WHO 2013 
37 
38 consolidated  guidelines  (3).  Based  on  our  data,  advanced  disease  and  TB  co-infection  should  be 39 
40 
41 considered as warning signals requiring closer follow-up and counseling to improve treatment outcomes 
42 
43 and prolong  duration  of first line therapy.  Adherence  to cART  was found  to be a poor  indicator  of 
44 
45 treatment failure, maybe due to the low accuracy of self-reporting adherence monitoring. 
46 
47 
48 
49 About 26% (203/769) of patients substituted treatment with an overall incidence rate of 13.5 events per 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
up  visits,  the  Ugandan  children  were  followed  up  much  more  frequently  (monthly)  than  those  in 
Mozambique  (every  3  months).  This  difference  between  program  performances  may  have  provided 
further confounders, potentially influencing the trends observed in older children at lower risk of failure 
and the higher rate of drug substitution observed in infants. 
13 
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1 
2 
3 (88/769, 11,4%), drug interaction in TB/HIV co-treatment (25.7%) was another major reason to substitute 
4 
5 drugs. Drug availability (17.3%) was another considerable reason, reflecting the importance of ensuring 
6 
7 adequate  and  continuous  supply  of  cART  in  settings  where  drug  costs  are  still  a  major  barrier  for 
8 
9 PLWHA. Reasons for drug substitution were not classified prospectively but assessed from inspection of 
11 
12 patient clinical charts, potentially leading to inaccurate classifications. 
13 
14 
15 
16 Higher rates of drug substitution were observed among children starting AZT-containing or EFV-based 
17 
18 regimens. Increased drug substitution while on AZT is often the result of AZT-related anemia as well- 19 
20 
21 described  previously  (23, 31, 36). AZT toxicity  was more  prevalent  among  the Mozambique  cohort, 
22 
23 where children were younger and malnutrition and/or more advanced WHO disease stages were observed, 
24 
25 suggesting that AZT anemia may have been exacerbated. Despite the lack of more robust evidence, our 
26 
27 findings suggest that AZT may not be the preferred NRTI to be used in these settings, particularly in 
28 
29 younger children. 
31 
32 Further description  of EFV substitution  was not possible in this dataset due to the limited number of 
33 
34 children receiving this drug, and we could not rule out specific EFV-related toxicity. 
35 
36 
37 
38 As previously mentioned, our results may be confounded by country specific differences. Mozambique 39 
40 
41 patients were younger, had a more advanced WHO stage and a lower BMI z-score at cART initiation. 
42 
43 These differences  may   reflect clinicians’  preference  in first-line treatment choice, accounting  for the 
44 
45 wider use of AZT and EFV in Uganda  as much as for the increased  choice  of NVP-based  regimen 
46 
47 observed  in children  from  Mozambique.  Country  specific  differences  may potentially  confound  the 
48 
49 relationships seen between cART regimen and treatment failure and drug substitution. In terms of follow- 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
6. WHO. WHO HIV drug resistance report 2012. Geneva, Switzerland: World Health Organization, 
2012. 
14 
http://mc.manuscriptcentral.com/jpids 
 
10 
30 
Manuscripts submitted to Journal of the Pediatric Infectious Diseases Society Page 14 of 37 
 
 
1 
2 
3 
4 
5 In conclusion, our data reinforce the need for simplification of more effective clinical and immunological 
6 
7 criteria for prompt recognition of cART treatment failure. Children presenting with advanced disease and 
8 
9 TB co-infection should be targeted for closer and more sensitive monitoring of treatment response. This 
11 
12 should  be matched with a constant provision of appropriate antiretrovirals and with optimization of first 
13 
14 line drugs and treatment sequencing. Supply of new paediatric formulations  for second line regimens and 
15 
16 drug optimization  should be considered  as critical milestones  to allow scaling up of early cART and 
17 
18 reduction of treatment failure in children. 19 
20 
21 
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Variable 
Value 
Included children 
n=862 
Excluded children 
n=213 (20%
) 
p-value 
G
ender 
M
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Fem
ale 
449 (52) 
413 (48) 
99 (46) 
113 (53) 
*  
0.049 
Country 
M
ozam
bique 
Uganda 
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Year of birth 
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edian (IQ
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2005-2009 
m
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2002 (1998-2005) 
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2001 (1996-2005) 
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<0.01
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Age at  treatm
ent 
initiation (years) 
M
edian (IQ
R) 
 
< 12 m
onths 
12- 35 m
onths 
36-59 m
onths 
5-8 years 
>8 years 
M
issing 
4.83 (2.09-9.11) 
 
62 (7) 
256 (30) 
120 (14) 
157 (18) 
267 (31) 
0 (0) 
6.33 (2.62-11.56) 
 
11 (5) 
48 (23) 
22 (10) 
40 (19) 
92 (43) 
8 (4) 
   
<0.01
¥ 
 
<0.01
* 
W
HO
 clinical stage at 
treatm
ent initiation 
Stage I or II 
Stage III w
ith TB 
Stage III w
/o TB 
Stage IV w
ith TB 
Stage IV w
/o TB 
Unknow
n 
75 (9) 
36 (4) 
57 (7) 
10 (1) 
47 (6) 
637 (74) 
14 (7) 
11 (5) 
22 (10) 
6 (3) 
13 (6) 
147 (69) 
  
0.14
* 
Age at enrolm
ent 
(years) 
M
edian (IQ
R) 
M
issing 
3.94 (1.48-8.09) 
0 (0) 
5.57 (1.61-9.47) 
8 (4) 
 
¥  
0.01 
Initial treatm
ent 
regim
en 
3TC+4DT+N
VP 
3TC+AZT+NVP 
3TC+AZT+EFV 
3TC+4DT+EFV 
3TC+AZT+ABC 
O
ther triple 
O
ther dual 
m
issing 
369 (43) 
231 (27) 
80 (9) 
57 (7) 
48 (6) 
68 (8) 
3 (0) 
6 (1) 
70 (33) 
60 (28) 
35 (16) 
15 (7) 
15 (7) 
15 (7) 
1 (<1) 
2 (1) 
   
*  
0.06 
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Table 1. B
aseline characteristics of 862 children included and 213 children excluded from
 analyses due to m
issing data.  
3 4 5 6 7 8 9 10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
* Pearson chi square test  
39 
¥ Kruskal-W
allis test  
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
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6 
Gender 
M
ale 
382 (51.62) 
260 (52.85) 
122 (49.19) 
7 
 
Fem
ale 
358 (48.38) 
232 (47.15) 
126 (50.81) 
8 
Age at treatm
ent initiation 
M
edian (IQ
R) 
5.05 (7.00) 
3.42 (5.49) 
8.22 (7.13) 
9 
(n=205) 
< 12 m
onths 
51 (6.89) 
44 (8.94) 
7 (2.82) 
 
M
anuscripts subm
itted to Journal of the Pediatric Infectious D
iseases Society  
Page 22 of 37  
  
1 2 
Table 2. B
aseline characteristics of children included in the treatm
ent failure analysis – dem
ographics and treatm
ent.  
3 4  
Variable  
Value  
5 
    
10 
12- 35 m
onths 
36-59 m
onths  
11 
ш 5 years  
12 
BM
I for age  
All children 
n=740 (100.00%
) 
     
216 (29.19) 
97 (13.11) 
376 (50.81) 
-0.92 (1.94)  
M
ozam
bique 
n= 492 (66.49%
) 
     
186 (37.80) 
68 (13.82) 
194 (39.43) 
-1.10 (1.95)  
U
ganda 
n= 248 (33.51%
) 
     
30 (12.10) 
29 (11.69) 
182 (73.39) 
-0.75 (1.82)  
p-value ® 
  
0.348 
 
<0.001 
<0.001 
13 
z-score  
M
edian (IQ
R) 
(n=564) 
(n=327) 
(n=237) 
0.019 
14 
W
HO
 disease stage  
Stage I or II  
15 
Stage III w
ith TB 
16 
Stage III w
/o TB 
17 
Stage IV w
ith TB 
Stage IV w
/o TB 
18 
Unknow
n 
19 
Initial treatm
ent regim
en  
3TC+d4T+NVP  
20 
3TC+AZT+NVP  
21 
3TC+AZT+EFV 
22 
3TC+d4T+EFV 
23 
3TC+AZT+LPV/r 
3TC+d4T+LPV/r  
24 
3TC+d4T+ABC  
25 
3TC+AZT+ABC 
26 
O
ther * 
174 (23.51) 
83 (11.22) 
305 (41.22) 
52 (7.03) 
101 (13.65) 
25 (3.38) 
 325 (43.92) 
195 (26.35) 
69 (9.32) 
50 (6.76) 
18 (2.43) 
6 (0.81) 
25 (3.38) 
40 (5.41) 
12 (1.62) 
46 (9.35) 
68 (13.82) 
224 (45.53) 
48 (9.76) 
81 (16.46) 
25 (5.08) 
 269 (54.67) 
114 (23.17) 
13 (2.64) 
24 (4.88) 
0 (0.00) 
0 (0.00) 
25 (5.08) 
39 (7.93) 
8 (1.63) 
128 (51.61) 
15 (6.05) 
81 (32.66) 
4 (1.61) 
20 (8.06) 
0  (0.00) 
 56 (22.58) 
81 (32.66) 
56 (22.58) 
26 (10.48) 
18 (7.26) 
6 (2.42) 
0 (0.00) 
1 (0.40) 
4 (1.61) 
 <0.001 
     <0.001 
27 
Initial treatm
ent regim
en (by 
28 
m
ost potent com
ponent) 
29 
30 
31  
 EFV-containing 
N
VP-containing 
LPV/r-containing 
ABC-containing ** 
O
ther * 
 120 (16.22) 
523 (70.68) 
24 (3.24) 
67 (9.05) 
6 (0.81) 
 37 (7.52) 
383 (77.85) 
0 (0.00) 
66 (13.41) 
6 (1.22) 
 83 (33.47) 
140 (56.45) 
24 (9.68) 
1 (0.40) 
0 (0.00) 
<0.001 
32 
Adherence  
Good 
485 (65.54) 
294 (59.76) 
191 (77.02) 
<0.001 
33 
  
Poor  
255 (34.46)  
198 (40.24)  
57 (22.98)  
 
CD4 percent (m
ean, 95%
 CI)  
<12 m
onths  
34 
12-35 m
onths  
35 
36-59 m
onths 
36 
>5 years 
15.95 (9.60) 
14.50 (8.70) 
12.16 (7.90) 
9.60 (10.00) 
15.60 (9.20) 
15.00 (8.20) 
12.85 (7.05) 
11.05 (10.00) 
18.93 (4.60) 
10.62 (8.12) 
11.81 (8.77) 
8.47 (9.76) 
<0.001 
37 
CD4 count 
38 
(m
ean cells/m
m
3, 95%
 CI) 
39 
40 
41 
CD4 count z-score  
42 
 <12 m
onths 
12-35 m
onths 
36-59 m
onths 
>5 years 
 M
edian (IQ
R) 
 784.00 (971.00) 
721.00 (606.00) 
467.00 (395.50) 
239.00 (286.00) 
 
-0.30 (1.07) 
( n=736) 
 746.50 (765.50) 
730.50 (585.00) 
420.50 (292.50) 
265.00 (363.00) 
 
-0.14 (1.12) 
(n=492) 
 1404.00 (1145.00) 
554.00 (765.00) 
551.00 (509.00) 
226.00 (224.00) 
 
-0.54 (0.69) 
(n=244) 
 <0.001 
    <0.001 
43 
44 
45 
46 
47 
48 
49 
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Classification of  
3 
Im
m
unodeficiency ** 
4 5 6 7 8  
  N
ot significant 
M
ild 
Advanced 
Severe 
  58 (7.84) 
35 (4.73) 
66 (8.92) 
581 (78.51) 
  40 (8.13) 
19 (3.86) 
37 (7.52) 
396 (80.49) 
  18 (7.26) 
16 (6.45) 
29 (11.69) 
185 (74.60) 
  0.092 
* O
ther regim
ens include m
ono or dual therapies and those w
ith m
issing inform
ation on cART regim
en  
9 
** ABC-containing regim
en include a 3 N
RTI regim
en containing ABC  
10 
*  O
ther regim
ens include only those w
ithout an EFV, N
VP, LPV/r, or ABC com
ponent, regardless of num
ber of com
ponents 
11 
** Im
m
unodeficiency w
as classified as m
ild (CD4%
 of 30-35, 25-30, 20-25 and CD4 cell count of 350-499 for children <=11 m
onths, 12-35 m
onths, 36-59 m
onths or >=5 years, respectively), 
12 
advanced (CD4%
 of 25-29, 20-24, 15-19 and CD4 cell count of 200-349  for children <=11 m
onths, 12-35 m
onths, 36-59 m
onths or >=5 years, respectively) and severe (CD4%
 <25, <20, <15 
and CD4 cell count < 200/<15%
 for children <=11 m
onths, 12-35 m
onths, 36-59 m
onths or >=5 years, respectively) according to the W
HO
 2006 thresholds 
13 
® P-values refer to differences betw
een M
ozam
bique and Uganda sub-cohorts on baseline characteristics  
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
44 
45 
46 
47 
48 
49 
http://m
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Variable 
Person 
tim
e 
( years) 
781.2 
62.0 
187.5 
53.8 
3.9 
 
Events 
 
150 
18 
37 
10 
3 
 
Crude Incidence 
rate† (95%
C I) 
 
19.2 (16.4,22.5) 
29.0 (18.3,46.1) 
19.7 (14.3,27.2) 
18.6 (10.0,34.5) 
76.1 (24.6,236.1) 
U
nadjusted 
Relative 
H azard 
Reference 
1.38 
1.09 
1.08 
3.32 
  
95%
CI 
  
(0.84,2.25) 
(0.76,1.56) 
(0.56,2.08) 
(1.05,10.43) 
 
p-value 
   
0.20 
0.65 
0.81 
0.04 
Adjusted 
Relative 
H azard 
Reference 
0.76 
0.95 
1.03 
3.73 
 
95%
CI 
   
(0.43,1.34) 
(0.64,1.41) 
(0.53,2.02) 
(1.17,11.89) 
 
p-value 
   
0.34 
0.80 
0.93 
0.03 
Treatm
ent type  
N
VP-containing 
ABC-containing * 
EFV-containing 
LPV/r-containing 
O
ther ** 
BM
I for age z-score  
tertiles  
Low
est tertile 
M
iddle tertile 
Highest tertile 
Unknow
n 
 
410.7 
260.6 
154.1 
263.1 
 
96 
42 
38 
42 
 
23.4 (19.1,28.6) 
16.1 (11.9,21.8) 
24. 7 (17.9,33.9) 
16.0 (11.8,21.6) 
 
Reference 
0.69 
1.04 
0.68 
  
(0.48,0.99) 
(0.71,1.51) 
(0.48,0.98) 
  
0.04 
0.85 
0.04 
 
 
 
 
 
 
 
 
 
 
 
 
G
ender  
Fem
ale 
M
ale 
540.7 
547.8 
100 
118 
18.5 (15.2,22.5) 
21.5 (18.0,25.8) 
Reference 
1.17 
 
(0.89,1.52) 
 
0.26 
 
 
 
 
 
 
Country of  
M
ozam
bique 
treatm
ent  
Uganda  
681.5 
407.0 
143 
75 
21.0 (17.8,24.7) 
18.4 (14.7,23.1) 
Reference 
0.91 
 
(0.69,1.21) 
 
0.51 
 
 
 
Adherence  
G
ood 
Poor 
1027.3 
61.1 
202 
16 
19.7 (17.1, 22.6) 
26.2 (16.0, 42.7) 
Reference 
1.24 
 
(0.74,2.06) 
 
0.41 
 
 
 
 
 
 
Classification of  
N
ot significant 
im
m
unodeficiency 
 ** 
 
Advanced 
Severe 
78.6 
57.9 
90.3 
861.7 
10 
11 
13 
184 
12.7 (6.8,23.6) 
19.0 (10.5,34.3) 
14.4 (8.4,24.8) 
21.4 (18.5,24. 7) 
0.58 
0.89 
0.64 
Reference 
(0.31,1.10) 
(0.49,1.64) 
(0.36,1.12) 
0.10 
0.72 
0.12 
 
 
 
 
 
 
 
 
 
 
 
 
Age group  
0-11 m
onths 
12-35 m
onths 
35-59 m
onths 
>= 5 years 
46.0 
275.5 
176.8 
590. 1 
13 
64 
23 
118 
28.2 (16.4,48.6) 
23.2 (18.2,29.7) 
13.0 (8.6,19.6) 
20.0 (16.7,24.0) 
1.28 
1.12 
0.67 
Reference 
(0.72,2.23) 
(0.83,1.52) 
(0.43,1.05) 
0.41 
0.46 
0.08 
1.08 
1.08 
0.64 
Reference 
(0.59,1.96) 
(0.77,1.50) 
(0.41,1.00) 
0.80 
0.66 
0.05 
W
HO
 disease stage  
Stage 1 or 2 
at baseline  
Stage 3 or 4 w
ith 
TB 
Stage 3 w
/o TB 
Stage 4 w
/o TB 
Unknow
n 
289.0 
 
145.8 
510.9 
106.3 
36.5 
52 
 
50 
83 
29 
4 
18.0 (13.7,23.6) 
 
34.3 (26.0,45.2) 
16.2 (13.1,20.1) 
27.3 (19.0,39.3) 
11.0 (4.1,29.2) 
1.12 
 
1.96 
Reference 
1.54 
0.65 
(0.79,1.58) 
 
(1.38,2.79) 
(0.78,7.7) 
(1.01,2.35) 
(0.24,1.78) 
0.52 
<0.001 
 
0.045 
0.40 
1.17 
 
2.27 
Reference 
1.57 
0.67 
(0.81,1.67) 
(1.50,3.42) 
(1.02,2.414) 
(0.24,1.82) 
0.40 
 
<0.001 
  
0.04 
0.43 
 
M
anuscripts subm
itted to Journal of the Pediatric Infectious D
iseases Society  
Page 24 of 37  
  1 2 
Table 3. R
elative hazards for treatm
ent failure in children from
 M
ozam
bique and U
ganda (n=740 children)  
3 4 5 6 7 8 9 10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
M
ild 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
† - per 100 years 
40 
* ABC-containing regim
en include a 3 N
RTI regim
en containing ABC  
41 
** O
ther regim
ens include only those w
ithout an EFV, NVP, LPV/r, or ABC com
ponent, regardless of num
ber of com
ponents 
42 
** Im
m
unodeficiency w
as classified as m
ild (CD4%
 of 30-35, 25-30, 20-25 and CD4 cell count of 350-499 for children <=11 m
onths, 12-35 m
onths, 36-59 m
onths or >=5 years, respectively), advanced (CD4%
 of 
25-29, 20-24, 15-19 and CD4 cell count of 200-349  for children <=11 m
onths, 12-35 m
onths, 36-59 m
onths or >=5 years, respectively) and severe (CD4%
 <25, <20, <15  and CD4 cell count  < 200/<15%
 for  
43 
children <=11 m
onths, 12-35 m
onths, 36-59 m
onths or >=5 years, respectively) according to the W
HO
 2006 thresholds 
43 
44 
45 
46 
47 
48 
49 
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Table 4. B
aseline characteristics of children included in the drug substitution analysis– dem
ographics and treatm
ent.  
3 4  5 
Variable  
Value  
All children 
6 
n=769 (100.0%
) 
7  
M
ozam
bique 
n= 491 (63.9%
) 
U
g anda  
n= 278 (36.15%
)  
p-value 
Gender  
M
ale 
Fem
ale 
9  
400 (52.0) 
369 (48.0) 
261 (53.2) 
230 (46.8) 
139 (50.0)  
139 (50.0)  
0.400 
10  
11 
Age at treatm
ent initiation 
(N
=205)  
12 
13 
BM
I for age  
M
edian (IQ
R) 
< 12 m
onths 
12- 35 m
onths 
36-59 m
onths 
ш 5 years 
5.2 (7.0) 
50 (6.5) 
209 (27.2) 
112 (14.6) 
398 (51.8) 
-0.8 (2.0)  
3.7 (5.5) 
43 (8.8) 
175 (35.6) 
76 (15.5) 
197 (40.1) 
-1.0 (2.0)  
8.2 (7.2) 
7 (2.5) 
34 (12.2) 
36   (13.0) 
201 (72.3) 
-0.8 (1.9)  
<0.001 
<0.001 
14 
z-score  
M
edian (IQ
R) 
15  
 (n=598) 
 (n=335) 
(n=263) 
0.110 
16 
17  
18 
W
HO
 disease stage 
19 
20 
21 
22 
23 
Initial treatm
ent regim
en  
24 
25 
26 
27 
28 
Initial treatm
ent regim
en (by 
29 
m
ost potent com
ponent) 
30 
31  
32 
Adherence 
33 
34 
CD4 percent (m
ean, 95%
 CI) 
35 
36 
37 
38 
CD4 count (m
ean, 95%
 CI)  
39 
40 
41  
Stage I or II 
Stage III w
ith TB 
Stage III w
/o TB 
Stage IV w
ith TB 
Stage IV w
/o TB 
Unknow
n 
 3TC+d4T+N
VP 
3TC+AZT+N
VP 
3TC+AZT+EFV 
3TC+d4T+EFV 
3TC+AZT+LPV/r 
3TC+d4T+LPV/r 
O
ther * 
 EFV-containing 
N
VP-containing 
LPV/r-containing 
O
ther ** 
 G
ood 
Poor 
<12 m
onths 
12-35 m
onths 
36-59 m
onths 
>5 years 
 <12 m
onths 
12-35 m
onths 
36-59 m
onths 
>5 years 
190 (24.7) 
62 (8.1) 
343 (44.6) 
26 (3.4) 
124 (16.1) 
24 (3.1) 
 369 (48.0) 
231 (30.0) 
80 (10.4) 
57 (7.4) 
18 (2.3) 
7 (0.9) 
7 (0.9) 
 138 (18.0) 
603 (78.4) 
25 (3.3) 
3 (0.4) 
 542 (70.5) 
227 (29.5) 
 15.7 (9.2) 
15.0 (9.5) 
12.1 (8.7) 
9.7 (9.9) 
 857 (879) 
759 (617) 
455 (428) 
242 (270) 
 -0.26 (0.81)  
51 (10.4) 
45 (9.2) 
249 (50.7) 
21 (4.3) 
101 (20.6) 
24 (4.9) 
 
303 (61.7) 
141 (28.7) 
16 (3.3) 
28 (5.7) 
0 (0.0) 
0 (0.0) 
3 (0.6) 
 
44 (9.0) 
444 (90.4) 
0 (0.0) 
3 (0.6) 
 
321 (65.4) 
170 (34.6) 
 
14.3 (9.3) 
15.6 (9.4) 
12.9 (9.0) 
11.3 (9.7) 
 
784 (888) 
767 (624) 
411.5 (431.5) 
260 (337) 
 -0.14 (0.96)  
139 (50.0) 
17 (6.1) 
94 (33.8) 
5 (1.8) 
23 (8.3) 
0 (0.0) 
 66 (23.7) 
90 (32.4) 
64 (23.0) 
29 (10.4) 
18 (2.3) 
7 (2.5) 
4 (1.4) 
 94 (33.8) 
159 (57.2) 
25 (9.0) 
0 (0.0) 
 221 (79.5) 
57 (20.5) 
 18.9 (4.6) 
10.7 (8.1) 
11.9 (8.3) 
8.6 (9.9) 
 1404 (1145) 
554 (697) 
524 (583) 
232 (230.5) 
 -0.42 (0.53)  
<0.001 
     <0.001 
      <0.001 
    <0.001 
 <0.001 
    <0.001 
    <0.001  
42 
CD4 count z-score  
M
edian (IQ
R) 
(n=765) 
(n=491) 
(n=274) 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
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65 (8.5) 
42 (8.6) 
23 (8.3) 
0.650 
42 (5.5) 
25 (5.1) 
17 (6.1) 
 
74 (9.6) 
43 (8.8) 
31 (11.2) 
 
588 (76.5) 
381 (77.6) 
207 (74.5) 
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Classification of 
4 
Im
m
unodeficiency ** 
5 6 7  
  N
ot significant 
M
ild 
Advanced 
Severe 
8 
*   O
ther regim
ens include m
ono or dual therapies and those w
ith m
issing inform
ation on cART regim
en 
**   O
ther regim
ens include only those w
ithout an EFV, N
VP, LPV/r, or ABC com
ponent, regardless of num
ber of com
ponents  
9 
**  Im
m
unodeficiency w
as classified as m
ild (CD4%
 of 30-35, 25-30, 20-25 and CD4 cell count of 350-499 for children <=11 m
onths, 12-35 m
onths, 36-59 m
onths or >=5 years, respectively), advanced  
10 
(CD4%
 of 25-29, 20-24, 15-19 and CD4 cell count of 200-349  for children <=11 m
onths, 12-35 m
onths, 36-59 m
onths or >=5 years, respectively) and severe (CD4%
 <25, <20, <15  and CD4 cell count 
11 
< 200/<15%
 for children <=11 m
onths, 12-35 m
onths, 36-59 m
onths or >=5 years, respectively) according to the W
HO
 2006 thresholds 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
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Variable 
Person tim
e 
(years) 
 
Events 
Crude Incidence 
rate
†  (95%
CI) 
Unadjusted Relative 
Hazard 
 
95%
CI 
 
p-value 
Adjusted Relative 
Hazard 
 
95%
CI 
 
p-value 
Treatm
entType  
N
VP-containing 
EFV-containing 
LPV/r-containing 
O
ther * 
981.9 
241.4 
80.2 
6.8 
131 
66 
4 1 
13.3 (11.2, 15.8) 
27.3 (21.5, 34.8) 
5.0 (1.9, 13.3) 
14.7 (2.1, 104.6) 
Reference 
2.02 
0.28 
1.24 
 
1.50, 2.72 
0.10, 0.78 
0.17, 8.86 
 
<0.001 
0.014 
0.83 
 
 
 
 
 
 
 
 
 
 
 
 
Treatm
entType 2 
3TC+D4T+NVP 
 
3TC+AZT+NVP 
 
3TC+D4T+EFV 
3TC+AZT+EFV 
3TC+D4T+LPV/r 
3TC+AZT+LPV/r 
O
ther ** 
667.7 
 
309.4 
98.8 
139.5 
22.7 
57.5 
14.6 
48 
 
82 
42 
24 
3 1 2 
7.2 (5.4, 9.5) 
 
26.5 (21.3, 32.9) 
42.5 (31.4, 57.5) 
17.2 (11.5, 25.7) 
13.2 (4.3, 41.0) 
1.7 (0.24, 12.3) 
13.7 (3.4, 54.8) 
Reference 
 
3.53 
5.55 
2.37 
1.56 
0.17 
2.10 
  
2.47, 5.04 
3.66, 8.42 
1.45, 3.88 
0.48, 5.05 
0.02, 1.27 
0.51, 8.64 
  
<0.001 
<0.001 
<0.001 
0.46 
0.09 
0.31 
Reference 
 
3.29 
3.22 
1.74 
1.68 
0.15 
1.25 
  
2.27, 4.76 
2.02, 5.13 
1.03, 2.95 
0.51, 5.53 
0.02, 1.09 
0.29, 5.35 
  
<0.001 
<0.001 
0.037 
0.39 
0.06 
0.76 
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I for age z-score  
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est tertile 
tertiles                               M
iddle tertile 
Highest tertile 
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n 
303.6 
376.7 
341.0 
289.0 
60 
50 
47 
45 
19.8 (15.3, 25.5) 
13.3 (10.1, 17.5) 
13.8 (10.4, 18.3) 
15.6 (11.6, 20.9) 
Reference 
0.69 
1.41 
1.21 
 
0.48, 1.01 
0.48, 1.04 
0.56, 1.21 
 
0.06 
0.08 
0.33 
  
  
  
 
 
 
 
 
 
Gender  
Fem
ale 
M
ale 
635.4 
674.9 
98 
104 
15.4 (12.7, 18.8) 
15.4(12.7, 18.7) 
Reference 
1.00 
 
0.76, 1.32 
 
0.99 
 
 
 
 
 
 
Country of  
M
ozam
bique 
treatm
ent  
Uganda 
785.0 
525.4 
114 
88 
14.5 (12.1, 17.4) 
16.8 (13.6, 20.6) 
Reference 
1.15 
 
0.87, 1.52 
 
0.33 
 
 
 
 
 
 
Adherence  
G
ood 
Poor 
884.0 
426.4 
166 
36 
18.8 (16.1, 21.9) 
8.4 (6.1, 11.7) 
Reference 
0.45 
 
0.31, 0.64 
 
<0.001 
Reference 
0.53 
 
0.37, 0.77 
 
<0.001 
Classification of  
N
ot significant 
im
m
unodeficiency **  
M
ild  
Advanced 
Severe 
96.6 
63.8 
109.6 
1040.4 
14 
13 
17 
158 
14.5 (8.6, 24.5) 
20.4 (11.8, 35.1) 
15.5(9.6, 24.9) 
15.2 (13.0, 17.7) 
0.95 
1.32 
1.06 
Reference 
0.55, 1.65 
0.75, 2.33 
0.64, 1.75 
     
1.23 
2.23 
1.16 
Reference 
0.70, 2.16 
1.24, 4.02 
0.70, 1.93 
0.47 
<0.001 
0.57 
Age group  
0-11 m
onths 
12-35 m
onths 
35-59 m
onths 
>= 5 years 
46.3 
319.9 
200.7 
743.5 
15 
47 
32 
108 
32.4 (19.5, 53.8) 
14.7 (11.0, 19.6) 
15.9 (11.3, 22.6) 
14.5 (12.0, 17..5) 
2.19 
1.02 
1.05 
Reference 
1.28, 3.72 
0.72, 1.44 
0.71, 1.56 
     
2.74 
1.03 
0.77 
Reference 
1.54, 4.90 
0.70, 1.50 
0.51, 1.18 
<0.001 
0.89 
0.24 
W
HO
 disease stage  
Stage 1 or 2 
at baseline  
Stage 3 or 4 w
ith TB 
Stage 3 w
/o TB 
Stage 4 w
/o TB 
Unknow
n 
362.0 
119.2 
624.2 
155.5 
49.3 
52 
60 
70 
18 
2 
14.4 (10.9,18.8) 
50.3 (39.1, 64.8) 
11.2 (8.9, 14.2) 
11.6 (7.3, 18.4) 
4.1 (1.01, 16.2) 
1.27 
4.45 
Reference 
1.01 
0.41 
0.88, 1.81 
3.14, 6.30 
  
0.60, 1.69 
0.10, 1.67 
      
1.21 
3.38 
Reference 
0.96 
0.47 
0.83, 1.77 
2.28, 5.01 
  
0.56, 1.63 
0.11, 1.94 
0.32 
<0.001 
  
0.87 
0.30 
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1 
2 
3 Title: Predictors of treatment failure in HIV positive children receiving combination antiretroviral therapy: 
4 
5 cohort data from Mozambique and Uganda 
6 
7 Dear Editor, 
8 
9 We thank you and the Reviewers for the helpful comments on our manuscript. We have responded to each 
10 point in turn, and include both the Reviewers’ comments (in italics) and our responses below 
11 
12 Reviewer: 1 
14 Comments to the Author 
15 The authors have done an excellent job of compiling outcomes on a large cohort of children initiating ART in 
16 two NGO-supported programs in Mozambique and Uganda.   There are limited data on outcomes of ART- 17 
18 treated outcomes, and as pointed out by the authors, a need to better understand predictors of treatment 
19 failure as well as how children are managed outside of research studies.  Please see specific comments by page 
20 and, when appropriate, by line. 21 
22 
23 
24 1.   Page 1: title. I believe that the commonly used term is ‘combination antiretroviral therapy’ rather than 25 
26 ‘combined antiretroviral therapy.’ If the authors have intentionally chosen the word ‘combined’ it 
27 would be important to both define and justify in the text. 
28 
29 Thank you for pointing this out. We revised the text using the most common definition “combination 
30 
31 antiretroviral therapy”. 
32 
33 
34 
35 2.   Page 4 line 52. The description of the studies provided in this paragraph would benefit from more 
36 specificity. P1060 examined optimal starting regimen in infants and young children, for example.  Also 
37 the authors may want to also include reference to the recently published Technau paper (PIDJ 2013) 
38 
39 which suggests somewhat lower field efficacy of ABC. 
40 
41 As suggested, the following sentence was added to the text: “Findings from the P1060 trial reported an 
42 increased risk of failure starting a nevirapine (NVP)-based cART in infants and young children” AND 
43 “Conflicting results were reported concerning the use of abacavir (ABC) as first line regimen: Green et 
44 
45 al. suggested that abacavir (ABC) may be preferable to zidovudine (AZT) combination with lamivudine 
46 (3TC) (25), while poorer early virological outcomes were recently observed in children starting 
47 ABC/3TC-based first line regimens, compared to d4T/3TC (26, 27)”. 
48 
49 
50 
51 3.   Page 6 line 12. The authors note that cART was prescribed after counseling and written consent by the 
52 
53 caregiver.   Can they please discuss the consent more fully? Were they consented to participate in a 
54 study? Or consented to start ART? . The previous paragraph section describes this study as a 
55 retrospective chart review and no mention is made of consenting parents/caregivers. Also were older 
56 
57 children asked to sign an assent? 
58 
59 
60 
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1 
2 
3 A written consent was collected when enrolling in the programme and before starting cART but was 
4 
5 not collected to participate to this study, as we conducted a retrospective analysis of the routine 
6 clinical records. 
7 
8 
9 
10 4.   Page 6, line 52. It would be useful to restate the definitions of immunodeficiency as described in the 
11 WHO 2006 guidelines.  Given the passage of time and changing guidelines most readers can no longer 
12 
13 remember these definitions.  They can be included as a footnote in the table or in the text. 
14 
15 As suggested, WHO 2006 criteria for immunodeficiency were included in the tables, as a footnote. 
16 
17 
18 
19 5.   Page 7, line 29. Please explain further why these children were excluded from the analysis? 
20 
21 Children with ABC were excluded from the drug substitution analysis because the majority of ABC- 
22 related drug substitution was done systematically at the end of TB treatment for which ABC had been 
23 
24 started to reduce drug-drug interaction. In the text: “For analysis of cART drug substitution, children 
25 who received an ABC component in their initial cART regimen were excluded, as first line ABC 
26 treatment was systematically administered to children diagnosed with active TB and all patients 
27 
28 initially on ABC were routinely switched to EFV once the TB infection cleared.” 
29 
30 
31 
32 6.   P7 statistical analyses. Did the authors consider including calendar year as a variable in the multivariate 
33 analysis?  Given the duration of the observation period, general changes and improvements in care over 
34 the time period, and clinician learning that likely occurred, year of enrollment may be an important 
35 
36 factor to include. 
37 
38 Calendar year was initially considered but was not found to be associated with either switching or 
39 failure, at univariate analysis. For this reason it was not included in the multivariate analysis. 
40 
41 
42 
43 7.   Page 8 results. I would recommend that the authors first describe the characteristics of the cohort they 
44 analyzed followed by those who were excluded from study. 
45 
46 
47 Differences between children excluded and included in the study are shown in revised table 1 and are 
48 summarized in the text as follows: “Two hundred and thirteen (20%) children were excluded from the 
49 study due to missing data (table 1). Children excluded from both treatment failure and drug 
50 substitution analyses were more likely to be Ugandan (p<0.01), female (p=0.049), younger (p<0.01) and 
52 enrolled and starting cART later (p 0.01 and <0.01, respectively) than children included in the study.” 
53 We chose to describe characteristics of the treatment failure and drug substitution cohorts separately, 
54 as the two analyses were conducted among slightly different cohorts due to differing inclusion and 
56 exclusion criteria (refer to page 7, lines 12-34). We think that adding a detailed description of the entire 
57 population, with both the treatment failure and drug substitution cohorts combined, would become 
58 lengthy and confusing without adding much information. 
59 
60 
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1 
2 
3 8.   Given all the information in Table 2, I would recommend that the authors summarize the characteristics 
4 
5 of cohort and also identify any meaningful differences between those in Uganda and those in 
6 Mozambique. It would also be important to reflect back to the reader how the excluded children differ 
7 from those studied and consider commenting on these differences and their implications in the 
8 
9 discussion, especially if viewed as a limitation.  Other studies have identified HIV positive patients with 
10 missing key data (particularly CD4) at enrollment as particularly vulnerable to poor outcomes. 
11 
12 Differences between Uganda and Mozambique were reported in table 2 and table 4. In particular, in 
13 both analyses, children from Mozambique were the majority (66% in treatment failure (TF) cohort, 64% 14 
15 in drug substitution (DS) cohort). Mozambique patients were younger at treatment initiation (p<0.010 
16 in TF cohort, p<0.01 in DS cohort), had higher baseline WHO disease stage (p<0.010 in TF cohort, 
17 p<0.010 in DS cohort), were more likely to have a baseline cART regimen containing NVP (p<0.01 in TF 
18 
19 cohort, p<0.010 in DS cohort) and poor adherence to cART (p<0.010 in TF cohort, p<0.010 in DS 
20 cohort), and had less negative CD4 count z-scores (p<0.010 in TF cohort, p<0.010 in DS cohort) in both 
21 treatment failure and substitution analyses. In the treatment failure cohort, children from 
22 
23 Mozambique also had more negative baseline BMI z-scores (p=0.02). As this information is provided in 
24 tables 2 and 4, we decided not to add an extensive paragraph on country differences to the results 
25 section in order to devote more text to key results and discussion. In the discussion section country 
26 
27 differences were highlighted as follow: “As previously mentioned, our results may be confounded by 
28 country specific differences. Mozambique patients were younger, had a more advanced WHO stage 
29 and a lower BMI z-score at cART initiation. These differences may reflect clinicians’ preference in first- 
30 
31 line treatment choice, accounting for the wider use of AZT and EFV in Uganda as much as for the 
32 increased choice of NVP-based regimen observed in children from Mozambique.  Country specific 
33 differences may potentially confound the relationships seen between cART regimen and treatment 
34 
35 failure and drug substitution. In terms of follow-up visits, the Ugandan children were followed up much 
36 more frequently (monthly) than those in Mozambique (every 3 months). This difference between 
37 program performances may have provided further confounders, potentially influencing the trends 
38 
39 observed in older children at lower risk of failure and the higher rate of drug substitution observed in 
40 infants.” 
41 
42 
43 
44 9.   The authors should also consider including a table and/or description of how children met treatment 
45 failure criteria – how many were immunologic, how many were clinical, what were the most common 
46 clinical findings, etc.  This information would be very useful to the reader and might help to understand 
48 the discrepancy between what was determined on retrospective chart review and how children were 
49 clinically managed. 
50 
51 As suggested, rate of immunological failure was added in the “Treatment failure analysis” paragraph: 
52 
53 “A total of 218 treatment failure events (29% 95%CI [26-33]) occurred, with a crude incidence rate of 
54 20.0 events per 100 person-years (95%CI 17.5-22.9). Median time to treatment failure was 379 days 
55 (IQR 229-649). Immunological failure alone occurred in 100 (46%) children while clinical failure alone 
56 
57 was found in 116/218 (53%) cases. Two children (1%) had concomitant clinical and immunological 
58 failure.” 
57 
58 
59 
60 
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1 
2 
3 10. Page 8 line 53. Please distinguish between ‘dropped out’ and LTF. 
4 
5 Children LTFU were those who missed follow-up visits for more than 6 months while children were 6 
7 dropped out of care if confirmed HIV-negative, or if aged more than 18 years old (in this case they were 
8 referred to adult HIV clinic). In the text we modified as follows(refer to “Methods - Data collection” 
9 paragraph): “For children without treatment failure or drug-substitution, follow-up was censored at 10 
11 date of death, loss to follow up (LTFU, defined as missing follow-up visits for more than 6 months), 
12 transferred to other clinic, confirmed HIV-negative or aged more than 18 years old, last CD4 
13 measurement, or last anthropometric or adherence record, whichever occurred latest.” 14 
15 
16 
17 11. While the numbers are small, drug substitution analyses often excluded ARV changes for treatment 18 
19 failure. Why have the authors decided to include treatment failure cases in the drug substitution 
20 analysis? 
21 
22 In the drug substitution analyses, ‘treatment failure’ was as reported by the treating physician, rather 
23 
24 than assessed using CD4 counts and WHO disease staging. As physician report in this case may be 
25 incomplete or at times inaccurate, we did not feel it appropriate to drop these children from the 
26 analysis. In addition, we think that it could be interesting to show both reported and calculated 
27 
28 treatment failure rates. 
29 
30 
31 
32 12. The authors do not comment on the baseline characteristics or difference in characteristics between 
33 countries. The table is probably unnecessary. A table, however, providing more information on the 
34 drug substitutions including more descriptive information on the toxicities of each drug and the 
35 substitution decisions would be of great interest. 
37 
38 We agree with this suggestion but unfortunately JPIDS allows no more than 5 tables. In addition, 
39 unfortunately at this time we cannot provide detailed information for all patients that switched for 
40 toxicity, due to missing data. 
41 
42 
43 
44 13. Furthermore, the authors should clarify whether there were specific clinic protocols to identify and 
45 
46 manage drug toxicities – in particular, was Hg monitored for children on AZT and where there specified 
47 indications for discontinuation/change? 
48 
49 Toxicity to antiretroviral drugs was managed following the WHO guidelines available at the time of the 
50 study. In particular, clinicians mainly refer to WHO 2006 guidelines where severe anaemia was defined 
52 as Hb<7.5 g/dl. In both countries full blood count was routinely assessed every 6 month or more 
53 frequently if any clinical suspect of anaemia, independently of the type of cART regimen (refer to 
54 methods, page 6 line 43). 55 
56 
57 
58 
59 
60 
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1 
2 
3 14. Discussion 
4 
5 Page 10, line 54. Please clarify whether the reasons provided for delayed switching are actual reasons 
6 provided by clinic staff or hypotheses provided by the authors. 
7 
8 Reasons provided in the discussion (page 10, line 54) are author’s hypotheses, based on the program 
9 setting. In the text: “In our program we hypothesize that limited availability and costs of second line 10 
11 drugs may be major barriers to second line therapy.” 
12 
13 
14 
15 15. The authors hypothesize that death or lost-to-follow-up prior to switch may have contributed to the low 
16 rate of switching.  Few children in the study died and the lost-to-follow-up rate among the cohort of 
17 children included in the analysis was comparatively low.   Were these children over-represented among 18 
19 those who met treatment failure criteria?   Can the authors examine this in their analysis? 
20 
21 "Unfortunately we cannot provide detailed information on mortality and/or LTFU events occurred after 
22 the recognition of treatment failure, therefore this sentence was removed from the manuscript: 
23 
24 “Under-diagnosis of treatment failure or the occurrence of death or lost to follow-up before switching 
25 cART in children with treatment failure may have contributed to the low rate of switching observed.” 
26 
27 
28 
29 16. Page 11, line 10. Please clarify this sentence. 
30 
31 We have clarified the sentence as follows: “It should be noted that in the drug substitution analysis 
32 reasons for switching may be misclassified, as these data were collected retrospectively and are based 33 
34 on clinician report. ” 
35 
36 
37 
38 17. Page 11, line 36.  While the findings in this paper reflect the realities of clinical care in low resource 
39 settings, I question the validity of the comparison with the clinical trials.   In table 2 it is noted that only 
40 24 children of the 740 children included in the treatment failure analysis initiated a PI-based regimen 
41 
42 and over 95% initiated NNRTI therapy. There may be a comparison to be had between EFV and NVP but 
43 I suggest that any conclusions about PI-based treatment be reconsidered. 
44 
45 We agree with this comment and we therefore revised the paragraph as follows: “Treatment failure 
46 was not different between PI-based and NNRTI-based regimens, however this finding is of difficult 
48 interpretation since only a limited number of children were receiving a PI-based regimen at the time of 
49 the study. Few randomized trials investigated the most effective first-line cART regimen in HIV-positive 
50 children. The P1060 trial (13, 23) showed an increased risk of virological failure in children (<3 years) on 
52 NPV-based cART, regardless of PMTCT exposure, however this was not confirmed by the PENPACT trial 
53 conducted in older children of high income countries (24). Due to the nature of our cohort’s age and 
54 lack of reliable PMTCT exposure data, our observational retrospective findings are not comparable to 55 
56 those from either controlled trial.” 
58 
59 
60 
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1 
2 
3 18. Page 11 line 59.  The authors make an important point about the role of viral load monitoring to 
4 
5 identify treatment failure and the potential delays in switching to second line with clinical and 
6 immunologic criteria.  However, the primary findings of the paper don’t speak to either viral load 
7 monitoring or the sensitivity and specificity of clinical or immunologic criteria. Rather, they 
8 
9 demonstrated that in the field clinicians did not switch to second line when children met existing 
10 treatment failure criteria. One major drawback of the analysis is that the authors are unable to 
11 determine whether the clinicians applied and/or recognized that the children met criteria and decided 
12 
13 not to change treatment or whether the criteria were too complicated or difficult to use in the clinical 
14 setting so that clinicians could not recognize/diagnose treatment failure. 
15 
16 We completely agree with this comment. Our results suggest the need of a qualitative assay to better 
17 explore reasons of delay in cART switching among children with immunological/clinical treatment 
18 
19 failure. In the text we modified as follows: “Determining when to switch to second line cART is a critical 
20 decision in settings where virological monitoring is not available. Although evidence shows that viral 
21 load (VL) is not essential to identify treatment failure (34), using clinical and immunological parameters 
22 
23 leads to delays in switching to second line therapy (17), resulting in longer exposure to failing regimens 
24 which contributes to development of drug-resistant HIV strains (6). In our study reasons for delays to 
25 cART switching were not completely clarified, in particular we were unable to understand if clinicians 
26 
27 didn’t switch cART in children with recognized treatment failure or if clinical/immunological criteria 
28 were too complicated to recognize treatment failure. Earlier cART initiation and VL monitoring are 
29 currently recommended by WHO 2013 consolidated guidelines (3).” 
30 
31 
32 
33 19. page 12 line 45.  As noted earlier, it would be helpful to know if there were criteria for monitoring 
34 
35 hemoglobin and changing drugs based on anemia at the sites. Also, while the authors suggest that ABC 
36 may better tolerated, they have minimal experience in their cohort with ABC. Rather, their data 
37 suggests that D4T is better tolerated compared with AZT.  While no longer recommended because of 
38 
39 long term metabolic complications, the experience in the field with D4T, particularly for young children 
40 and for initiating treatment, has been good. 
41 
42 In both cohorts Hb levels were monitored every 6 months or more frequently, if indicated by clinicians 
43 (page 6 line 43). We agree with the comment on ABC and we modified as follow: “Higher rates of drug 44 
45 substitution were observed among children starting AZT-containing or EFV-based regimens. Increased 
46 drug substitution while on AZT is often the result of AZT-related anemia as well-described previously 
47 (23, 31, 36). AZT toxicity was more prevalent among the Mozambique cohort, where children were 
48 
49 younger and malnutrition and/or more advanced WHO disease stages were observed, suggesting that 
50 AZT anemia may have been exacerbated. Despite the lack of more robust evidence, our findings 
51 suggest that AZT may not be the preferred NRTI to be used in these settings, particularly in younger 
52 
53 children.” 
54 
55 
56 
57 Reviewer: 2 
58 
59 
60 
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1 
2 
3 The authors present some interesting data from the 2 cohorts in Africa. Treatment failure in children is 
4 
5 particularly topical as the WHO roll out the updated consolidated 2013 guidelines, where viral load 
6 monitoring and stricter criteria for virologoc failure are defined. The topic suggests that the subject is 
7 treatment failure, however, analysis of drug substitution is also a big focus. In my opinion, these 2 
8 
9 topics should be dealt with separately. I suggest that for this paper adhering to the topic of treatment 
10 failure will help focus it better. It is of course important to refer to the data on drug substitution to 
11 demonstrate the fact that only small proportion of children switch therapy because of treatment 
12 
13 failure. 
14 
15 Thank you very much for this comment. There was much discussion on whether to include treatment 
16 failure and drug substitution in the same paper or to separate the two topics. We decided to combine 
17 treatment failure and drug substitution for several reasons. First, we thought it was extremely 
18 
19 important to look at the rate of switching to second line therapy after analyzing treatment failure. It 
20 was also interesting to look at cases of treatment failure reported by clinicians, together with the 
21 retrospective analysis of treatment failure based on clinical and immunological findings. Despite the 
22 
23 complexity of combining these two topics, we think that this combination gives a wider perspective of 
24 management of cART in HIV-positive children of low-middle income countries. 
25 
26 Some specific comments: 
27 
28 
29 
30 1.   I think table 1 is not very helpful on its own, it might be more interesting to compare those who were 
31 included to those who were excluded. 
32 
33 Thank you for this comment. Kindly refer to new TABLE 1. 
34 
35 2.   In table 2 it is not clear what the p-values refer to, maybe this needs to be more specific, could have 36 
37 footnotes and mention how these were derived. 
38 
39 The followed footnote was add to TABLE 2: “p-values refer to differences between Mozambique and 
40 Uganda sub-cohorts on baseline characteristics” 
41 
42 3.   Since it appears there is some relationship between TB and treatment failure, I would like to see if 
43 possible, more detailed analysis of the initial regimens used together with TB treatment, to assess 
45 whether drug regimens used during TB treatment might be associated with treatment failure? 
46 
47 We agree that TB treatment may interact with cART, and that the proposed analysis could provide very 
48 useful information for clinicians. Unfortunately, data available on TB treatment in this cohort is 
49 incomplete and, in our opinion, not reliable enough to conduct this analysis. 
50 
51 
52 4.   WHO/Unicef usually use weight-for-age  z-scores to assess malnutrition particularly for young children 
53 and I wonder why the authors have chosen to use BMI z-scores? 
54 
55 In our study we chose to use BMI for age z-scores instead of weight-for-age z-scores because BMI 
56 provides a more appropriate assessment for chronic malnutrition, as it reflects both weight and height. 
57 As weight for age z-scores, BMI for age z-score has been used in several studies conducted in HIV- 
58 
59 
60 
http://mc.manuscriptcentral.com/jpids 
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1 
2 
3 positive children (3Cs4kids Analysis and Writing Committee, AIDS 2008; Landes M et al, PLoS One. 
4 2012; Jacobson DL et al, Am J Clin Nutr. 2011). 5 
6 
7 5.   The authors discuss the updated 2013 WHO guidelines in terms of earlier treatment start for children 
8 but fail to discuss the criteria for switching. If viral load were available, treatment failure would likely be 
9 detected earlier and implications for these 2 countries needs to be discussed. 
10 
11 Both countries mainly referred to WHO 2006 guidelines for cART switching, however we do not have 
12 information on adherence to these guidelines at the sites where data were collected for this study. 
14 Regarding implications of VL testing in Uganda and Mozambique, please refer to the following text in 
15 the background section of the manuscript: “Delays in detecting treatment failure and switching to 
16 second line therapy lead to the development of HIV drug-resistance, compromising subsequent 
17 regimens (6, 21). This is particularly relevant for children, due to the lack of paediatric formulations” 
18 and “Earlier cART initiation and VL monitoring are currently recommended by WHO 2013 consolidated 
19 guidelines (3). Our results suggest that more efforts should be done to qualitatively assess reasons of 
20 
21 delay in switching to second line cART, particularly in light of the scaling up of VL monitoring in LMIC.” 
22 This implies that more prompt switching to second line therapy when appropriate would reduce the 
23 development of HIV drug resistance and the compromise of subsequent regimens. Viral load 
24 monitoring would probably anticipate the diagnosis of treatment failure, but efforts should be done to 
25 better explore any reason of delay/not starting second line cART, in the program setting. 
26 
27 6.   Finally, there are some grammatical errors. In the first line of the abstract "delays detecting... is" should 28 
29 be "are", and line 12, "evaluated for..." delete "for". 
30 
31 Thank you for pointing this out, all these grammatical errors were corrected. 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
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Short summary  
This study analysed for the first time EBV types and load in HIV-1-infected African children. 
Findings indicate that antiretroviral treatment, by limiting HIV-1 replication, microbial translocation 
and related immune activation, prevents super-infection with EBV types and keeps EBV viremia 
down.  
Abstract  
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Background: Epstein-Barr Virus (EBV) is involved in a wide range of malignancies, particularly in 
immunocompromised subjects. Besides immunodepression, immune activation may also affect 
dynamics of EBV infection. In Africa, EBV primary infection occurs during early childhood, but 
little is known about EBV load in HIV-1 infected children.  
Methods: Dried Blood Spot samples from 213 HIV-1 infected children, 140 on antiretroviral 
therapy (ART), were collected at the Nsambya Hospital in Kampala, Uganda. DNA was extracted 
and analysed for quantification of EBV types 1 and 2 by multiplex real-time PCR, and for 
quantification of 16S ribosomial DNA (16S rDNA), a marker of microbial translocation, by real-
time PCR. RNA was extracted and used to quantify HIV-1 RNA in peripheral blood. 
Results: Ninety-two of 140(66%) children on ART and 57 of 73(78%) ART-naive children had 
detectable EBV levels. Co-infection with both EBV types was significantly less frequent in ART-
treated than in ART-naïve children (OR=0.54, 95%CI 0.30;0.98, p=0.042); EBV-DNA levels were 
significantly lower in the former (3.99±0.59 vs 4.22±0.54 log10 copies/ml; p=0.0059) and tended to 
be inversely associated with time on ART. EBV-DNA levels were also significantly higher in 
children with HIV-1 RNA>3 log10 copies/ml of blood (regression coefficient=0.32 [95%CI 
0.05;0.59]; p=0.0197) and correlated with circulating 16S rDNA levels (rs=0.250 [95%CI 
0.02;0.46]; p=0.0310). 
Conclusions: These findings suggest that ART, by limiting HIV-1 replication, microbial 
translocation and related immune activation, prevents super-infection with both EBV types and 
keeps EBV viremia down, thus potentially reducing the risk of EBV-associated lymphomas. 
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1. Introduction 
Epstein-Barr Virus (EBV) is associated with a wide range of malignancies, particularly in 
immunocompromised subjects, ranging from lymphoproliferative disorders to B-cell non-Hodgkin's 
lymphomas (NHL) [1,2]. Besides immunodepression, chronic immune activation, a hallmark of 
Human Immunodeficiency Virus type 1 (HIV)-1 pathogenesis [3], may play a critical role in the 
genesis of B-cell lymphomas [4,5]. Cell activation driven by HIV-1 antigens, together with 
impaired immunosurveillance against EBV, may result in chronic B-cell stimulation and expansion 
of EBV-infected B-cells [6-9], thus increasing the risk of EBV-related malignancies. The factors 
contributing to HIV-1-induced B-cell activation and expansion of EBV-infected cells are largely 
unknown. Massive HIV-1-induced T-cell depletion causes damage to intestinal mucosa, promoting 
translocation of microbial products into circulation. Pathogen-associated molecular patterns 
(PAMPs), such as 16S ribosomal DNA (16S rDNA), trigger a potent innate immune response 
through the engagement of several Toll-like receptors (TLRs), which also involve B-cells, causing 
polyclonal B-cell activation [10].  
 
Antiretroviral therapy (ART) has greatly modified the natural course of HIV-1 infection, resulting in 
decreased HIV-1 load, increased CD4+ T cells, and decreased HIV-1-associated opportunistic 
infections, indicating the restoration of immune function [11]. Although the incidence of HIV-1 
related malignancies, such as Kaposi sarcoma (KS), has declined markedly following expanded 
access to ART, the incidence of NHL still remains elevated [12]. Two EBV types are recognized, 
type 1 and type 2. EBV type 1 is more common in most populations; 80% to 90% of EBV isolates 
from Caucasian and Southeast-Asian populations are type 1. EBV type 2 shows a prevalence almost 
equal to EBV type 1 in populations in Africa and New Guinea [13]. HIV-1 infectedsubjects may 
have either EBV type 1 or type 2, and co-infection with both types is also possible [13]. 
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In Africa, EBV primary infection occurs during infancy and early childhood, and EBV-associated 
lymphomas represent a substantial cause of morbidity and mortality in children. NHL commonly 
occurs in African children, endemic Burkitt’s Lymphoma (BL) being the most common type of 
cancer [14]. Endemic BL is closely associated with EBV and accounts for up to 75% of all 
childhood malignancies [15], reaching 5-10 cases per 100000 of annual incidence in Central Africa 
[16]. Other tumors, such as EBV-associated immunoblastic lymphomas, may occur in HIV-1 
infectedchildren [17,18]. 
 
To date, there are no available data about EBV types and viremia in the context of HIV-1 infection 
in African children. This absence may partly be due to the lack of adequately equipped laboratories 
and expertise in developing countries. The use of Dried Blood Spots (DBS) sampling may represent 
a more feasible method to collect and store blood samples and may be instrumental in expanding 
studies in resource-limited settings.  
 
 
2. Material and Methods  
2.1 Patients and sample collection 
This is a cross-sectional study, conducted in the Home Care Department of the St. Raphael of St. 
Francis Hospital at Nsambya in Kampala, Uganda. Blood samples from 213 HIV-1 infected 
children (0-18 years) who attended to Home Care Department from March 2010 to July 2010 were 
collected. At the time of sampling for this study, 140 (66%) children were on ART. Ninety-seven 
children received Nevirapine (NVP)-based regimens, 34 Efavirenz (EFV)-based therapy, and 8 a 
Lopinavir/ritonavir (LPV/r)-based treatment (Table 1). Blood from each child was collected in 
ethylenediaminetetraacetic acid (EDTA)-containing tubes by trained nurses. Fifty µl of this blood 
were spotted onto each of the five circles of Protein Saver TM 903 Card (Whatman GmbH, 
Hahnestra, Germany). DBS were dried at room temperature overnight, stored in individual ziplock 
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bags containing a desiccant, and shipped to the laboratory of the Viral-Oncology Unit and AIDS 
Reference Center, Section of Oncology and Immunology, Padova, Italy. The study was approved by 
the Internal Review Board and Ethics Committee of Nsambya Hospital and registered by the 
Uganda National Council for Science and Technology (Ref. HS724). 
 
2.2 DNA elution 
From each 50µl DBS, three 3 mm-diameter circles, equivalent to 5 µl of whole blood each (15 µl 
total), were used to extract DNA with the Qiagen DNA MicroKit (Qiagen, Hilden, Germany) and 
were resuspended in a final volume of 50 µl. To check whether the eluted DNA could be amplified, 
5µl of final elution were amplified for the human telomerase reverse transcriptase (TERT) gene 
(Gen Bank accession: AF128893), employed as housekeeping gene. Amplification was carried out 
as previously described [19].  
 
2.3 EBV-DNA typing and quantification 
A quantitative method, based on multiplex real-time PCR assay, was employed to quantify EBV 
types 1 and EBV type 2, as described elsewhere [20]. Each PCR was performed in a 25µl reaction 
mix containing 5µl of eluted DNA (corresponding to 1.5µl of blood). A standard reference curve 
was obtained by five-fold serial dilution of two amplicons, one for EBV type 1 and one for EBV 
type 2, and amplification was performed as already described [20]. The multiplex assay showed a 
dynamic range from 5 to 2x105 copies. The lower limit of detection was up to 1 copy and was 
established by analysing replicate dilution samples containing 1 EBV copy. According to Poisson 
distribution, repeated measurement of these samples gave positive results for EBV detection in 9 
out of 15 replicates. As amplification was carried out in a final volume of 1.5 ȝl blood, a sample 
was positive when there are at least 660 EBV-DNA copies/ml blood. Results are expressed as log10 
EBV-DNA copies/ml. 
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2.4 16S rDNA quantification  
A quantitative method based on real-time PCR assay was performed to quantify 16S rDNA, with 
the primer pair and probe as described [21]. A standard curve was generated from five-fold serial 
dilutions of plasmid DNA containing known copy numbers of the template. The assay showed a 
dynamic range from 3 to 2.5x105 copies. Levels of 16S rDNA were quantified in 109 available 
samples. Results are expressed as log10 16S rDNA copies/ȝl 
 
2.5 HIV-1 RNA quantification 
For each sample, two entire DBS, corresponding to 100 ȝl of whole blood, were used to extract 
RNA with the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). RNA was eluted with 75 
ȝl of the elution buffer heated to 70°C. HIV-1 RNA levels were determined with the Amplicor HIV-
1 Monitor Test (Roche Diagnostic Systems, Branchburg, NJ, USA). The lower limit of detection 
with the DBS samples was 170 HIV-1 RNA copies/ml of blood. Results are expressed in log10 HIV-
1 RNA copies/ml of blood. As HIV-1 RNA of up to 3 log10 copies/ml plasma is currently considered 
the most appropriate cut-off to define treatment failure [22], and also for prevention of mother-to-
child transmission of HIV ART was recommended for all women with HIV- R1A levels of 3 
log10 copies/ml of plasma [23], the relationship between EBV and HIV-1 was estimated according 
to this cut-off value.  
 
2.6 Statistical analyses 
EBV-DNA, HIV-1 RNA and 16S rDNA data were log10 transformed to obtain more normal 
distributions. Chi-square test for categorical variables and Kruskal-Wallis test for continuous 
variables were employed. Logistic regression analysis was employed to assess the relationship 
between EBV detection status and whether or not ART was received, after adjustment for multiple 
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confounders such as CD4 Z-score, WHO stage, age, gender. Logistic regression analysis and 
Spearman's correlation coefficient were used to evaluate relationships between status and levels of 
EBV-DNA and time on ART. Linear regression analysis was used to assess the relationship between 
HIV-1 RNA load and EBV-DNA levels in univariate analysis and after adjustment for multiple 
confounders. The association between EBV-DNA and circulating bacterial 16S rDNA levels was 
evaluated by Spearman's correlation and by a linear regression model. All statistical analyses were 
performed with software SPSS v.18 and STATA v.12. 
 
3. Results 
3.1 EBV-DNA levels in children 
Table 1 lists the baseline characteristics of the 213 HIV-1 infected children. A total of 149 children, 
92 out of 140 (66%) on ART and 57 out of 73 (78%) ART-naive had detectable EBV in blood. EBV 
types 1 or 2 were detected in 31 (22%) and 21 (15%) children on ART, and in 15 (21%) and 11 
(15%) ART-naive children, respectively. Co-infection with both EBV types was observed in 40 
(29%) ART-treated and 31 (42%) ART-naive children. Children on ART had less probability of 
being co-infected with both EBV types than ART-naive children (OR=0.54 [95% CI 0.30;0.98]; 
p=0.0423), and overall ART-treated children were less likely to carry detectable EBV-DNA than 
ART-naive children (OR=0.54 [95% CI 0.28;1.04]; p=0.0637) (Table 2). These findings were 
confirmed in the multivariate analysis, after adjustment for CD4-Z score, age, gender, and WHO 
stage (OR=0.50 [95% CI 0.23;1.08]; p= 0.0696, and OR=0.40 [95% CI 0.1;0.97]; p=0.0426, 
respectively) (Table 2). 
 
Mean (± Standard Deviation) levels of EBV-DNA were similar in children infected with either EBV 
type 1 (3.80±0.52 log10 copies/ml) or type 2 (3.92±0.54 log10 copies/ml), but they were higher in 
children co-infected with both viruses (4.34±0.54 log10 copies/ml) (Figure 1A). No significant 
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differences in mean levels of EBV types 1 or 2 were found between ART-treated or ART-naive 
children, whereas e mean levels of co-infection with both EBV types were significantly lower in 
children on ART (4.23±0.54 vs 4.47±0.50 log10 copies/ml; p=0.0210). Overall, total EBV-DNA load 
was significantly lower in ART-treated than in ART-naive children (3.99±0.59 vs 4.22±0.54 log10 
copies/ml; p=0.0059) (Figure 1B). EBV-DNA load tended to be inversely associated with the time 
on ART (rs=-0.201 [95% CI -0.394;0.009]; p=0.061). In particular, after adjustment for WHO 
stage and CD4-Z score, the detection of EBV type 2 was less frequent according to the time on ART 
(OR=0.811 [95% CI 0.659;0.997]; p=0.048). 
 
3.2 EBV-DNA levels in relation to HIV-1 load 
Total HIV-1 RNA (cell-associated and plasma) levels were evaluated in the DBS samples of 204 
HIV-1 infected children. One hundred and ninety-one (94%) children, 125 out of 134 (93%) on 
ART and 66 out of 70 (94%) ART-naive, had detectable HIV-1 RNA. Such levels were 
significantly lower in ART-treated than in ART-naive children (3.55±0.66 vs 4.18±0.83 log10 
copies/ml; p<0.0001). EBV-DNA levels were significantly higher in children with HIV-1 RNA >3 
log10 copies/ml of blood, in both univariate analysis (regression coefficient=0.32 [95% CI 
0.05;0.59]; p=0.0197) and multivariate analyses, after adjusting for age, gender, WHO stage, CD4 
Z-score, and ART (regression coefficient=0.33 [95% CI 0.30;0.63]; p=0.0318) (Table 3).  
 
3.3 EBV-DNA levels in relation to markers of immune activation 
Levels of 16S rDNA were significantly lower in ART-treated than in ART-naive children (2.09±0.23 
vs 2.16±0.25 log10 copies/ȝl; p=0.007) (Figure 2A). In a total of 109 children, 72 had detectable 
EBV, 30 had EBV type 1, 13 type 2, and 29 were co-infected with both EBV types. Levels of 16S 
rDNA were similar in children infected with EBV type 1 (2.09±0.27 log10 copies/ȝl) or EBV type 2 
(2.14±0.11 log10 copies/ȝl), but higher in children co-infected with both EBV types (2.22±0.12 log10 
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copies/ȝl) (Figure 2B). Levels of 16S rDNA significantly correlated with EBV-DNA levels 
(rs=0.250 [95% CI 0.02;0.46]; p=0.0310) (Figure 2C). A linear regression model confirmed the 
significant relationship between 16S rDNA and EBV (regression coefficient=1.01 [95% CI 
1.00;1.02]; p=0.0197).  
 
Discussion 
This is the first study describing the relationship between HIV-1 infection, markers of microbial 
translocation, and EBV types and viremia in HIV-1 infected African children. First of all, we found 
that HIV-1 infected children were more co-infected with both EBV types than with only type 1 or 
type 2. Although healthy individuals usually harbor a single EBV type, HIV-1 infected subjects may 
be infected with both, as observed in this study. The fact that EBV type 1 transforms B cells in vitro 
more efficiently than type 2 has suggested type-specific differences in oncogenic activity in vivo 
[13,24]. However, both types have been found in HIV-1-related lymphomas [7,13,24,25], indicating 
that both viruses may play an oncogenic role in the context of a weakened immune system. In 
addition, LMP1, the master oncoprotein of EBV, differs among the EBV strains, according to the 
number of 33 base-pair repeat elements, but not specifically between the two types [26,27].  
 
We found that children co-infected with both EBV types had higher EBV levels than those infected 
with only type 1 or type 2. Co-infection and levels of EBV are also related to blood levels of HIV-1 
RNA and 16S rDNA, a marker of microbial translocation [10]. These results suggest that HIV-1 
replication and circulating microbial products may lead to EBV replication and expansion of EBV-
infected B-cells, thus increasing the EBV-DNA load. Super-infection with both EBV types may 
represent an additional risk.  
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Our results show that ART affects EBV infection and levels. Overall, ART-treated children were 
less likely to have detectable EBV levels. In particular, they had a lower probability of being co-
infected with both EBV types and, overall, their EBV levels were significantly lower than in ART-
naïve children. Of interest, EBV-DNA load tended to be inversely associated with time on ART, and 
children with a prolonged time on ART had lower EBV-DNA levels. These findings indicate that 
ART constrains EBV super-infection and keeps EBV viremia down.  
 
As expected, HIV-1 RNA load in total blood (cell-associated and plasma) was significantly lower in 
ART-treated than in ART-naive children, but surprisingly, many children on ART (93%) had 
detectable HIV-1 RNA levels. This finding has two possible explanations. First, poor adherence to 
therapy may lead to a weak virological response, with persistent detectable plasma viremia. Second, 
the amount of HIV-1 RNA extracted from DBS is due to plasma viremia and cell-associated viral 
RNA. Cell-associated HIV-1 RNA may persist even in patients with undetectable plasma viremia 
[28,29] and may be considered as an indicator of residual virus replication in ART-treated patients 
[30]. The introduction of ART has resulted in a significant reduction in HIV-1 load and has reduced 
circulating levels of bacterial 16S rDNA [21]. As expected, we found that levels of circulating 
bacterial 16S rDNA were significantly lower in ART-treated than in ART-naive children. Overall, 
the relationships among EBV, HIV-1 and 16S rDNA indicate that ART, by limiting HIV-1 
replication and reservoirs, microbial translocation and chronic immune activation, impedes super-
infection by both EBV types, preventing stimulation of B-cells and expansion of EBV-infected B-
cells, thus reducing the risk of developing EBV-associated B-cell lymphomas. 
 
DBS filter papers are commonly used to diagnose and monitor different DNA/RNA viral loads [31]. 
However, to date only one study [32] has investigated EBV-DNA levels from DBS. EBV viral load 
assessment in peripheral blood may be an important instrument for diagnosing and monitoring 
11 
 
EBV-associated lymphoproliferative diseases, particularly in some regions of Africa, such as 
Uganda, where EBV sero-prevalence is nearly universal, with acquisition of infection in early 
childhood. Our results show that it is possible to quantify EBV-DNA, HIV-1 RNA and 16S rDNA 
by DBS sampling, thus improving the diagnostic and monitoring capabilities in resource-limited 
settings. 
 
Our findings should be interpreted in the light of some potential limitations. First, the DBS 
specimens were collected in Uganda, stored at room temperature, and shipped to Italy in a median 
time of 49 days (range 34-64 days). While amplification failure has been described when specimens 
are stored at room temperature for more than 30 days [33], the influence of storage conditions on 
the EBV amplification is unknown. Second, although multivariate analyses were carried out, 
potential additional confounders, such as comorbities or type of therapy, cannot be enterely ruled 
out. 
 
In conclusion, HIV-1, inducing microbial translocation and a state of persistent immune activation, 
may lead to EBV replication and expansion of EBV-infected B-cells, thus increasing the EBV-DNA 
load. Super-infection by both types of EBV in HIV-1 infected subjects may represent an additional 
risk for the onset of EBV-related malignancies. ART, by limiting HIV-1 replication, microbial 
translocation and related immune activation, may prevent super-infection by both EBV types and 
keep EBV viremia down, thus reducing the risk of EBV-associated lymphomas. 
 
Funding 
This work was supported by the PENTA Foundation. 
 
 
12 
 
Conflict of interest 
None of the authors declares any conflict of interest 
 
Acknowledgments  
The authors would like to thank Jason Brenchley for providing the 16S rDNA plasmid.  
These data were partially presented at the 20th Conference on Retroviruses and Opportunistic 
Infections (CROI) 2013, March 3-6 2013, Atlanta, USA. 
 
References 
1. Beral V, Newton R. Overview of the epidemiology of immunodeficiency-associated 
cancers. J Natl Cancer Inst Monogr, 1998; 23: 1-6.  
2. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and 
gamma-herpesviruses. Blood, 2009; 113: 1213-24. 
3. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of 
AIDS. Annu Rev Med, 2009; 60: 471-84. 
4. Grulich AE, Wan X, Law MG, et al. B-cell stimulation and prolonged immune deficiency 
are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS, 2002; 14: 133-40.  
5. Moir S, Fauci AS. B-cells in HIV infection and disease. Nat Rev Immunol, 2009; 9: 235-45. 
6. Gaidano G, Dalla-Favera R. Molecular pathogenesis of AIDS-related lymphomas. Adv 
Cancer Res, 1995; 67: 113-53. 
13 
 
7. Ometto L, Menin C, Masiero S, et al. Molecular profile of Epstein-Barr virus in human 
immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood. 1997; 
90: 313-22. 
8. Righetti E, Ballon G, Ometto L, et al. Dynamics of Epstein-Barr virus in HIV-1 infected 
subjects on highly active antiretroviral therapy. AIDS, 2002; 16: 63-73. 
9. Burighel N, Ghezzi S, Nozza S, et al. Differential dynamics of Epstein-Barr virus in 
individuals infected with human immunodeficiency virus-1 receiving intermittent 
interleukin-2 and antiretroviral therapy. Haematologica, 2006; 91: 244-7. 
10. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic 
immune activation in chronic HIV infection. Nat Med, 2006; 12: 1365-71.  
11. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among 
patients with advanced human immunodeficiency virus infection. HIV Outpatient Study 
Investigators. N Engl J Med. 1998; 338: 853-60. 
12. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals 
with Acquired Immunodeficiency Syndrome in the United States. Cancer, 2011; 117: 1089-
96 
13. Rickinson AB, Kieff E. Epstein-Barr Virus. In: Fields Virology, 5th ed, Knipe DM, Howley 
PM (Ed), Lippincott Williams and Wilkins, Philadelphia 2007. pp. 2656-2688 
14. Walusansa V, Okuku F, Orem J. Burkitt lymphoma in Uganda, the legacy of Denis Burkitt 
and an update on the disease status. Br J Haematol, 2012; 156: 757-60. 
14 
 
15. Cader FZ, Kearns P, Young L, Murray P, Vockerodt M. The contribution of the Epstein-
Barr virus to the pathogenesis of childhood lymphomas. Cancer Treat Rev, 2010; 36: 348-
53. 
16. Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. Lancet. 2012 ; 379: 1234-
44. 
17. Mueller BU. Cancers in children infected with the human immunodeficiency virus. 
Oncologist. 1999; 4: 309-17. 
18. Davidson A, Hendricks M. Experience with B-cell lymphoma at a South African centre in 
the HIV Era. Transfus Apher Sci. 2013; 49: 31-9. 
19. Abbate I, Zanchetta M, Gatti M, et al. Multicenter comparative study of Epstein-Barr virus 
DNA quantification for virological monitoring in transplanted patients. J Clin Virol, 2011; 
50: 224-9. 
20. Petrara MR, Cattelan AM, Zanchetta M, et al. Epstein-Barr virus load and immune 
activation in human immunodeficiency virus type 1-infected patients. J Clin Virol, 2012; 
53:195-200. 
21. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with 
immune activation and the magnitude of immune restoration in persons with antiretroviral-
treated HIV infection. J Infect Dis, 2009; 199: 1177-85.  
22. Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV 
Infection. Geneva: World Health Organization; 2013. Available from: 
www.who.int/hiv/pub/guidelines/arv2013 
15 
 
23. Jamieson DJ, Clark J, Kourtis AP, et al. Recommendations for human immunodeficiency 
virus screening, prophylaxis, and treatment for pregnant women in the United States. Am J 
Obstet Gynecol 2007; 197: S26-32 
24. Rickinson AB, Young LS, Rowe M. Influence of the Epstein-Barr virus nuclear antigen 
EBNA2 on the growth phenotype of virus transformed B cells. J Virol, 1987; 61: 1310. 
25. Buisson M, Morand P, Peoc'h M, Bouchard O, Bourgeat MJ, Seigneurin JM. Development 
of an Epstein-Barr virus type 2 (EBV-2)-associated hepatic B cell non-Hodgkin's lymphoma 
in an HIV-1-infected patient following a change in the EBV dominant type. Leukemia. 
1999; 13: 298-301. 
26. Miller WE, Edwards RH, Walling DM, Raab-Traub N. Sequence variation in the Epstein-
Barr virus latent membrane protein 1. J Gen Virol. 1994; 75: 2729-40. 
27. Mainou BA, Raab-Traub N. LMP1 strain variants: biological and molecular properties. J 
Virol. 2006; 80: 6458-68. 
28. Zanchetta M, Walker S, Burighel N, et al. Long-term decay of the HIV-1 reservoir in HIV-
1-infected children treated with highly active antiretroviral therapy. J Infect Dis. 2006; 193: 
1718-27. 
29. Pinzone MR, Di Rosa M, Cacopardo B, Nunnari G. HIV RNA suppression and immune 
restoration: can we do better? Clin Dev Immunol, 2012; 2012: 515962. 
30. Pasternak AO, Lukashov VV, Berkhout B. Cell-associated HIV RNA: a dynamic biomarker 
of viral persistence. Retrovirology. 2013;10: 41. 
16 
 
31. Snijdewind IJ, van Kampen JJ, Fraaij PL, van der Ende ME, Osterhaus AD, Gruters RA. 
Current and future applications of dried blood spots in viral disease management. Antiviral 
Res, 2012; 93: 309-21 
32. Kabyemera R, Masalu N, Rambau P, etal. Relationship between Non-Hodgkin's lymphoma 
and blood levels of Epstein-Barr Virus in children in north-western Tanzania: a case control 
study. BMC Pediatr, 2013; 13: 4.  
33. Parkin N, de Mendoza C, Schuurman R, et al. WHO DBS Genotyping Working Group. 
Evaluation of in-house genotyping assay performance using dried blood spot specimens in 
the Global World Health Organization laboratory network. Clin Infect Dis. 2012; 54 Suppl 
4: S273-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
Table 1. Baseline characteristics of HIV-1 infected children 
Characteristics* No. children (%) 
Children on ART (n=213) No 73 (34) 
Yes 140 (66) 
WHO Stage (n=209) I 60 (29) 
II 120 (57) 
III 27 (13) 
 IV 2 (1) 
WHO stage of children on ART (n=140) I 23 (16) 
II 97 (69) 
III 18 (13) 
 IV 2 (2) 
ART type (n=140) NVP Based 97 (69) 
EFV Based 34 (24) 
LPV/r Based 8 (6) 
3-NRTI 1 (1) 
CD4 cell/ȝl (n=177) < 350 18 (10) 
350-750 68 (38) 
750-1000 41 (23) 
>1000 50 (29) 
*All characteristics referred to the time of sample collection 
 
 
 
Table 2. EBV detection among HIV-1 infected ART-treated vs ART-naive children 
18 
 
EBV 
detection 
ART-
treated 
ART-
naive OR (95% CI) p-value 
n (%) n (%) univariate multivariate* univariate multivariate* 
EBV type 1 31 (22) 15 (21) 1.10  (0.55;2.20) 
0.85  
(0.35;2.06) 0.7884 0.7278 
EBV type 2 21 (15) 11 (15) 0.99  (0.45;2.20) 
1.00 
 (0.37;2.71) 0.9894 0.9971 
EBV type 1+ 2 40 (29) 31 (42) 0.54  (0.30;0.98) 
0.50  
(0.23;1.08) 0.0423 0.0696 
EBV total 92 (66) 57 (78) 0.54  (0.28;1.04) 
0.40  
(0.17;0.97) 0.0637 0.0426 
* Covariates considered for multivariate model: age, gender, CD4 Z-score, WHO stage 
 
 
19 
 
Table 3. Multivariate regression analyses of EBV-DNA levels in HIV-1 infected children  
EBV 
detection 
Covariatea Regression coefficient 
(95% CI) 
p-value 
  univariate multivariate* univariate multivariate* 
EBV type 1 HIV-1 RNA >3 log10b 
0.30  
(-0.08;0.69) 
0.38  
(-0.11;0.87) 0.1216 0.1233 
EBV type 2 HIV-1 RNA >3 log10b 
0.06  
(-0.51;0.63) 
0.15  
(-0.45;0.76) 0.8274 0.6004 
EBV type 1+ 2 HIV-1 RNA >3 log10b 
0.25 
 (-0.19;0.69) 
0.27  
(-0.21;0.75) 0.2548 0.2639 
EBV total HIV-1 RNA >3 log10b 
0.32  
(0.05;0.57) 
0.33  
(0.30;0.63) 0.0197 0.0318 
a Other covariates in multivariate model: gender, age, CD4 Z-score, WHO stage, ART 
bHIV-1 RNA load is expressed as log10 copies/ml of blood 
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 Legends to Figures 
 
Figure 1. EBV-DNA load in HIV-1 infected children. EBV-DNA levels in HIV-1 infected 
children sub-grouped by A) type of infection with EBV and B) therapy. Each plot represents one 
child. Lines indicate the mean values. 
 
Figure 2. 16S rDNA levels in HIV-1 infected children. 16S rDNA levels in HIV-1 infected 
children sub-grouped according to A) therapy: on ART or ART-naive, B) type of infection with 
EBV, and C) correlation with EBV-DNA levels. Each plot represents one child. Lines indicate the 
mean values. 
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Abstract  (250 w)  1 
Background:  Delays detecting treatment failure (TF) often occur when combined antiretroviral 2 
therapy (cART) is monitored using clinical and immunological criteria.  We describe viral load 3 
(VL) measurement using dried blood spots (DBS) and explore the accuracy of clinical and 4 
immunological criteria for TF in a cohort of HIV-1-infected children.   5 
Methods: 949 HIV-infected children followed with monthly clinical visits and 6 monthly CD4 6 
testing at the Home Care Department, Nsambya Hospital (Uganda), were studied. Whole blood 7 
was collected on DBS from 204 children for VL testing and HIV-1 RNA was quantified by real-8 
time PCR using ROCHE COBAS TaqMan System. TF was defined using WHO 2010 criteria.  9 
Results: Overall, 104 (F 53) children on cART for >24 months were included in analyses. At 10 
DBS collection, median time from cART initiation was 34.19 months (IQR 32.87); median CD4 11 
count and CD4% were 412 (IQR 439) and 11.8% (IQR 10.1). Thirty (28.8%) children had 12 
VL<1000 cp/ml, while 46/104 (44.2%) and 28/104 (26.9%) had VL of 1000-5000 and >5000 13 
cp/ml. Thirteen (12.5%) children had TF according to immunological (1/13) and/or clinical 14 
criteria (12/13). Of those, 3 clinical failure had VL <1000 cp/ml, 6 had VL 1000-5000 cp/ml and 15 
3 had VL >5000 cp/ml; one immunological failure had VL >5000 cp/ml. Clinical and 16 
immunological criteria poorly predicted VL  above either 1000 or 5000 cp/ml whole blood 17 
thresholds.  18 
Conclusion:  High VL can be detected despite absence of clinical and immunological failure. 19 
Using DBS for VL monitoring is feasible and should be implemented to detect TF in children 20 
living in low-middle income countries.  21 
 22 
 23 
 24 
 4 
 
Introduction  (2035 words)   25 
In most low-middle income countries (LMIC) HIV-1-infected children receiving combination 26 
antiretroviral treatment (cART) are monitored using clinical and immunological criteria. Large 27 
randomized trials didn’t show any additional benefit in terms of disease progression and 28 
mortality using routine laboratory monitoring, compare to clinical monitoring alone (1, 2). 29 
Additionally, ARROW trial reported high virological response in children, at 3.7 years of follow-30 
up (2). Several other evidences reported high rates of virological suppression in children up to 5-31 
6 years after treatment initiation (3), however delays in detecting treatment failure by clinical and 32 
immunological monitoring alone were often described, as a result of a very low sensitivity in 33 
predicting virological failure (4, 5). 34 
The 2013 WHO Consolidated Guidelines now recommend VL monitoring as the preferred  35 
approach to detect treatment failure in LMIC (6). However, an effective implementation of VL 36 
monitoring is very challenging due to the high cost of virological assays, lack of adequate 37 
laboratory facilities and appropriate specimens handling (6).  38 
Dried blood spots (DBS) for virological monitoring seems to be a very promising tool in LMIC. 39 
Filter papers used for DBS collection could be easily and safely shipped and HIV-1 nucleic acids 40 
amplification is usually  successful  after storing DBS for less than 1-2 weeks at room 41 
temperature (7), facilitating specimen collection from rural and very remote areas  (8). However, 42 
several challenges can affect the accuracy and the use of DBS for VL monitoring within routine 43 
clinical practice. Variability in amplification rates has been described for several commercial and 44 
in-house methods for RNA extraction and amplification (7, 9). In addition, HIV-1 RNA levels  45 
extracted from DBS reflect the contribution of plasma plus cell-associated viral nucleic acids, 46 
therefore most studies agree that whole blood samples yield  higher levels than plasma samples, 47 
 5 
 
particularly at low HIV-1 RNA plasma levels (9-11). Environmental factors like prolonged 48 
storage at high temperatures and humidity may also underestimate VL from DBS, compared to 49 
plasma (7, 12).  50 
 51 
The aim of this study was to evaluate the accuracy of clinical and immunological criteria based 52 
on the detection of VL greater than 1000 and 5000 cp/ml whole blood at DBS in a cohort of 53 
HIV-1-infected children in Uganda.   54 
 55 
Methods   56 
An observational cohort study was set up among HIV-1-infected children enrolled at the Home 57 
Care Department (NHC) of St. Raphael of St. Francis Nsambya Hospital in Kampala, Uganda. 58 
All children were evaluated monthly for clinical follow-up and self-reported adherence. 59 
Laboratory investigations including full blood count, liver function tests, creatinine and CD4 cell 60 
count were carried out every 6 months, or more frequently if clinically required. WHO 2006 61 
guidelines (13) were followed for initiation of Cotrimoxazole prophylaxis, cART, and 62 
management of opportunistic infections. In the absence of contraindications, cART was 63 
prescribed after counselling and written consent from the caregiver.  64 
Quantitative HIV-1-RNA detection was not part of routine examinations, however in 2010 DBS 65 
were collected for quantitative HIV-1 RNA detection in HIV-1-positive children enrolled in a 66 
parallel study investigating the Epstein-Barr Virus (M.R. Petrara et al, presented at the 20th 67 
Conference on Retroviruses and Opportunistic Infections – CROI 2013, Atlanta, GA, US, 3 to 6 68 
March 2013).  Whole blood samples were collected in EDTA-containing tubes by trained nurses; 69 
50 µl of EDTA-blood were spotted onto each of the 5 circles of the Protein Saver TM 903 Card 70 
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(Whatman GmbH, Hahnestra, Germany) and left to dry overnight at room temperature. DBS 71 
were stored in individual zip-lock bags containing a desiccant and sent after a median time of 43 72 
days (IQR 15-63) to the reference laboratory of Viral Oncology Unit, AIDS Reference Centre 73 
(Padova, Italy). Roche Cobas taqman internal QS was included to the samples before the 74 
QIAGEN extraction. For each sample R1A was e[tracted from  two  ȝl of DBS (total whole 75 
blood volume of  ȝl) using 4IAamp 9iral R1A Mini Kit (4iagen) and eluted using  ȝl of 76 
the elution buffer heated at 70°C (High Pure RNA Isolation Kit, Roche Diagnostics). Total HIV-77 
1 RNA (cell-associated and plasma) levels were determined using the Amplicor HIV-1 Monitor 78 
Test (Roche Diagnostic Systems), with estimated lower limit of detection of 2.23 log10 (170 79 
cp/ml) HIV-1 RNA copies/ml, according to   the spot volume and final RNA elution. Results 80 
were expressed as HIV-1 RNA copies/ml  whole blood.  81 
Clinical and immunological treatment failure were defined using WHO 2010 criteria 82 
(immunological failure  CD count of  cells/mm or CD  for child of -5 years of 83 
age and CD count of  cells/mm for child ! years of age clinical failure: new WHO 84 
stage 3-4 event occurred >24 weeks after cART initiation)(14). DBS collected from children who 85 
received cART for >24 weeks were included in the analyses.   Gender, age, CD4 cell 86 
count/percentage, WHO stage, self-reported adherence and antiretroviral regimens at first cART 87 
and at DBS collection were assessed, as were median time from cART initiation to DBS 88 
collection and from specimen collection to laboratory analysis. Primary analyses included 89 
assessment of proportions of children with clinical failure (CF) and/or immunological failure (IF) 90 
and with VL <1000, 1000-5000, and >5000 cp/ml. Differences in demographic and clinical 91 
characteristics among children falling into these three groups were assessed using the Kruskal-92 
Wallis test for continuous variables and the Chi-square test for categorical variables.  The 93 
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predictive value of CF and/or IF for VL greater than  either 1000 or 5000 cp/ml was assessed 94 
using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), 95 
and area under the curve (AUC) statistics from receiver operating characteristic (ROC) curves. 96 
All analyses were carried out using STATA 12 (College Station, TX).  97 
 98 
Results    99 
DBS were collected from 204 (M 103, F 101) children with median age of 7.70 years, (IQR 100 
5.42-11.26) at specimen collection. 104 (M 51, F 53) out of 204 (51%) children tested for VL 101 
received cART for >24 months and were included in this analysis. Baseline characteristics and 102 
univariate analysis are included in Table 1. 103 
At cART initiation median age was 6.44 years (IQR 4.05-8.72). The majority (97/104, 93.27%) 104 
of children started an non-nucleoside reverse transcriptase inhibitors (NNRTI)-based cART 105 
while 7 (6.73%) started a protease inhibitor (PI)-based regimen. At birth, 2 children were 106 
exposed to Nevirapine (NVP) for prevention of mother to child transmission (PMTCT), 35 107 
children were not and for 67 children history of  PMTCT was unknown. 108 
Among cART-treated children, DBS were collected at a median of 34.19 months (IQR 19.57-109 
52.44) after cART initiation. VL was detected from DBS stored at ambient temperature for a 110 
median time of 49 days (IQR 34-64, i.e. time from blood collection in Uganda to DBS shipment 111 
to the laboratory in Italy. At the time of specimen collection, 68 (65.4%) children were still 112 
receiving the first cART regimen, while 36 (34.6%) substituted at least one drug (1 drug 113 
substitution was reported for 27 children,  2 and 3 substitutions occurred in  8 and 1 children, 114 
respectively). Overall, 96/104 children (92.31%) were still receiving an NNRTI-based regimens 115 
at specimen collection (65.63% of these on first-line), while 8/104 (7.69%) were on PI-based 116 
regimens (62.5% on first-line ). Drug substitutions most frequently involved NRTI drugs (16 117 
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children substituted 3TC-D4T with AZT-3TC and 16  did the reverse) while 9 children 118 
substituted EFV with NVP and 4 NVP with EFV. Reasons for drug substitution were reported 119 
only for 7/36 children: 4 children developed AZT-related toxicity, in 2 cases the reason was drug 120 
stock out and in one drug interactions. Only one child switched from 3TC-D4T-NVP to AZT-121 
3TC-LPV/r because of clinical failure.  Poor adherence (defined as assumption of <95% doses 122 
received, as per self-report) was reported only for 1 child out of 104 (0.96%), considering  the 123 
period of time between first cART and DBS collection.  124 
Thirty (28.8%) children had VL<1000 cp/ml after a median time of 41.63 months (IQR 28.52-125 
54.28) from cART initiation, while VL of 1000-5000 and >5000 cp/ml were detected 126 
respectively in 46/104 (44.2%) and 28/104 (26.9%) children at median of 31.31 (IQR 15.47-127 
45.60) and 37.72 (IQR 21.16-55.62) months after cART initiation.  128 
At the time of DBS collection 13 (12.5%) children had treatment failure using immunological 129 
and/or clinical criteria, 1 with immunological failure and 12 with clinical failure (6/12 without 130 
immunological failure and 6/12 with no concomitant CD4 cell data). Of those, 3 clinical failures 131 
had VL (DBS) <1000 cp/ml, 6 had VL (DBS) 1000-5000 cp/ml and 3 clinical and 1 132 
immunological failures had VL (DBS) >5000 cp/ml. All these children were receiving an 133 
NNRTI-based regimen and 8/12 had cART substitution before DBS collection. None switched 134 
from NNRTI-based to PI-based regimen before DBS collection. At univariate analysis neither 135 
initial regimen (p= 0.117, Chi-square test)  nor cART regimen at the time of specimen collection 136 
(p=0.850, Chi-square test) were associated with virological levels .  137 
The sensitivity and specificity of clinical and/or immunological criteria in detecting VF as per 138 
WHO 2010 were very low at either 1000 or 5000 cp/ml whole blood VL thresholds (Table 2).    139 
 140 
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Discussion  141 
Our findings suggest that a high proportion of children may have detectable viral load after at 142 
least 24 weeks of cART in the absence of clinical and immunological failure. Despite an 143 
observed low rate of clinical and immunological failure, 71.2% children had VL >1000 cp/ml on 144 
DBS specimens, 26.9% with VL>5000 cp/ml. The majority (92.3%) of children were receiving 145 
an NNRTI-based therapy (mostly were on AZT-3TC-NVP). Even though a single VL 146 
determination cannot define virological failure,  VL >5000 cp/ml  on whole blood was detected 147 
in more than a quarter of children.   148 
Our findings are in contrast with data reported by other studies conducted in LMIC, accounting 149 
for virological suppression (<400 cp/ml) rates up to 85% at 48 weeks in children on NNRTI-150 
based regimens, even if previously exposed to NVP (3, 15). In our cohort, a single determination 151 
of VL makes hard to discriminate between treatment failure and slow but progressive decrease of 152 
viral load from a very high initial viremia, particularly for the VL 1000-5000 cp/ml group. 153 
However, DBS were collected at a median time of more than 2,5 years (34.19 months, IQR 154 
19.57-52.44) after cART initiation, therefore slow virological response is unlikely (16, 17). 155 
Adherence to cART may have been overestimated, particularly for older children/adolescents at 156 
major risk of poor adherence (18), considering that it was self-reported. Furthermore, lack of 157 
data on cART resistances makes difficult to give an exhaustive explanation on the virological 158 
outcomes observed in the cohort.  159 
As previously mentioned, HIV-1 RNA levels extracted from DBS reflect both plasma viremia  160 
and cell-associated viral nucleic acids. Whole blood viremia may reflect cell-associated residual 161 
HIV-1 replication occurring in children receiving cART and with undetectable plasma VL (19).  162 
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Studies reported high correlations between viral loads assessed using plasma and DBS when 163 
plasma VL was greater than 3000 cp/ml (10, 20), therefore in our cohort VL may be slightly 164 
overestimated particularly in <1000 and 1000-5000 cp/ml groups. A potential contamination of 165 
HIV-1 DNA cannot be excluded. However, considering the number of cells in the DBS sample 166 
(21) and the low percentage of HIV-infected CD4+ cells with positive HIV-1 DNA (22-24), the 167 
amount of viral  DNA detected in our assay should be  consistently low.  168 
It should also be noted that the prolonged storage of  DBS at room temperature  as a results of 169 
operational challenges, including lack of an appropriate facility to freeze and store specimens, 170 
may have slightly altered the whole blood viremia. The optimal period of keeping DBS at room 171 
temperature it has been reported to be 14 days (7), while our specimens were stored at room 172 
temperature for a median of 49 days (IQR 34-64).  173 
Lastly, clinical and immunological failure was assessed retrospectively based on routinely 174 
collected data, potentially leading to inaccurate classifications.  175 
 In our cohort immunological and clinical criteria as per WHO 2010 guidelines poorly predict the 176 
presence of a viral load greater than either 1000 cp/ml or 5000 cp/ml (whole blood)  from DBS.  177 
The low sensitivity and positive predictive values for immunological and/or clinical failure 178 
confirm those reported by literature (4) (L. Barlow-Mosha L et al, presented at the 19th 179 
International AIDS Conference 2012, Washington, US, 22 to 27 July 2012). This finding further 180 
support the WHO recommendations that VL monitoring should be implemented and used to 181 
earlier identify cases of treatment failure  (6).  182 
 183 
This study provides data on virological outcome in a program setting among children on cART 184 
routinely monitored by clinical and immunological criteria alone. We confirm that VL 185 
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monitoring using DBS is feasible in LMIC. Studies are needed to improve the accuracy of viral 186 
load determination from DBS to increase test accuracy and detect early virological failure.  187 
 188 
 189 
 190 
 191 
 192 
 193 
 194 
 195 
 196 
 197 
 198 
 199 
 200 
 201 
 202 
 203 
 204 
 205 
 206 
 207 
 208 
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TABLES AND FIGURES  209 
 210 
Table 1. Univariate analysis of 104 cART experienced HIV-positive children with VL <1000, 211 
1000-5000, and > 5000 cp/ml whole blood. 212 
 213 
 Overall 
(n=104) 
VL<1000 
(n=30, 28.8%) 
VL 1000-5000 
(n=46, 44.2%) 
VL>5000 
(n=28, 26.9%) 
p-value 
for trends 
Male 51 (49.04%) 14 (46.67%) 19 (41.30%) 18 (64.29%) 0.152 
At cART initiation      
     Age (years) 6.55 (9.21-
3.67) 
6.44 (4.05-8.72) 6.81 (4.22-
9.77) 
5.75 (2.70-
8.92) 
0.534 
     CD4 cell count 412 (674-235) 527 (245-732) 341 (254-628) 567 (198-574) 0.849 
     CD4 % 11.8 (18-7.9) 12.1 (9.07-
18.59) 
9.82 (7.38-
17.40) 
10.64 (7.62-
16.01) 
0.685 
     WHO stage     0.542 
          I 10 (9.62%) 3 (10.00%) 3 (6.52%) 4 (14.29%)  
          II 66 (63.46%) 21 (70.00%) 28 (60.87%) 17 (60.71%)  
          III 26 (25.00%) 5 (16.67%) 15 (32.61%) 6 (21.43%)  
          IV 2 (1.92%) 1 (3.33%) 0 (0.00%) 1 (3.57%)  
First cART regimen:      0.117 
3TC+D4T+EFV 11 (10.58%) 4 (3.85%) 6 (13.04%) 1 (3.57%)  
3TC+d4T+LPV/r 2 (1.92%) 1 (3.33%) 0 (0%) 1 (3.57%)  
3TC+D4T+NVP 20 (19.23%) 6 (20%) 9 (19.57%) 5 (17.86%)  
AZT+3TC+EFV 25 (24.04%) 8 (26.67%) 12 (26.09%) 5 (17.86%)  
AZT+3TC+LPV/r 5 (4.81%) 1 (3.33%) 3 (6.52%) 1 (3.57%)  
AZT+3TC+NVP 41 (39.42%) 10 (33.33%) 16 (34.78%) 15 (53.57%)  
NNRTI-based first regimen 97 (93.27%) 28 (93.33%) 43 (93.48%) 26 (92.86%) 0.117 
PI-based first regimen 7 (6.73%) 2 (6.67%) 3 (6.52%) 2 (7.14%) 0.117 
cART regimen at VL 
testing* 
    0.687 
     3TC-D4T-EFV 8 (7.69%) 3 (10%) 5 (10.87%) 0 (0%)  
     3TC-D4T-LPV/r 1 (0.96%) 0 (0%) 1 (2.17%) 1 (3.57%)  
     3TC-D4T-NVP 26 (25.00%) 2 (6.66%) 11 (23.91%) 10 (35.71%)  
     AZT-3TC-EFV 23 (22.12%) 9 (30%) 9 (1.96%) 6 (21.43%)  
     AZT-3TC-LPV/r 7 (6.73%) 3 (10%) 2 (4.35%) 1 (3.57%)  
     AZT-3TC-NVP 39 (37.50%) 13 (43.33%) 18 (39.13%) 10 (35.71%)  
NNRTI-based regimen at VL 
testing 
96 (92.31%) 27 (90.00%) 43 (93.48%) 26 (92.86%) 0.850 
PI-based regimen at VL 
testing 
8 (7.69%) 3 (10.00%) 3 (6.52%) 2 (7.14%) 0.850 
Median time from cART 
initiation to DBS collection 
(months/IQR) 
34.19 
(19.57-52.44) 
41.63 
(28.52-54.28) 
31.31 
(15.47-45.60) 
37.72 
(21.16-55.62) 
0.255 
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* ART regimen at time of VL testing represents first ART regimen for patients with no drug 214 
substitutions and most recent ART regimen prior to VL testing for those with substitutions 215 
 216 
Table 2. CD4 and clinical failure to predict virological failure for VL>1000 cp/ml and VL>5000 217 
cp/ml whole blood , respectively) in cART experienced children.  218 
 219 
  
  
Virological failure (VL>1000 cp/ml) *  
 
AUC sensitivity specificity PPV NPV 
/ϰчϮϬϬ Žƌ чϭϬй ĨŽƌ ĐŚŝůĚ Ϯ-5 years and CD4 
чϭϬϬ ĨŽƌ ĐŚŝůĚ хϱ ǇĞĂƌƐ ĂŶĚͬŽƌ ĐůŝŶŝĐĂů ĨĂŝůƵƌĞ 0.5176  13.51 90.00 76.92 29.67 
 
Virological failure (VL >5000 cp/ml) **  
 
AUC sensitivity specificity PPV NPV 
/ϰчϮϬϬ Žƌ чϭϬй ĨŽƌ ĐŚŝůĚ Ϯ-5 years and CD4 
чϭϬϬ ĨŽƌ ĐŚŝůĚ хϱ ǇĞĂƌƐ ĂŶĚͬŽƌ ĐůŝŶŝĐĂů ĨĂŝůƵƌĞ 0.5122 14.29 88.16 30.77 73.63 
  220 
* n=30 for VL <1000 cp/ml; n=74 for VL >=1000 cp/ml whole blood 221 
** n=76 for VL <5000 cp/ml; n=28 for VL >5000 cp/ml whole blood 222 
 223 
 224 
 225 
226 
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